

FORM PTO-1390
(REV. 11-2000)

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTORNEY'S DOCKET NUMBER

TRANSMITTAL LETTER TO THE UNITED STATES
DESIGNATED/ELECTED OFFICE (DO/EO/US)
CONCERNING A FILING UNDER 35 U.S.C. 371

Mewburn

U.S. APPLICATION NO. (if known, see 37 CFR 1.5)

not yet assigned
09/890220INTERNATIONAL APPLICATION NO.
PCT/GB00/00248INTERNATIONAL FILING DATE
28 January 2000PRIORITY DATE CLAIMED
28 January 1995TITLE OF INVENTION METHODS AND MEANS FOR MODIFICATION OF PLANT CHARACTERISTICS
USING THE VERNALIZATION GENE VRN2

APPLICANT(S) FOR DO/EO/US

DEAN, Caroline; GENDALL, Anthony

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☒ This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below.
4. ☒ The US has been elected by the expiration of 19 months from the priority date (Article 31).
5. ☒ A copy of the International Application as filed (35 U.S.C. 371(c)(2))
 - a. ☐ is attached hereto (required only if not communicated by the International Bureau).
 - b. ☒ has been communicated by the International Bureau.
 - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☐ An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).
 - a. ☐ is attached hereto.
 - b. ☐ has been previously submitted under 35 U.S.C. 154(d)(4).
7. ☐ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))
 - a. ☐ are attached hereto (required only if not communicated by the International Bureau).
 - b. ☐ have been communicated by the International Bureau.
 - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
 - d. ☐ have not been made and will not be made.
8. ☐ An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
9. ☐ An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).
10. ☐ An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

Items 11 to 20 below concern document(s) or information included:

11. ☐ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
12. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13. ☒ A **FIRST** preliminary amendment.
14. ☐ A **SECOND** or **SUBSEQUENT** preliminary amendment.
15. ☐ A substitute specification.
16. ☐ A change of power of attorney and/or address letter.
17. ☐ A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821 - 1.825.
18. ☐ A second copy of the published international application under 35 U.S.C. 154(d)(4).
19. ☐ A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).
20. ☒ Other items or information:
Copy of Form PCT/IB/308

U.S. APPLICATION NO. (if known, see 37 CFR 1.5)
09/89022
not yet assigned

INTERNATIONAL APPLICATION NO
PCT/GB00/00248

ATTORNEY'S DOCKET NUMBER
Mewburn

21. ☒ The following fees are submitted:

CALCULATIONS PTO USE ONLY

BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)):

Neither international preliminary examination fee (37 CFR 1.482)
nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO
and International Search Report not prepared by the EPO or JPO. \$1000.00

International preliminary examination fee (37 CFR 1.482) not paid to
USPTO but International Search Report prepared by the EPO or JPO **\$860.00**

International preliminary examination fee (37 CFR 1.482) not paid to USPTO
but international search fee (37 CFR 1.445(a)(2)) paid to USPTO **\$710.00**

International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4)	\$690.00
--	----------

International preliminary examination fee (37 CFR 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4)	\$100.00
--	-----------------

ENTER APPROPRIATE BASIC FEE AMOUNT =

\$ 866.00

Surcharge of \$130.00 for furnishing the oath or declaration later than ☐ 20 ☐ 30 months from the earliest claimed priority date (37 CFR 1.492(e)).

\$ 130.00

CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE
--------	--------------	--------------	------

Total claims	10 - 20 =	0	x \$18.00
--------------	-----------	---	-----------

Independent claims	2 - 3 =	0	x \$80.00
--------------------	---------	---	-----------

MULTIPLE DEPENDENT CLAIM(S) (if applicable)	+ \$270.00
---	------------

TOTAL OF ABOVE CALCULATIONS =

\$	990.
----	------

☐ Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.

9

SUBTOTAL =

\$ 990

Processing fee of \$130.00 for furnishing the English translation later than ☐ 20 ☐ 30 months from the earliest claimed priority date (37 CFR 1.492(f)).

1

TOTAL NATIONAL FEE =

\$	990
----	-----

Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). **\$40.00** per property +

9

TOTAL FEES ENCLOSED =

\$	390
----	-----

Amount to be refunded:

\$

charged:

\$

a. ☒ A check in the amount of \$ 990.00 to cover the above fees is enclosed.

b. ☐ Please charge my Deposit Account No. _____ in the amount of \$ _____ to cover the above fees.
A duplicate copy of this sheet is enclosed.

c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 04-1406. A duplicate copy of this sheet is enclosed.

d. ☐ Fees are to be charged to a credit card. **WARNING:** Information on this form may become public. **Credit card information should not be included on this form.** Provide credit card information and authorization on PTO-2038.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137 (a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO

Kathleen D. Rigaut, Ph.D., J.D.
DANN, DORFMAN, HERRELL AND SKILLMAN
1601 Market Street, Suite 720
Philadelphia, Pennsylvania 19103
U.S.A.

ing status

Kathleen D. Rigaut
SIGNATURE

Kathleen D. Rigaut, Ph.D., J.D.
NAME

43,047
REGISTRATION NUMBER

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of :
: Caroline Dean, et al. :
: Serial No. 09/890,220 :
: Filed July 27, 2001 :
: For: METHODS AND MEANS FOR :
: MODIFICATION OF PLANT :
: CHARACTERISTICS USING THE :
: VERNALIZATION GENE VRN2 :

PRELIMINARY AMENDMENT

Please amend the above-identified patent application as follows:

In the specification:

At page 88 of the application, on a separate sheet, please add the following abstract:

--An isolated nucleic acid obtainable from the VRN2 locus of a plant, which nucleic acid encodes a polypeptide which is capable of affecting one or more physical characteristics of a plant into which the nucleic acid is introduced, the physical characteristics being selected from vernalization response, flowering time, leaf size, and/or shape or shade avoidance response; alleles, fragment and derivatives thereof; polypeptides encoded by such nucleic acids; antibodies to such peptides.--

In the claims:

Please add the following new claims:

60. An isolated nucleic acid which comprises a variant sequence which is a homologous variant of a nucleotide sequence selected from the group consisting of SEQ ID NO: 1,

SEQ ID: NO: 3, SEQ ID NO: 4, SEQ ID NO: 6, and SEQ ID NO: 7 and which shares at least 50% identity therewith, said variant being capable of affecting one or more physical characteristics of a plant into which the nucleic acid is introduced, the physical characteristics being selected from vernalization response, flowering time, leaf size and/or shape or shade avoidance response, said isolated nucleic acid optionally comprising a sequence having promoter and/or regulatory function.

61. A nucleic acid according to claim 60 wherein the variant is an allelic variant of a nucleotide sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID: NO: 3, SEQ ID NO: 4, SEQ ID NO: 6, and SEQ ID NO: 7 or is a nucleic acid degenerative equivalent thereof.

62. A nucleic acid according to claim 60 wherein the variant sequence is a VRN2 sequence obtainable from a plant species other than *Arabidopsis thaliana*.

63. An isolated nucleic acid sequence according to claim 60, which is a derivative of said sequence by way of one or more of addition, insertion, deletion or substitution of a said nucleotide sequence, and wherein said derivative shares at least 50% homology with a nucleotide sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID: NO: 3, SEQ ID NO: 4, SEQ ID NO: 6, and SEQ ID NO: 7 and wherein the derivative sequence is either capable of affecting one or more physical characteristics of a plant into which the nucleic acid is introduced, the physical characteristics being selected from vernalization response, flowering time, leaf size and/or shape or shade avoidance response or has promoter and/or regulatory function.

64. An isolated nucleic acid which comprises a sequence

selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 6, and SEQ ID NO: 7 which is a fragment of a sequence and either is capable of affecting one or more physical characteristics of a plant into which the nucleic acid is introduced, the physical characteristics being selected from vernalization response, flowering time, leaf size and/or shape or shade avoidance response or has promoter and/or regulatory function.

65. An isolated nucleic acid which comprises a sequence which is the complement of a sequence of claim 60.

66. An isolated nucleic acid for use as a probe or primer which comprises a sequence that encodes an amino acid sequence that is partly, substantially or completely conserved between a VRN2 sequence of SEQ ID Nos. 2, 5 or 8 and at least one of the other sequences shown in Figure 8a or 8b, wherein said nucleic acid is 15 to 40 nucleotides in length.

67. An isolated nucleic acid for use as a probe or primer which comprises a sequence that is partly, substantially or completely conserved between two or more of the VRN2 nucleotide sequences selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 6, and SEQ ID NO: 7 or the complements thereof, wherein said nucleic acid is 15 to 40 nucleotides in length said nucleic acid optionally comprising a sequence having promoter and or regulatory function.

68. A nucleic acid according to claim 67 which is 19 to 28 nucleotides in length.

69. A pair of primers each comprising a nucleic acid according to claim 67.

70. A pair of primers according to claim 69 which is selected from:

VRN2-AP and VRN2-AJ;
VRN2-AO and VRN2-AS; and
VRN2-AI and VRN2-AJ.

71. A process for producing a nucleic acid which is a derivative according to claim 63 which process comprises the step of modifying a nucleotide sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 6, and SEQ ID NO: 7.

72. A method for identifying or cloning a nucleic acid according to claim 60 in a database search, which method comprises using a nucleotide sequence of a probe or primer comprising a sequence that is partly, substantially or completely conserved between two or more of the VRN2 nucleotide sequences selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 6, and SEQ ID NO: 7 or the complements thereof, wherein said probe or primer is 15 to 40 nucleotides in length.

73. A method for identifying or cloning a nucleic acid selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 6, and SEQ ID NO: 7, which method employs a probe or primer, said probe or primer comprising a sequence that encodes an amino acid sequence that is partly, substantially or completely conserved between a VRN2 sequence of SEQ ID Nos. 2, 5 or 8 and at least one of the other sequences shown in Figure 8a or 8b, wherein said nucleic acid is 15 to 40 nucleotides in length or a pair of primers selected from the group consisting of VRN2-AP and VRN2-AJ; VRN2-AO and VRN2-AS; and VRN2-AI and VRN2-AJ.

74. A method for determining the presence of a nucleic acid according claim 60 within the genetic make-up of a plant, which method employs a probe or primer, said probe or primer comprising a sequence that encodes an amino acid sequence that is partly, substantially or completely conserved between a VRN2 sequence of SEQ ID Nos. 2, 5 or 8 and at least one of the other sequences shown in Figure 8a or 8b, wherein said nucleic acid is 15 to 40 nucleotides in length, or a pair of primers selected from the group consisting of VRN2-AP and VRN2-AJ; VRN2-AO and VRN2-AS; and VRN2-AI and VRN2-AJ.

75. A method according to claim 73, which comprises the steps of:

(a) providing a preparation of nucleic acid from a plant cell;

(b) providing a nucleic acid molecule which is a probe, said probe comprising a sequence that encodes an amino acid sequence that is partly, substantially or completely conserved between a VRN2 sequence of SEQ ID Nos. 2, 5 or 8 and at least one of the other sequences shown in Figure 8a or 8b, wherein said probe is 15 to 40 nucleotides in length;

(c) contacting nucleic acid in said preparation with said probe under conditions for hybridisation; and

(d) identifying a nucleic acid selected from the group consisting of SEQ ID NO: 1, SEQ ID: NO: 3, SEQ ID NO: 4, SEQ ID NO: 6, and SEQ ID NO: 7, if present by its hybridisation with said nucleic acid probe.

76. A method according to claim 73, which method comprises the steps of:

(a) providing a preparation of nucleic acid from a plant cell;

(b) providing a pair of nucleic acid molecule primers suitable for PCR, at least one of said primers being a primer

which comprises a sequence that encodes an amino acid sequence that is partly, substantially or completely conserved between a VRN2 sequence of SEQ ID Nos. 2, 5 or 8 and at least one of the other sequences shown in Figure 8a or 8b, wherein said nucleic acid is 15 to 40 nucleotides in length;

(c) contacting nucleic acid in said preparation with said primers under conditions for performance of PCR;

(d) performing PCR and determining the presence or absence of an amplified PCR product.

77. A method according to claim 76 wherein the pair of nucleic acid molecule primers are VRN2-AP and VRN2-AJ; VRN2-AO and VRN2-AS; and VRN2-AI and VRN2-AJ.

78. A method of selecting a plant having a desired allele of the VRN2 gene, which method employs a probe or primer, said probe or primer comprising a sequence that encodes an amino acid sequence that is partly, substantially or completely conserved between a VRN2 sequence of SEQ ID Nos. 2, 5 or 8 and at least one of the other sequences shown in Figure 8a or 8b, wherein said nucleic acid is 15 to 40 nucleotides in length, or a pair of primers selected from the group consisting of VRN2-AP and VRN2-AJ; VRN2-AO and VRN2-AS; and VRN2-AI and VRN2-AJ.

79. A recombinant vector which comprises a nucleotide sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 6, and SEQ ID NO: 7 or a sequence degeneratively equivalent thereto.

80. A vector according to claim 79 wherein the nucleic acid comprised in the vector is capable of regulating one or more genes involved in the transition from vegetative to reproductive growth and/or capable of regulating one or more genes involved in the determination of leaf size and/or shape.

81. A vector according to claim 80 wherein the nucleic acid is operably linked to a promoter for transcription in a host cell, wherein the promoter is optionally an inducible promoter.

82. A vector according to claim 81 wherein the promoter is a constitutive promoter.

83. A vector according to any one of claims 79 which is a plant vector.

84. A method which comprises the step of introducing a vector according to claim 79 into a host cell such as to transform the host cell.

85. A host cell which is transformed with a heterologous nucleic acid selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 6, and SEQ ID NO: 7 and sequences degeneratively equivalent thereto.

86. A host cell according to claim 85 which is a plant cell, optionally present in a plant.

87. A method for producing a transgenic plant, which method comprises the steps of:

- (a) performing a method according to claim 84; and
- (b) regenerating a plant from the transformed host cell.

88. A transgenic plant which is obtainable by the method of claim 87, or which is a clone, or selfed or hybrid progeny or other descendant of said transgenic plant, which in each case includes the plant cell transformed with a heterologous nucleic acid selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 6, and SEQ ID NO: 7 and sequences degeneratively equivalent thereto.

89. A plant according to claim 88 which is an agricultural or horticultural plant.

90. A plant according to claim 89 selected from the list consisting of: rice, maize, wheat, barley, oats, rye, oil seed rape, sugar beet, sunflower, soybean, sorghum, lettuce, endive, cabbage, broccoli, cauliflower, carnation, geranium, tobacco, cotton, canola, tomato, mango, peach, apple, pear, strawberry, banana, melon, carrot, onion, pea, celery.

91. A plant according to claim 90 which is selected from tobacco, oil seed rape, rice and wheat.

92. A part or propagule from a plant which is a clone, or selfed or hybrid progeny or other descendant of said transgenic plant, which in each case includes the plant cell transformed with a heterologous nucleic acid selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 6, and SEQ ID NO: 7 and sequences degeneratively equivalent thereto.

93. An isolated polypeptide which is encoded by a nucleotide sequence according to claim 1.

94. A polypeptide according to claim 93 which comprises an amino acid sequence which consists of the sequence of SEQ ID Nos. 2, 5 or 8.

95. A polypeptide which is a fragment of a polypeptide of claim 94, having at least nine contiguous amino acids.

96. An isolated polypeptide which consists of the sequence of SEQ ID Nos. 2, 5 or 8.

97. An isolated polypeptide which is a fragment of a polypeptide according to claim 96 and which comprises at least 9 contiguous amino acids of that polypeptide.

98. A fragment according to claim 97 which comprises amino acids 90 to 111 (zinc finger motif), amino acids 63 to 132 (amino terminal region), amino acids 263 to 366 (carboxy terminus) or amino acids 263 to 328 (activation domain).

99. A polypeptide according to claim 93 which is capable of affecting one or more physical characteristics of a plant expressing said peptide, the physical characteristics being selected from vernalization response, flowering time, leaf size and/or shape or shade avoidance response.

100. An isolated nucleic acid which encodes a fragment according to claim 97.

101. An isolated nucleic acid which is the complement of the nucleic acid of claim 100.

102. A method of making the polypeptide of a sequence selected from the group consisting of SEQ ID NO: 2, 5, or 8, which method comprises the step of causing or allowing expression from a nucleic acid encoding SEQ ID NOS 2, 5, or 8.

103. An antibody which has specific binding affinity for a polypeptide according to claim 93.

104. A polypeptide which comprises the antigen-binding site of the antibody of claim 103.

105. A method for affecting a physical characteristic of a plant selected from vernalization response, flowering time, leaf size and/or shape or shade avoidance response, which method comprises either the step of:

(i) causing or allowing transcription from a nucleic acid which comprises a sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID: NO: 3, SEQ ID NO: 4, SEQ ID NO: 6, and SEQ ID NO: 7 or a fragment of said sequence

which is capable of affecting one or more physical characteristics of a plant into which the nucleic acid is introduced, the physical characteristics being selected from vernalization response, flowering time, leaf size and/or shape or shade avoidance response or has promoter and/or regulatory function.

106. A method according to claim 105 which method comprises causing or allowing transcription from said nucleic acid thereby reducing VRN2 expression by co-suppression.

REMARKS

The purpose of this preliminary amendment is insert an abstract of the disclosure into the specification and to reinstate claims canceled in the first preliminary amendment.

Favorable consideration leading to prompt allowance of the present application is respectfully requested.

Respectfully submitted,
DANN, DORFMAN, HERRELL AND SKILLMAN
A Professional Corporation

By: Kathleen D. Rigaut
Kathleen D. Rigaut, Ph.D., J.D.
PTO Registration No. 43,047

Telephone: (215) 563-4100
Facsimile: (215) 563-4044

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of :
: Caroline Dean, et al. :
: Serial No. Not yet assigned :
: (PCT/GB00/00248) :
: Int. App. filed 01/28/00 :
: :
: For: METHODS AND MEANS FOR :
: MODIFICATION OF PLANT :
: CHARACTERISTICS USING THE :
: VERNALIZATION GENE VRN2 :

PRELIMINARY AMENDMENT

Before calculation of the filing fee, please amend the above-identified patent application as follows:

In the specification:

At page 1, line 3, please insert the following priority claim:

--The present application is the U.S. National Phase of PCT/GB00/00248 filed January 28, 2000 which claims priority to GB 9901927.5 filed January 28, 1999 under 35 U.S.C.

§119(e), the entire disclosure of which is incorporated by reference herein.--

In the claims:

3. (Amended) A nucleic acid according to claim 1 which comprises a VRN2 nucleotide sequence which encodes a polypeptide of SEQ ID No. 2.

5. (Amended) A nucleic acid according to claim 1 which comprises a VRN2 nucleotide sequence which encodes a polypeptide of SEQ ID No. 5.

7. (Amended) A nucleic acid according to claim 1 which comprises a VRN2 nucleotide sequence which encodes a polypeptide of SEQ ID No. 8.

Please cancel claims 11-59.


REMARKS

The purpose of this preliminary amendment is insert a priority claim into the application and to remove existing multiple dependencies from the claims. Claims 11-59 have been canceled. Applicants intend to submit claims directed to the subject matter of canceled claims 11-59 via preliminary amendment in the very near future.

Favorable consideration leading to prompt allowance of the present application is respectfully requested.

Respectfully submitted,
DANN, DORFMAN, HERRELL AND SKILLMAN
A Professional Corporation

By:



Telephone: (215) 563-4100

Facsimile: (215) 563-4044

Kathleen D. Rigaut, Ph.D., J.D.
PTO Registration No. 43,047

Enclosures: Marked up draft of amended claims.

**METHODS AND MEANS FOR MODIFICATION OF PLANT CHARACTERISTICS
USING THE VERNALIZATION GENE VRN2**

The present invention relates generally to modification of characteristics of plants, especially vernalization response, flowering time, leaf shape and/or shade avoidance response, and has arisen on the basis of cloning of the VRN2 gene and mutant alleles of *Arabidopsis thaliana*, and identification of homologues in other species.

In different embodiments, the present invention provides for manipulation of flowering time and/or other characteristics of plants, e.g. by up or down regulating VRN2 gene expression. The present invention also provides for modification of the extent of alteration of a relevant plant characteristic through the use of gene alleles, mutants and variants.

Plants must integrate a wide variety of environmental signals in order to maximize their reproductive success. Part of this integration must involve perception of the seasons, both to ensure the plant flowers during the correct season (for which it is adapted) and to synchronise its flowering with other members of its own species, to increase the chances of cross-fertilization. *Arabidopsis thaliana* serves as a model plant, for it exhibits responses to a wide variety of environmental stimuli that are observed in many species. Flowering in naturally occurring strains (ecotypes) of *Arabidopsis* can be promoted either by long days (increased photoperiod) or by vernalization, a long cold treatment that mimics the cold of winter. While many aspects of the photoperiodic response are now understood, the vernalization pathway has received relatively less attention. The inventors have used a late flowering, vernalization responsive mutant of *Arabidopsis*, the *fca* mutant, as a background in which to isolate mutants that exhibit a reduced vernalization response, the VRN mutants.

Vernalization is the low temperature promotion of flowering. It can also be thought of as the cold aspect of the winter season, which also includes reduced daylight hours. Many species of plants that grow in temperate or cooler climes have an obligate requirement for vernalization in order to flower. Such plants typically germinate in autumn, and over-winter as vegetative plants, and flower in milder conditions of spring. Vernalization thus acts as a cue, to allow plants to sense the seasons, and to time their flowering to maximise their chance of reproductive success.

Species for which flowering is important to crop production are numerous, essentially all crops which are grown from seed, with important examples being the cereals, rice and maize, probably the most agronomically important in warmer climatic zones, and wheat, barley, oats and rye in more temperate climates. Important seed products are oil seed rape, sugar beet, maize, sunflower, soybean and sorghum. Many crops which are harvested for their roots are, of course, grown annually from seed and the production of seed of any kind is very dependent upon the ability of the plant to flower, to be pollinated and to set seed. In horticulture, control of the timing of flowering is important. Horticultural plants whose flowering may be controlled include lettuce, endive and vegetable brassicas including cabbage, broccoli and cauliflower, and carnations and geraniums.

Arabidopsis thaliana is a facultative long day plant, flowering early under long days and late under short days. Because it has a small, well-characterized genome, is relatively easily transformed and regenerated and has a rapid growing cycle, *Arabidopsis* is an ideal model plant in which to study flowering and its control.

In addition to cloning the VRN2 gene, the inventors have unexpectedly found indication that VRN2 is a transcription factor, which in itself opens several exciting avenues for application of the present invention. Without being bound by

theory or in anyway limiting the scope of the present invention, VRN2 may be required for a normal vernalization response because it acts as a regulator of genes that ultimately lead to the transition from vegetative to reproductive growth. In such a model, cold, or a downstream molecule involved in cold perception, may regulate the activity or expression of the VRN2 protein, which in turn may regulate the expression of a large number of genes that ultimately lead to flowering. Furthermore, the shade avoidance phenotype exhibited by the *vrn2-1* mutant, as demonstrated experimentally below, provides indication that VRN2 also plays a role in regulating leaf shape, particularly in response to increased far-red light. Together, these two processes affected by a deficiency or reduction of VRN2 activity provide for a number of approaches of agronomic interest.

First, forced expression of VRN2 (for example under the control of a strong and constitutive promoter, such as the Ca MV 35 S promoter) in a wild-type background may be used alter the vernalization requirement of a plant prior to flowering. As a large number of commercial cultivars of several species, including (diploid) wheat, barley, and sugar beet, have a requirement for vernalization to flower, modification of this requirement, by reducing the duration of vernalization required, or changing the optimum temperature, or abrogating the requirement altogether, is of agronomic usefulness. For instance, a winter crop that can be sown and left in the ground for a shorter period than usual (i.e. a reduced vernalization time) may benefit from reduced risk of damage associated with severe winter weather conditions, as the crops are exposed to winter conditions for a shorter time.

Second, down-regulation of VRN2 expression, for instance by means of an antisense VRN2 cDNA, may be used to recapitulate the reduction in shade avoidance phenotype observed in *vrn2-1* mutants. This may be used in situations where crowding of the crop is a problem. Based on experimental evidence provided

herein on the phenotype of *vrn2-1* mutants, such plants are expected to exhibit less of a response to such conditions, and to produce leaves that are essentially normal i.e. as if they had not been grown in dense or crowded conditions. The normal shade avoidance phenotype is a reduction in leaf size, which reduces shade in overcrowded conditions; *vrn2-1* mutants, defective in VRN2 production, show less reduction in leaf size under conditions which would normally lead to the shade avoidance phenotype. This effect can therefore be reproduced for example by using antisense VRN2 cDNA to downregulate VRN2 expression, preventing or reducing the leaf avoidance response even in overcrowded conditions.

Third, the individual isolated domains of the VRN2 protein may be used in their own right. DNA binding of the zinc finger of VRN2 may be used to direct or control gene expression in a precise manner. The VRN2 zinc finger may recognize specific DNA sequences that represent elements in the promoters of its normal target genes. By creating fusion proteins, comprising the DNA binding (zinc finger) domain of VRN2, and an activation or repression domain from a heterologous protein, the expression of VRN2 target genes may be controlled. This allows for a precise control of the expression of those genes that are normally targets of VRN2. Given that such genes, alone or in combination, ultimately control the transition to flowering (usually following vernalization), their directed expression in other conditions may also be used to elicit changes in flowering and/or one or more other plant characteristics. The expression of (normally far-red responsive) target genes also be controlled using VRN2 fusion proteins containing the zinc finger of VRN2. Furthermore, the use of the zinc finger domain of VRN2 in conventional SELEX or one-hybrid experiments may be used to reveal the target genes or DNA sequences normally bound by VRN2.

The acidic activation domain of VRN2 may be used to regulate the activity of a fusion protein, including a DNA-binding protein of known specificity, and the activation domain of

VRN2. This allows for regulation of target genes of other DNA binding proteins involved in flowering, or of target genes in completely unrelated processes.

5 The inventors have cloned, characterised and manipulated the VRN2 gene of *Arabidopsis thaliana*, both *Columbia* and *Landsberg erecta* types, and identified alternatively spliced and mutant forms, also homologues in other species.

10 In the light of the inventors' experimental work, a first aspect of the present invention provides a nucleic acid isolate encoding a polypeptide including a VRN2 amino acid sequence shown herein (e.g. SEQ ID NO: 2; SEQ ID NO: 5), which may include a coding sequence shown herein (e.g. SEQ ID NO: 1; 15 SEQ ID NO: 4).

Allelic forms and alternatively spliced forms of the gene have been identified. Such polypeptides and encoding nucleic acid (e.g. as in SEQ ID NO: 8, encoded by SEQ ID NO: 7) are each 20 further provided as an aspect of the invention, as are polypeptides and nucleic acid including the mutations identified herein.

Nucleic acid according to the present invention may have the 25 sequence of the VRN2 gene of *Arabidopsis thaliana* as indicated in SEQ ID NO: 1, SEQ ID NO: 3 (*Landsberg erecta* genomic sequence), SEQ ID NO: 4 or SEQ ID NO: 6 (*Columbia* genomic sequence), or be a mutant, variant, derivative or allele or a homologue of the sequence provided. Preferred mutants, 30 variants, derivatives and alleles are those which encode a protein which retains a functional characteristic of the protein encoded by the wild-type gene, especially the ability to alter vernalization response, flowering time, leaf shape and/or shade avoidance response.

35 A mutant, variant, derivative, allele or homologue in accordance with the present invention may have the ability to

affect a physical characteristic of a plant, especially vernalization response, flowering time, leaf shape and/or shade avoidance response, as discussed.

- 5 Polynucleotides which are not 100% identical to the sequences shown herein but fall within the scope of the invention can be obtained in a number of ways.

Other VRN2 variants (for example allelic forms) of the gene
10 described herein may be obtained for example by probing cDNA or genomic DNA libraries made from *Arabidopsis thaliana* plants or cells.

In addition, other plant, monocot or dicot, homologues of the
15 gene may be obtained. Such sequences may be obtained by making or obtaining cDNA libraries made from dividing cells or tissues or genomic DNA libraries from other plant species, and probing such libraries with probes comprising all or part of a
20 nucleic acid of the invention under conditions of medium to high stringency (for example for hybridization on a solid support (filter) overnight incubation at 42°C in a solution containing 50% formamide, 5xSSC (750 mM NaCl, 75 mM sodium citrate), 50 mM sodium phosphate (pH7.6), 5x Denhardt's
25 solution, 10% dextran sulphate and 20 µg/ml salmon sperm DNA, followed by washing in 0.03M sodium chloride and 0.03M sodium citrate (i.e. 0.2x SSC) at from about 50°C to about 60°C).

Thus the present invention provides an isolated nucleic acid which hybridizes to the nucleotide sequence shown in a figure
30 herein under the abovementioned hybridization and washing conditions. Such a nucleic acid is suitable for use as a probe for detecting the VRN2 gene, for example in Southern blots.

35 Suitable probe and primer sequences are disclosed herein.

Alternatively, polynucleotides of the invention may be obtained by site directed mutagenesis of the sequences of

shown in the figures or allelic variants thereof. This may be useful where for example silent codon changes are required to sequences to optimise codon preferences for a particular host cell in which the polynucleotide sequences are being
5 expressed. Other sequence changes may be desired in order to introduce restriction enzyme recognition sites, or to alter the property or function of the polypeptides encoded by the polynucleotides. Further changes may be desirable to represent particular coding changes which are required to
10 provide, for example, conservative substitutions.

In the context of cloning, it may be necessary for one or more gene fragments to be ligated to generate a full-length coding sequence. Also, where a full-length encoding nucleic acid
15 molecule has not been obtained, a smaller molecule representing part of the full molecule, may be used to obtain full-length clones. Inserts may be prepared from partial cDNA clones and used to screen cDNA libraries. The full-length clones isolated may be subcloned into expression vectors and
20 activity assayed by transfection into suitable host cells, e.g. with a reporter plasmid.

The present invention also extends to nucleic acid comprising transcriptional control sequences for the *VRN2* gene. Such
25 control sequences will be found 5' to the open reading frame of the gene and are obtainable by probing a genomic DNA library with a nucleic acid of the invention, selecting a clone which hybridizes under conditions of medium to high stringency, and sequencing the clone 5' to the open reading
30 frame of the gene. Where only a small amount of sequence is present in the 5' region, this sequence may be used to reprobe the library to genome walk further upstream. Analysis of the upstream region will reveal control regions for gene expression including control regions common to many genes (i.e.
35 TATA and CAAT boxes) and other control regions, usually located from 1 to 10,000, such as 1 to 1000 or 50 to 500 nucleotides upstream of the start of transcription.

To confirm that such regions are the control regions of the gene, they may be linked to a reported gene (such as β -galactosidase) and tested in any suitable *in vitro* or *in vivo* system. For example the construct of the control region (e.g. comprising 50 to 500 nucleotides upstream of the start of transcription) and the reporter gene may be used to produce a transgenic plant and the pattern of expression, both spatially and developmentally, may be compared with that of the *VRN2* gene. Where substantially similar patterns of expression are found, this shows that the construct comprises substantially all of the control region of the wild type gene.

SEQ ID NO: 3 and SEQ ID NO: 6 show the nucleotide sequence of the *VRN2* genomic region including promoter, respectively for *Landsberg erecta* and *Columbia* ecotypes of *Arabidopsis thaliana*, also 3' regulatory elements.

The control region may be mutated to identify specific subregions responsible for transcriptional control. This may be achieved by a number of techniques well known in the art as such, including DNase protection footprint assays, in which the control region is brought into contact with an extract from a cell in which the *VRN2* gene is actively expressed, and the regions of the control region which bind factors in that extract is determined.

Isolated nucleic acid comprising such control regions obtainable by such a method form a further aspect of the present invention.

30

The present invention further extends to genomic DNA exon sequences found between the introns encoding a *VRN2* gene in plant. Such exon sequences may be obtained in a manner analogous to that described above for the transcriptional control sequences, with the appropriate genome walking being conducted between the intron sequences. The locations of the exons may be determined by comparing genomic and cDNA

35

sequences of the gene, observing where the sequences line up and diverge, and looking for consensus splice sequences which define intron/exon boundaries.

- 5 As noted above, changes to a sequence, to produce a mutant, variant or derivative, may be by one or more of addition, insertion, deletion or substitution of one or more nucleotides in the nucleic acid, leading to the addition, insertion, deletion or substitution of one or more amino acids in the
10 encoded polypeptide. Of course, changes to the nucleic acid which make no difference to the encoded amino acid sequence ("degeneratively equivalent") are included.

Preferred nucleic acid sequences according to the present
15 invention are shown herein, for instance see SEQ ID NO: 1 and SEQ ID NO: 4, of which the respective predicted encoded amino acid sequences of polypeptides according to the present invention are shown in SEQ ID NO: 2 and SEQ ID NO: 5.

- 20 A mutant, allele, variant or derivative amino acid sequence in accordance with the present invention may include within a sequence shown herein a single amino acid change with respect to the sequence shown with the relevant SEQ ID NO: or in the relevant figure, or 2, 3, 4, 5, 6, 7, 8, or 9 changes, about
25 10, 15, 20, 30, 40 or 50 changes, or greater than about 50, 60, 70, 80 or 90 changes. In addition to one or more changes within the amino acid sequence shown in the relevant figure, a mutant, allele, variant or derivative amino acid sequence may include additional amino acids at the C-terminus and/or N-
30 terminus.

A sequence related to a sequence specifically disclosed herein shares homology with that sequence. Homology may be at the nucleotide sequence and/or amino acid sequence level.

- 35 Preferably, the nucleic acid and/or amino acid sequence shares homology with the coding sequence or the sequence encoded by a nucleotide sequence shown herein, for instance SEQ ID NO: 2 or SEQ ID NO: 5, preferably at least about 50%, or 60%, or 70%,

or 80% homology, most preferably at least about 90%, 95%, 96%, 97%, 98% or 99% homology.

As is well-understood, homology at the amino acid level is generally in terms of amino acid similarity or identity. Similarity allows for "conservative variation", i.e. substitution of one hydrophobic residue such as isoleucine, valine, leucine or methionine for another, or the substitution of one polar residue for another, such as arginine for lysine, glutamic for aspartic acid, or glutamine for asparagine. Similarity may be as defined and determined by the TBLASTN program, of Altschul et al. (1990) *J. Mol. Biol.* 215: 403-10, which is in standard use in the art, or, and this may be preferred, either of the standard programs BestFit and GAP, which are part of the Wisconsin Package, Version 8, September 1994, (Genetics Computer Group, 575 Science Drive, Madison, Wisconsin, USA, Wisconsin 53711). BestFit makes an optimal alignment of the best segment of similarity between two sequences. Optimal alignments are found by inserting gaps to maximize the number of matches using the local homology algorithm of Smith and Waterman (Advances in Applied Mathematics (1981) 2, pp. 482-489). GAP uses the Needleman and Wunsch algorithm to align two complete sequences that maximizes the number of matches and minimizes the number of gaps. Generally, the default parameters are used, with a gap creation penalty = 12 and gap extension penalty = 4.

Homology is generally over the full-length of the relevant sequence shown herein, that is unless stated otherwise, or it may be over a contiguous sequence of about or greater than about 20, 25, 30, 33, 40, 50, 67, 133, 167, 200, 233, 267, 300, 333, 400, 450, 500, 550, 600 or more amino acids or codons, compared with the relevant amino acid sequence or nucleotide sequence as the case may be.

In highly preferred embodiments, all percentage homologies referred to herein refer to percentage sequence identity.

In this context, percent (%) amino acid sequence identity with respect to a particular reference sequence is defined as the percentage of amino acid residues in a candidate sequence that are identical with the amino acid residues in the reference sequence, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity, and not considering any conservative substitutions as part of the sequence identity.

The % identity values used herein may be determined by WU-BLAST-2 which was obtained from [Altschul et al., Methods in Enzymology, 266:460-480 (1996); <http://blast.wustl.edu/blast/README.html>]. WU-BLAST-2 uses several search parameters, most of which are set to the default values. The adjustable parameters are set with the following values: overlap span =1, overlap fraction= 0.125, word threshold (T) = 11. The HSPS and HSPS2 parameters are dynamic values and are established by the program itself depending upon the composition of the particular sequence and composition of the particular database against which the sequence of interest is being searched; however, the values may be adjusted to increase sensitivity.

A% amino acid sequence identity value is determined by the number of matching identical residues divided by the total number of residues of the "longer" sequence in the aligned region. The "longer" sequence is the one having the most actual residues in the aligned region (gaps introduced by WU-Blast-2 to maximize the alignment score are ignored).

In a similar manner, percent (%) nucleic acid sequence identity with respect to a reference nucleic acid sequence is defined as the percentage of nucleotide residues in a candidate sequence that are identical with the nucleotide residues in the reference sequence. The identity values may be determined by the BLASTN module of WU-BLAST-2 set to the

default parameters, with overlap span and overlap fraction set to 1 and 0.125, respectively.

5 Nucleic acid according to the present invention may consist essentially of or consist of the relevant coding sequence. Nucleic acid according to the present invention may include a promoter or other regulatory sequence as discussed further elsewhere herein, and such regulatory sequence may be heterologous to the coding sequence, that is to say not
10 naturally operably linked therewith. Nucleic acid according to the present invention may be cDNA or lacking one or more introns which occur naturally, or may be in any non-naturally occurring form. A coding sequence in accordance with the present invention may be included with a larger nucleic acid
15 molecule of less than about 10,000 nucleotides, less than about 5,000 nucleotides or less than about 2,000 nucleotides.

Also provided by an aspect of the present invention is nucleic acid including or consisting essentially of a sequence of
20 nucleotides complementary to a nucleotide sequence hybridisable with any encoding sequence provided herein. Another way of looking at this would be for nucleic acid according to this aspect to be hybridisable with a nucleotide sequence complementary to any encoding sequence provided
25 herein. Of course, DNA is generally double-stranded and blotting techniques such as Southern hybridisation are often performed following separation of the strands without a distinction being drawn between which of the strands is hybridising. Preferably the hybridisable nucleic acid or its
30 complement encode a product able to influence a physical characteristic of a plant, particularly vernalization response, flowering time, leaf shape and/or shade avoidance response, e.g. in *Arabidopsis thaliana*. Preferred conditions for hybridisation are familiar to those skilled in the art,
35 but are generally stringent enough for there to be positive hybridisation between the sequences of interest to the exclusion of other sequences.

The nucleic acid, which may contain for example DNA encoding a polypeptide including the amino acid sequence of VRN2 or other polypeptide disclosed herein, as genomic or cDNA, may be in the form of a recombinant and preferably replicable vector, for example a plasmid, cosmid, phage or *Agrobacterium* binary vector. The nucleic acid may be under the control of an appropriate promoter or other regulatory elements for expression in a host cell such as a microbial, e.g. bacterial, or plant cell. In the case of genomic DNA, this may contain its own promoter or other regulatory elements and in the case of cDNA this may be under the control of an appropriate promoter or other regulatory elements for expression in the host cell.

A vector including nucleic acid according to the present invention need not include a promoter or other regulatory sequence, particularly if the vector is to be used to introduce the nucleic acid into cells for recombination into the genome.

Those skilled in the art are well able to construct vectors and design protocols for recombinant gene expression. Suitable vectors can be chosen or constructed, containing appropriate regulatory sequences, including promoter sequences, terminator fragments, polyadenylation sequences, enhancer sequences, marker genes and other sequences as appropriate. For further details see, for example, *Molecular Cloning: a Laboratory Manual*: 2nd edition, Sambrook et al, 1989, Cold Spring Harbor Laboratory Press. Many known techniques and protocols for manipulation of nucleic acid, for example in preparation of nucleic acid constructs, mutagenesis, sequencing, introduction of DNA into cells and gene expression, and analysis of proteins, are described in detail in *Current Protocols in Molecular Biology*, Second Edition, Ausubel et al. eds., John Wiley & Sons, 1992. The disclosures of Sambrook et al. and Ausubel et al. are incorporated herein by reference. Specific procedures and

vectors previously used with wide success upon plants are described by Bevan (Nucl. Acids Res. 12, 8711-8721 (1984)) and Guerineau and Mullineaux (1993) (Plant transformation and expression vectors. In: Plant Molecular Biology Labfax (Croy RRD ed) Oxford, BIOS Scientific Publishers, pp 121-148).

Selectable genetic markers may be used consisting of chimaeric genes that confer selectable phenotypes such as resistance to antibiotics such as kanamycin, hygromycin, phosphinotricin, chlorsulfuron, methotrexate, gentamycin, spectinomycin, imidazolinones and glyphosate.

Nucleic acid molecules and vectors according to the present invention may be provided isolated and/or purified from their natural environment, in substantially pure or homogeneous form, or free or substantially free of nucleic acid or genes of the species of interest or origin other than the sequence encoding a polypeptide with the required function. Nucleic acid according to the present invention may include cDNA, RNA, genomic DNA and may be wholly or partially synthetic. The term "isolate" encompasses all these possibilities. Where a DNA sequence is specified, e.g. with reference to a figure, unless context requires otherwise the RNA equivalent, with U substituted for T where it occurs, is encompassed.

When introducing a chosen gene construct into a cell, certain considerations must be taken into account, well known to those skilled in the art. The nucleic acid to be inserted should be assembled within a construct which contains effective regulatory elements which will drive transcription. There must be available a method of transporting the construct into the cell. Once the construct is within the cell membrane, integration into the endogenous chromosomal material either will or will not occur. Finally, as far as plants are concerned the target cell type must be such that cells can be regenerated into whole plants.

Plants transformed with the DNA segment containing the sequence may be produced by standard techniques which are already known for the genetic manipulation of plants. DNA can be transformed into plant cells using any suitable technology, such as a disarmed Ti-plasmid vector carried by *Agrobacterium* exploiting its natural gene transfer ability (EP-A-270355, EP-A-0116718, NAR 12(22) 8711 - 87215 1984), particle or microprojectile bombardment (US 5100792, EP-A-444882, EP-A-434616) microinjection (WO 92/09696, WO 94/00583, EP 331083, EP 175966, Green et al. (1987) *Plant Tissue and Cell Culture*, Academic Press), electroporation (EP 290395, WO 8706614) other forms of direct DNA uptake (DE 4005152, WO 9012096, US 4684611), liposome mediated DNA uptake (e.g. Freeman et al. *Plant Cell Physiol.* 29: 1353 (1984)), or the vortexing method (e.g. Kindle, *PNAS U.S.A.* 87: 1228 (1990d) Physical methods for the transformation of plant cells are reviewed in Oard, 1991, *Biotech. Adv.* 9: 1-11.

Agrobacterium transformation is widely used by those skilled in the art to transform dicotyledonous species. There are various approaches used for the routine production of stable, fertile transgenic plants in almost all economically relevant monocot plants (Toriyama, et al. (1988) *Bio/Technology* 6, 1072-1074; Zhang, et al. (1988) *Plant Cell Rep.* 7, 379-384; Zhang, et al. (1988) *Theor Appl Genet* 76, 835-840; Shimamoto, et al. (1989) *Nature* 338, 274-276; Datta, et al. (1990) *Bio/Technology* 8, 736-740; Christou, et al. (1991) *Bio/Technology* 9, 957-962; Peng, et al. (1991) International Rice Research Institute, Manila, Philippines 563-574; Cao, et al. (1992) *Plant Cell Rep.* 11, 585-591; Li, et al. (1993) *Plant Cell Rep.* 12, 250-255; Rathore, et al. (1993) *Plant Molecular Biology* 21, 871-884; Fromm, et al. (1990) *Bio/Technology* 8, 833-839; Gordon-Kamm, et al. (1990) *Plant Cell* 2, 603-618; D'Halluin, et al. (1992) *Plant Cell* 4, 1495-1505; Walters, et al. (1992) *Plant Molecular Biology* 18, 189-

200; Koziel, et al. (1993) *Biotechnology* 11, 194-200; Vasil, I. K. (1994) *Plant Molecular Biology* 25, 925-937; Weeks, et al. (1993) *Plant Physiology* 102, 1077-1084; Somers, et al. (1992) *Bio/Technology* 10, 1589-1594; WO92/14828). In

5 particular, *Agrobacterium* mediated transformation is now emerging also as an highly efficient alternative transformation method in monocots (Hiei et al. (1994) *The Plant Journal* 6, 271-282).

10 The generation of fertile transgenic plants has been achieved in the cereals rice, maize, wheat, oat, and barley (reviewed in Shimamoto, K. (1994) *Current Opinion in Biotechnology* 5, 158-162.; Vasil, et al. (1992) *Bio/Technology* 10, 667-674; Vain et al., 1995, *Biotechnology Advances* 13 (4): 653-671; 15 Vasil, 1996, *Nature Biotechnology* 14 page 702).

Microprojectile bombardment, electroporation and direct DNA uptake are preferred where *Agrobacterium* is inefficient or ineffective. Alternatively, a combination of different 20 techniques may be employed to enhance the efficiency of the transformation process, eg bombardment with *Agrobacterium* coated microparticles (EP-A-486234) or microprojectile bombardment to induce wounding followed by co-cultivation with *Agrobacterium* (EP-A-486233).

25 Following transformation, a plant may be regenerated, e.g. from single cells, callus tissue or leaf discs, as is standard in the art. Almost any plant can be entirely regenerated from cells, tissues and organs of the plant. Available techniques 30 are reviewed in Vasil et al., *Cell Culture and Somatic Cell Genetics of Plants, Vol I, II and III, Laboratory Procedures and Their Applications*, Academic Press, 1984, and Weissbach and Weissbach, *Methods for Plant Molecular Biology*, Academic Press, 1989.

35

The particular choice of a transformation technology will be determined by its efficiency to transform certain plant species as well as the experience and preference of the person practising the invention with a particular methodology of choice. It will be apparent to the skilled person that the particular choice of a transformation system to introduce nucleic acid into plant cells is not essential to or a limitation of the invention, nor is the choice of technique for plant regeneration.

A VRN2 gene and modified versions thereof (alleles, mutants, variants and derivatives thereof), and other nucleic acid provided herein, including species homologues, may be used to modify vernalization response, flowering time, leaf shape and/or shade avoidance response in a transgenic plant. Nucleic acid such as a vector as described herein may be used for the production of a transgenic plant. Such a plant may possess an altered phenotype, particular in terms of vernalization response, flowering time, leaf shape and/or shade avoidance response compared with wild-type (that is to say a plant that is wild-type for VRN2 or the relevant homologue thereof).

The invention further encompasses a host cell transformed with nucleic acid or a vector according to the present invention, especially a plant or a microbial cell. Thus, a host cell, such as a plant cell, including heterologous nucleic acid according to the present invention is provided. Within the cell, the nucleic acid may be incorporated within the chromosome. There may be more than one heterologous nucleotide sequence per haploid genome.

Also according to the invention there is provided a plant cell having incorporated into its genome nucleic acid, particularly heterologous nucleic acid, as provided by the present invention, under operative control of a regulatory sequence for control of expression. The coding sequence may be operably linked to one or more regulatory sequences which may

be heterologous or foreign to the gene, such as not naturally associated with the gene for its expression. The nucleic acid according to the invention may be placed under the control of an externally inducible gene promoter to place expression
5 under the control of the user.

A suitable inducible promoter is the GST-II-27 gene promoter which has been shown to be induced by certain chemical compounds which can be applied to growing plants. The
10 promoter is functional in both monocotyledons and dicotyledons. It can therefore be used to control gene expression in a variety of genetically modified plants, including field crops such as canola, sunflower, tobacco, sugarbeet, cotton; cereals such as wheat, barley, rice, maize,
15 sorghum; fruit such as tomatoes, mangoes, peaches, apples, pears, strawberries, bananas, and melons; and vegetables such as carrot, lettuce, cabbage and onion. The GST-II-27 promoter is also suitable for use in a variety of tissues, including roots, leaves, stems and reproductive tissues.

A further aspect of the present invention provides a method of making such a plant cell involving introduction of nucleic acid or a suitable vector including the sequence of nucleotides into a plant cell and causing or allowing
20 recombination between the vector and the plant cell genome to introduce the sequence of nucleotides into the genome. The invention extends to plant cells containing nucleic acid according to the invention as a result of introduction of the nucleic acid into an ancestor cell.

The term "heterologous" may be used to indicate that the gene/sequence of nucleotides in question have been introduced into said cells of the plant or an ancestor thereof, using genetic engineering, ie by human intervention. A transgenic
35 plant cell, i.e. transgenic for the nucleic acid in question, may be provided. The transgene may be on an extra-genomic vector or incorporated, preferably stably, into the genome. A heterologous gene may replace an endogenous equivalent gene,

ie one which normally performs the same or a similar function, or the inserted sequence may be additional to the endogenous gene or other sequence. An advantage of introduction of a heterologous gene is the ability to place expression of a sequence under the control of a promoter of choice, in order to be able to influence expression according to preference. Furthermore, mutants, variants and derivatives of the wild-type gene, e.g. with higher or lower activity than wild-type, may be used in place of the endogenous gene. Nucleic acid heterologous, or exogenous or foreign, to a plant cell may be non-naturally occurring in cells of that type, variety or species. Thus, nucleic acid may include a coding sequence of or derived from a particular type of plant cell or species or variety of plant, placed within the context of a plant cell of a different type or species or variety of plant. A further possibility is for a nucleic acid sequence to be placed within a cell in which it or a homologue is found naturally, but wherein the nucleic acid sequence is linked and/or adjacent to nucleic acid which does not occur naturally within the cell, or cells of that type or species or variety of plant, such as operably linked to one or more regulatory sequences, such as a promoter sequence, for control of expression. A sequence within a plant or other host cell may be identifiably heterologous, exogenous or foreign.

Plants which include a plant cell according to the invention are also provided, along with any part or propagule thereof, seed, selfed or hybrid progeny and descendants. A plant according to the present invention may be one which does not breed true in one or more properties. Plant varieties may be excluded, particularly registrable plant varieties according to Plant Breeders' Rights. It is noted that a plant need not be considered a "plant variety" simply because it contains stably within its genome a transgene, introduced into a cell of the plant or an ancestor thereof.

In addition to a plant, the present invention provides any clone of such a plant, seed, selfed or hybrid progeny and

descendants, and any part of any of these, such as cuttings, seed. The invention provides any plant propagule, that is any part which may be used in reproduction or propagation, sexual or asexual, including cuttings, seed and so on. Also

5 encompassed by the invention is a plant which is a sexually or asexually propagated off-spring, clone or descendant of such a plant, or any part or propagule of said plant, off-spring, clone or descendant.

10 The invention further provides a method of influencing or affecting a physical characteristic of a plant, particularly vernalization response, flowering time, leaf shape and/or shade avoidance response, including causing or allowing expression of a heterologous nucleic acid sequence as
15 discussed within cells of the plant.

The invention further provides a method of inducing expression from nucleic acid encoding a VRN2 polypeptide, or a mutant, variant, allele or derivative of the sequence, or a homologue,
20 according to the disclosure herein, within cells of a plant (thereby producing the encoded polypeptide), following an earlier step of introduction of the nucleic acid into a cell of the plant or an ancestor thereof. Such a method may influence or affect a characteristic of the plant, such as
25 vernalization response, flowering time, leaf shape and/or shade avoidance response. This may be used in combination with any other gene, such as transgenes involved in flowering (e.g. *FCA*) or other phenotypic trait or desirable property.

30 The present invention also encompasses the expression product of any of the nucleic acid sequences disclosed and methods of making the expression product by expression from encoding nucleic acid therefore under suitable conditions, which may be in suitable host cells. Following expression, the product may
35 be isolated from the expression system and may be used as desired, for instance in formulation of a composition including at least one additional component.

The present invention also provides for the production and use of fragments of the full-length polypeptides disclosed herein, especially active portions thereof. An "active portion" of a polypeptide means a peptide which is less than said full
5 length polypeptide, but which retains an essential biological activity. In particular, the active portion retains the ability to alter vernalization response, flowering time, leaf shape and/or shade avoidance response in a plant, such as *Arabidopsis thaliana*.

10 A "fragment" of a polypeptide means a stretch of amino acid residues of at least about five to seven contiguous amino acids, often at least about seven to nine contiguous amino acids, typically at least about nine to 13 contiguous amino
15 acids and, most preferably, at least about 20 to 30 or more contiguous amino acids. Fragments of the polypeptides may include one or more epitopes useful for raising antibodies to a portion of any of the amino acid sequences disclosed herein. Preferred epitopes are those to which antibodies are able to
20 bind specifically, which may be taken to be binding a polypeptide or fragment thereof of the invention with an affinity which is at least about 1000x that of other polypeptides.

25 Among preferred VRN2 fragments according to the present invention are the zinc finger domain, DNA binding domain and other domains disclosed herein.

Purified protein according to the present invention, or a
30 fragment, mutant, derivative or variant thereof, e.g. produced recombinantly by expression from encoding nucleic acid therefor, may be used to raise antibodies employing techniques which are standard in the art. Antibodies and polypeptides comprising antigen-binding fragments of antibodies may be used
35 in identifying homologues from other species as discussed further below, also in identifying complexes containing VRN2 protein.

Methods of producing antibodies include immunising a mammal (e.g. human, mouse, rat, rabbit, horse, goat, sheep or monkey) with the protein or a fragment thereof. Antibodies may be obtained from immunised animals using any of a variety of techniques known in the art, and might be screened, preferably using binding of antibody to antigen of interest. For instance, Western blotting techniques or immunoprecipitation may be used (Armitage et al, 1992, Nature 357: 80-82).

Antibodies may be polyclonal or monoclonal.

As an alternative or supplement to immunising a mammal, antibodies with appropriate binding specificity may be obtained from a recombinantly produced library of expressed immunoglobulin variable domains, e.g. using lambda bacteriophage or filamentous bacteriophage which display functional immunoglobulin binding domains on their surfaces; for instance see WO92/01047.

Antibodies raised to a polypeptide or peptide can be used in the identification and/or isolation of homologous polypeptides, and then the encoding genes. Thus, the present invention provides a method of identifying or isolating a polypeptide with the desired function (in accordance with embodiments disclosed herein), comprising screening candidate polypeptides with a polypeptide comprising the antigen-binding domain of an antibody (for example whole antibody or a suitable fragment thereof, e.g. scFv, Fab) which is able to bind a polypeptide or fragment, variant or derivative thereof according to the present invention or preferably has binding specificity for such a polypeptide. Specific binding members such as antibodies and polypeptides comprising antigen binding domains of antibodies that bind and are preferably specific for a polypeptide or mutant, variant or derivative thereof according to the invention represent further aspects of the present invention, particularly in isolated and/or purified form, as do their use and methods which employ them.

Candidate polypeptides for screening may for instance be the products of an expression library created using nucleic acid derived from an plant of interest, or may be the product of a purification process from a natural source. A polypeptide
5 found to bind the antibody may be isolated and then may be subject to amino acid sequencing. Any suitable technique may be used to sequence the polypeptide either wholly or partially (for instance a fragment of the polypeptide may be sequenced). Amino acid sequence information may be used in obtaining
10 nucleic acid encoding the polypeptide, for instance by designing one or more oligonucleotides (e.g. a degenerate pool of oligonucleotides) for use as probes or primers in hybridization to candidate nucleic acid, or by searching computer sequence databases, as discussed further below.

15 A further aspect of the present invention provides a method of identifying and cloning *VRN2* homologues from plant species other than *Arabidopsis thaliana* which method employs a nucleotide sequence derived from that shown herein. As
20 discussed above, sequences derived from these may themselves be used in identifying and in cloning other sequences. The nucleotide sequence information provided herein, or any part thereof, may be used in a data-base search to find homologous sequences, expression products of which can be tested for
25 ability to influence a plant characteristic. These may have ability to alter vernalization response, flowering time, leaf shape and/or shade avoidance response in a plant. Alternatively, nucleic acid libraries may be screened using techniques well known to those skilled in the art and
30 homologous sequences thereby identified then tested.

The present invention also extends to nucleic acid encoding a *VRN2* homologue obtained using a nucleotide sequence derived from any of those shown herein.

35 In certain embodiments, nucleic acid according to the present invention encodes a polypeptide which has homology with all or part of *VRN2* amino acid sequence shown herein, in the terms

discussed already above (e.g. for length), which homology is greater over the length of the relevant part (i.e. fragment) than the homology shared between a respective part of the VRN2 amino acid sequence of *Arabidopsis thaliana*, and the other

5 sequences shown in Figure 8a or Figure 8b, and may be greater than about 5% greater, more preferably greater than about 10% greater, more preferably greater than about 20% greater, and more preferably greater than about 30% greater. Thus, to exemplify with reference to one embodiment, nucleic acid
10 encoding an amino acid mutant, variant or derivative of the amino acid sequence shown in SEQ ID NO: 2 may be provided wherein the encoded amino acid sequence includes a contiguous sequence of about 100 amino acids which has greater homology with a contiguous sequence of 100 amino acids within the amino
15 acid sequence of SEQ ID NO: 2 than any contiguous sequence of 100 amino acids within another sequence shown in Figure 8a or 8b, preferably greater than about 5% greater homology, and so on.

20 Similarly, nucleic acid according to certain embodiments of the present invention may have homology with all or part of a nucleotide sequence shown herein, in the terms discussed already above (e.g. for length), which homology is greater over the length of the relevant part (i.e. fragment) than the
25 homology shared with a respective part of the natural coding nucleotide sequence for the other amino acid sequences shown in Figure 8a or 8b and referenced herein, and may be greater than about 5% greater, more preferably greater than about 10% greater, more preferably greater than about 20% greater, and
30 more preferably greater than about 30% greater.

The provision of sequence information for the VRN2 gene of *Arabidopsis thaliana* enables the obtention of homologous sequences from other plant species. In particular,

35 homologues may be easily isolated from related, commercially important species that have a vernalization requirement, or show some response to vernalization. These would include all members of the Brassicaceae, and other dicots including

tobacco, sugarbeet, peas and celery. Monocots included in this category are the cereals rice, wheat and barley.

Thus, included within the scope of the present invention are
5 nucleic acid molecules which encode amino acid sequences which are homologues of *VRN2* of *Arabidopsis thaliana*. Homology may be at the nucleotide sequence and/or amino acid sequence level, as has already been discussed above. A homologue from a species other than *Arabidopsis thaliana* encodes a product
10 which causes a phenotype similar to that caused by the *VRN2* gene, generally including ability to alter vernalization response, flowering time, leaf shape and/or shade avoidance response in a plant, such as in *Arabidopsis thaliana*. In addition, mutants, derivatives or alleles of these genes may
15 have altered, e.g. increased or decreased, activity or ability compared with wild-type.

VRN2 gene homologues may also be identified from economically important monocotyledonous crop plants including the cereals
20 rice, wheat and barley. Although genes encoding the same protein in monocotyledonous and dicotyledonous plants show relatively little homology at the nucleotide level, amino acid sequences are conserved. Therefore it is possible to use public sequence databases to identify *Arabidopsis*, rice or
25 maize cDNA clone sequences that were obtained in random sequencing programmes and share homology to the gene of interest, as has been done for other genes isolated from *Arabidopsis* (e.g. CO; WO 96/14414). Of course, mutants, derivatives and alleles of these sequences are included within
30 the scope of the present invention in the same terms as discussed above for the *Arabidopsis thaliana VRN2* gene.

According to a further aspect, the present invention provides a method of identifying or a method of cloning a *VRN2*
35 homologue, e.g. from a species other than *Arabidopsis thaliana* the method employing a nucleotide sequence derived from any of those shown herein. For instance, such a method may employ an

oligonucleotide or oligonucleotides which comprises or consists of a sequence or sequences conserved between or encoding a sequence or sequences conserved between the sequences shown in Figure 8a or 8b, or a sequence or sequences conserved between the sequences of SEQ ID NO: 2 and SEQ ID NO: 5, or encoding sequences SEQ ID NO: 1 and SEQ ID NO: 4, to search for homologues. Thus, a method of obtaining nucleic acid is provided, comprising hybridisation of an oligonucleotide or a nucleic acid molecule comprising such an oligonucleotide to target/candidate nucleic acid. Target or candidate nucleic acid may, for example, comprise a genomic or cDNA library obtainable from an organism known to contain or suspected of containing such nucleic acid, either monocotyledonous or dicotyledonous. Successful hybridisation may be identified and target/candidate nucleic acid isolated for further investigation and/or use.

Hybridisation may involve probing nucleic acid and identifying positive hybridisation under suitably stringent conditions (in accordance with known techniques) and/or use of oligonucleotides as primers in a method of nucleic acid amplification, such as PCR. For probing, preferred conditions are those which are stringent enough for there to be a simple pattern with a small number of hybridisations identified as positive which can be investigated further. It is well known in the art to increase stringency of hybridisation gradually until only a few positive clones remain.

For instance, screening may initially be carried out under conditions, which comprise a temperature of about 37°C or more, a formamide concentration of less than about 50%, and a moderate to low salt (e.g. Standard Saline Citrate ('SSC') = 0.15 M sodium chloride; 0.15 M sodium citrate; pH 7) concentration.

Alternatively, a temperature of about 50°C or more and a high salt (e.g. 'SSPE' = 0.180 M sodium chloride; 9 mM disodium hydrogen phosphate; 9 mM sodium dihydrogen phosphate; 1 mM

sodium EDTA; pH 7.4). Preferably the screening is carried out at about 37°C, a formamide concentration of about 20%, and a salt concentration of about 5 X SSC, or a temperature of about 50°C and a salt concentration of about 2 X SSPE. These

5 conditions will allow the identification of sequences which have a substantial degree of homology (similarity, identity) with the probe sequence, without requiring the perfect homology for the identification of a stable hybrid.

10 Suitable conditions include, e.g. for detection of sequences that are about 80-90% identical, hybridization overnight at 42°C in 0.25M Na₂HPO₄, pH 7.2, 6.5% SDS, 10% dextran sulfate and a final wash at 55°C in 0.1X SSC, 0.1% SDS. For detection of sequences that are greater than about 90% identical,
15 suitable conditions include hybridization overnight at 65°C in 0.25M Na₂HPO₄, pH 7.2, 6.5% SDS, 10% dextran sulfate and a final wash at 60°C in 0.1X SSC, 0.1% SDS.

An alternative is a solution of 5x SSPE (final 0.9 M NaCl, 20 0.05M sodium phosphate, 0.005M ethylenediaminetetraacetic acid (EDTA) pH 7.7), 5X Denhardt's solution, 0.5% SDS (sodium dodecyl sulphate), at 65°C overnight, (for high stringency, highly similar sequences) or 50°C (for low stringency, less similar sequences). Washes in 0.2x SSC/0.1% SDS at 65°C for
25 high stringency, alternatively at 50-60°C in 1x SSC/0.1%SDS for low stringency.

The present invention extends to nucleic acid selectively hybridisable under high stringency with nucleic acid
30 identified herein.

As an alternative to probing, though still employing nucleic acid hybridisation, oligonucleotides designed to amplify DNA sequences may be used in PCR reactions or other methods
35 involving amplification of nucleic acid, using routine procedures. See for instance "PCR protocols; A Guide to Methods and Applications", Eds. Innis et al, 1990, Academic Press, New York.

Preferred amino acid sequences suitable for use in the design of probes or PCR primers for some purposes are sequences conserved (completely, substantially or partly) between the VRN2 sequence and at least one other of the sequences shown in

5 Figure 8a or 8b.

Preferred primers for amplification of conserved regions of VRN2 for use as probes to obtain genomic or cDNA clones may include the following:

10

Primers VRN2-AI and VRN2-AJ which, in RT-PCR, amplify a 1583 bp fragment that contains the complete VRN2 open reading frame, and portions of both the 5' and 3' untranslated sequences;

15

Primers VRN2-AP and VRN2-AJ which, in RT-PCR, amplify a 781 bp fragment that includes the conserved acidic region;

20

Primers VRN2-AO and VRN2-AS which, in RT-PCR, amplify a 493 bp fragment that includes the zinc-finger motif, and the second nuclear localization signal (NLS); and

25

Primers VRN2-AI and VRN2-AJ from genomic DNA, which amplify a 3605 bp product that includes most of the VRN2 gene, except the promoter and 3' regions (i.e. encompasses the same regions as the VRN2-AI/AJ pair above, but with the introns, useful for hybridisation to genomic DNA, less so for cDNA).

30

On the basis of amino acid sequence information oligonucleotide probes or primers may be designed, taking into account the degeneracy of the genetic code, and, where appropriate, codon usage of the organism from which the candidate nucleic acid is derived.

35

Preferably an oligonucleotide in accordance with certain embodiments of the invention, e.g. for use in nucleic acid amplification, is up to about 50 nucleotides, or about 40

nucleotides or about 30 or fewer nucleotides in length (e.g. 18, 21 or 24).

Assessment of whether or not such a PCR product corresponds to a homologue gene may be conducted in various ways. A PCR band from such a reaction might contain a complex mix of products. Individual products may be cloned and each one individually screened. It may be analysed by transformation to assess function on introduction into a plant of interest.

As noted, nucleic acid according to the present invention is obtainable using oligonucleotides, designed on the basis of sequence information provided herein, as probes or primers. Nucleic acid isolated and/or purified from one or more cells of a plant (see above), or a nucleic acid library derived from nucleic acid isolated and/or purified from the plant (e.g. a cDNA library derived from mRNA isolated from the plant), may be probed under conditions for selective hybridisation and/or subjected to a specific nucleic acid amplification reaction such as the polymerase chain reaction (PCR). The nucleic acid probed or used as template in the amplification reaction may be genomic DNA, cDNA or RNA. If necessary, one or more gene fragments may be ligated to generate a full-length coding sequence.

PCR primers derived from the VRN2 sequences disclosed herein may readily be tested for their specificity for amplifying nucleic acid according to the present invention, using both genomic DNA and RT-PCR templates. Cloning and subsequent sequencing of PCR products may be used to indicate amplification of the expected derived gene fragment. Full length cDNA clones can be obtained as described by 5' and 3' RACE technology if RT-PCR products are used as templates.

Various aspects of the present invention include the obtainable nucleic acid, methods of screening material, e.g. cell lysate, nucleic acid preparations, for the presence of

nucleic acid of interest, methods of obtaining the nucleic acid, and suitable primers and primer combinations.

The sequence information provided herein also allows the
5 design of diagnostic tests for determination of the presence
of a specific gene or allele thereof in any given plant,
cultivar, variety, population, landrace, part of a family or
other selection in a breeding programme or other such
genotype. A diagnostic test may be based on determination of
10 the presence or absence of a particular allele by means of
nucleic acid or polypeptide determination.

At the nucleic acid level, this may involve hybridisation of a
suitable oligo- or poly-nucleotide, such as a fragment of the
15 gene or a homologue thereof, including any homologue disclosed
herein, or any particular allele, such as an allele which
gives a desirable phenotype, such as any such allele disclosed
herein. The hybridisation may involve PCR designed to amplify
a product from a given allelic version of the gene, with
20 subsequent detection of an amplified product by any of a
number of possible methods including but not limited to gel
electrophoresis, capillary electrophoresis, direct
hybridisation of nucleotide sequence probes and so on. A
diagnostic test may be based on PCR designed to amplify
25 various alleles or any allele from the relevant locus, with a
test to distinguish the different possible alleles by any of a
number of possible methods, including DNA fragment size,
restriction site variation (e.g. CAPS - cleaved amplified
polymorphic sites) and so on. A diagnostic test may also be
30 based on a great number of possible variants of nucleic acid
analysis that will be apparent to those skilled in the art,
such as use of a synthetic sequence as a hybridisation probe.

Broadly, the methods divide into those screening for the
35 presence of nucleic acid sequences and those that rely on
detecting the presence or absence of a polypeptide. The
methods may make use of biological samples from one or more

plants or cells that are suspected to contain the nucleic acid sequences or polypeptide.

Exemplary approaches for detecting nucleic acid or
5 polypeptides include analysing a sample from the plant or plant cell by:

(a) comparing the sequence of nucleic acid in the sample with
all or part of a nucleotide sequence shown herein, to
10 determine whether the sample contains a mutation;

(b) determining the presence in the sample of a polypeptide
including a VRN2 amino acid sequence shown herein, or a
fragment thereof and, if present, determining whether the
15 polypeptide is full length, and/or is mutated, and/or is expressed at the normal level;

(c) performing DNA fingerprinting to compare the restriction
pattern produced when a restriction enzyme cuts nucleic acid
20 in the sample with the restriction pattern obtained from a nucleotide sequence shown herein, or from a known mutant, allele or variant thereof;

(d) contacting the sample with a specific binding member
25 capable of binding to nucleic acid including the nucleotide sequence as set out herein, or a fragment thereof, or a mutant, allele or variant thereof, the specific binding member including nucleic acid hybridisable with a VRN2 sequence
herein, or a polypeptide including a binding domain with
30 specificity for nucleic acid including a VRN2 sequence or polypeptide encoded by it, or a mutated form thereof, and determining binding of the specific binding member;

(e) performing PCR involving one or more primers based on a
35 nucleotide sequence shown herein to screen the sample for nucleic acid including the nucleotide sequence of SEQ ID NO: 1 or SEQ ID NO: 4 or a mutant, allele or variant thereof.

When screening for a *VRN2* allele nucleic acid, the nucleic acid in the sample will initially be amplified, e.g. using PCR, to increase the amount of the analyte as compared to other sequences present in the sample. This allows the target sequences to be detected with a high degree of sensitivity if they are present in the sample. This initial step may be avoided by using highly sensitive array techniques that are becoming increasingly important in the art.

- 10 A variant form of the gene may contain one or more insertions, deletions, substitutions and/or additions of one or more nucleotides compared with the wild-type sequence which may or may not disrupt or alter the gene function. Differences at the nucleic acid level are not necessarily reflected by a difference in the amino acid sequence of the encoded polypeptide. However, a mutation or other difference in a gene may result in a frame-shift or stop codon, which could seriously affect the nature of the polypeptide produced (if any), or a point mutation or gross mutational change to the encoded polypeptide, including insertion, deletion, substitution and/or addition of one or more amino acids or regions in the polypeptide. A mutation in a promoter sequence or other regulatory region may prevent or reduce expression from the gene or affect the processing or stability of the mRNA transcript.

Tests may be carried out on preparations containing genomic DNA, cDNA and/or mRNA. Testing cDNA or mRNA has the advantage of the complexity of the nucleic acid being reduced by the absence of intron sequences, but the possible disadvantage of extra time and effort being required in making the preparations. RNA is more difficult to manipulate than DNA because of the wide-spread occurrence of RN'ases.

- 35 Nucleic acid in a test sample may be sequenced and the sequence compared with a sequence shown herein to determine whether or not a difference is present. If so, the difference can be compared with known alleles to determine whether the

test nucleic acid contains one or more of the variations indicated, or the difference can be investigated for association with a desired phenotype.

- 5 The amplified nucleic acid may then be sequenced as above, and/or tested in any other way to determine the presence or absence of a particular feature. Nucleic acid for testing may be prepared from nucleic acid removed from cells or in a library using a variety of other techniques such as
10 restriction enzyme digest and electrophoresis.

15 Nucleic acid may be screened using a variant- or allele-specific probe. Such a probe corresponds in sequence to a region of the gene, or its complement, containing a sequence alteration known to be associated with alteration of ability to affect vernalization response, flowering time, leaf shape and/or shade avoidance response. Under suitably stringent conditions, specific hybridisation of such a probe to test nucleic acid is indicative of the presence of the sequence
20 alteration in the test nucleic acid. For efficient screening purposes, more than one probe may be used on the same test sample.

25 Allele- or variant-specific oligonucleotides may similarly be used in PCR to specifically amplify particular sequences if present in a test sample. Assessment of whether a PCR band contains a gene variant may be carried out in a number of ways familiar to those skilled in the art. The PCR product may for instance be treated in a way that enables one to display the
30 mutation or polymorphism on a denaturing polyacrylamide DNA sequencing gel, with specific bands that are linked to the gene variants being selected.

35 An alternative or supplement to looking for the presence of variant sequences in a test sample is to look for the presence of the normal sequence, e.g. using a suitably specific oligonucleotide probe or primer.

Approaches which rely on hybridisation between a probe and test nucleic acid and subsequent detection of a mismatch may be employed. Under appropriate conditions (temperature, pH etc.), an oligonucleotide probe will hybridise with a sequence which is not entirely complementary. The degree of base-pairing between the two molecules will be sufficient for them to anneal despite a mis-match. Various approaches are well known in the art for detecting the presence of a mis-match between two annealing nucleic acid molecules.

For instance, RN'ase A cleaves at the site of a mis-match. Cleavage can be detected by electrophoresing test nucleic acid to which the relevant probe or probe has annealed and looking for smaller molecules (i.e. molecules with higher electrophoretic mobility) than the full length probe/test hybrid. Other approaches rely on the use of enzymes such as resolvases or endonucleases.

Thus, an oligonucleotide probe that has the sequence of a region of the normal gene (either sense or anti-sense strand) in which mutations associated with particular phenotypes are known to occur may be annealed to test nucleic acid and the presence or absence of a mis-match determined. Detection of the presence of a mis-match may indicate the presence in the test nucleic acid of a mutation. On the other hand, an oligonucleotide probe that has the sequence of a region of the gene including a mutation may be annealed to test nucleic acid and the presence or absence of a mis-match determined. The presence of a mis-match may indicate that the nucleic acid in the test sample has the normal sequence, or a different mutant or allele sequence. In either case, a battery of probes to different regions of the gene may be employed.

The presence of differences in sequence of nucleic acid molecules may be detected by means of restriction enzyme digestion, such as in a method of DNA fingerprinting where the restriction pattern produced when one or more restriction enzymes are used to cut a sample of nucleic acid is compared

with the pattern obtained when a sample containing the normal gene or a variant or allele is digested with the same enzyme or enzymes.

- 5 The presence of absence of a lesion in a promoter or other regulatory sequence may also be assessed by determining the level of mRNA production by transcription or the level of polypeptide production by translation from the mRNA.
- 10 Nucleic acid isolated and/or purified from one or more cells of a plant or a nucleic acid library derived from nucleic acid isolated and/or purified from cells (e.g. a cDNA library derived from mRNA isolated from the cells), may be probed under conditions for selective hybridisation and/or subjected to a specific nucleic acid amplification reaction such as the polymerase chain reaction (PCR).

A method may include hybridisation of one or more (e.g. two) probes or primers to target nucleic acid. Where the nucleic acid is double-stranded DNA, hybridisation will generally be preceded by denaturation to produce single-stranded DNA. The hybridisation may be as part of a PCR procedure, or as part of a probing procedure not involving PCR. An example procedure would be a combination of PCR and low stringency hybridisation. A screening procedure, chosen from the many available to those skilled in the art, is used to identify successful hybridisation events and isolate hybridised nucleic acid.

- 30 Binding of a probe to target nucleic acid (e.g. DNA) may be measured using any of a variety of techniques at the disposal of those skilled in the art. For instance, probes may be radioactively, fluorescently or enzymatically labelled. Other methods not employing labelling of probe include examination of restriction fragment length polymorphisms, amplification using PCR, RNAase cleavage and allele specific oligonucleotide probing.

Probing may employ the standard Southern blotting technique. For instance DNA may be extracted from cells and digested with different restriction enzymes. Restriction fragments may then be separated by electrophoresis on an agarose gel, before

5 denaturation and transfer to a nitrocellulose filter.

Labelled probe may be hybridised to the DNA fragments on the filter and binding determined. DNA for probing may be prepared from RNA preparations from cells.

10 Preliminary experiments may be performed by hybridising under low stringency conditions various probes to Southern blots of DNA digested with restriction enzymes. Suitable conditions would be achieved when a large number of hybridising fragments were obtained while the background hybridisation was low.

15 Using these conditions nucleic acid libraries, e.g. cDNA libraries representative of expressed sequences, may be searched.

20 As noted, those skilled in the art are well able to employ suitable conditions of the desired stringency for selective hybridisation, taking into account factors such as oligonucleotide length and base composition, temperature and so on.

25 In some preferred embodiments of diagnostic assays according to the present invention, oligonucleotides according to the present invention that are fragments of any of the sequences shown herein, or any allele associated with a desired phenotype are at least about 10 nucleotides in length, more
30 preferably at least about 15 nucleotides in length, more preferably at least about 20 nucleotides in length, more preferably about 30 nucleotides in length. Such fragments themselves individually represent aspects of the present invention. Fragments and other oligonucleotides may be used
35 as primers or probes as discussed but may also be generated (e.g. by PCR) in methods concerned with determining the presence in a test sample of a sequence indicative of a desired phenotype.

There are various methods for determining the presence or absence in a test sample of a particular polypeptide, such as a polypeptide including the amino acid sequence shown in SEQ ID NO: 2 or SEQ ID NO: 5, or an amino acid sequence mutant, variant or allele thereof.

A sample may be tested for the presence of a binding partner for a specific binding member such as an antibody (or mixture of antibodies), specific for one or more particular variants of a polypeptide shown herein.

In such cases, the sample may be tested by being contacted with a specific binding member such as an antibody under appropriate conditions for specific binding, before binding is determined, for instance using a reporter system as discussed. Where a panel of antibodies is used, different reporting labels may be employed for each antibody so that binding of each can be determined.

A specific binding member such as an antibody may be used to isolate and/or purify its binding partner polypeptide from a test sample, to allow for sequence and/or biochemical analysis of the polypeptide to determine whether it has the sequence and/or properties of the wild-type polypeptide or a particular mutant, variant or allele thereof. Amino acid sequence is routine in the art using automated sequencing machines.

The use of diagnostic tests for alleles allows the researcher or plant breeder to establish, with full confidence and independent from time consuming biochemical tests, whether or not a desired allele is present in the plant of interest (or a cell thereof), whether the plant is a representative of a collection of other genetically identical plants (e.g. an inbred variety or cultivar) or one individual in a sample of related (e.g. breeders' selection) or unrelated plants.

In a breeding scheme based on selection and selfing of desirable individuals, nucleic acid or polypeptide diagnostics for the desirable allele or alleles in high throughput, low cost assays as provided by this invention, reliable selection for the can be made at early generations and on more material than would otherwise be possible. This gain in reliability of selection plus the time saving by being able to test material earlier and without costly phenotype screening is of considerable value in plant breeding.

Nucleic acid-based determination of the presence or absence of one or more desirable alleles may be combined with determination of the genotype of the flanking linked genomic DNA and other unlinked genomic DNA using established sets of markers such as RFLPs, microsatellites or SSRs, AFLPs, RAPDs etc. This enables the researcher or plant breeder to select for not only the presence of the desirable allele but also for individual plant or families of plants which have the most desirable combinations of linked and unlinked genetic background. Such recombinations of desirable material may occur only rarely within a given segregating breeding population or backcross progeny. Direct assay of the locus as afforded by the present invention allows the researcher to make a stepwise approach to fixing (making homozygous) the desired combination of flanking markers and alleles, by first identifying individuals fixed for one flanking marker and then identifying progeny fixed on the other side of the locus all the time knowing with confidence that the desirable allele is still present.

The present disclosure provides sufficient information for a person skilled in the art to obtain genomic DNA sequence for any given new or existing allele and devise a suitable nucleic acid- and/or polypeptide-based diagnostic assay. In designing a nucleic acid assay account is taken of the distinctive variation in sequence that characterises the particular variant allele.

Nucleic acid according to the invention may include a nucleotide sequence encoding a product involved in vernalization response, flowering time, leaf shape and/or shade avoidance response. Reducing or increasing the level of expression may be used to manipulate such a characteristic in a plant. This may involve use of anti-sense or sense regulation, discussed further below.

Nucleic acid according to the invention, such as a VRN2 gene or homologue, may be placed under the control of an externally inducible gene promoter to place expression under the control of the user. An advantage of introduction of a heterologous gene into a plant cell, particularly when the cell is comprised in a plant, is the ability to place expression of the gene under the control of a promoter of choice, in order to be able to influence gene expression, and therefore vernalization response, flowering time, leaf shape, shade avoidance response, and/or other characteristic, according to preference. Furthermore, mutants and derivatives of the wild-type gene, e.g. with higher or lower activity than wild-type, may be used in place of the endogenous gene.

In the present invention, over-expression may be achieved by introduction of the nucleotide sequence in a sense orientation. Thus, the present invention provides a method of influencing a physical characteristic of a plant, the method including causing or allowing expression of the product (polypeptide or nucleic acid transcript) encoded by heterologous nucleic acid according to the invention from that nucleic acid within cells of the plant.

Down-regulation of expression of a target gene may be achieved using anti-sense technology or "sense regulation" ("co-suppression").

In using anti-sense genes or partial gene sequences to down-regulate gene expression, a nucleotide sequence is placed under the control of a promoter in a "reverse orientation"

such that transcription yields RNA which is complementary to normal mRNA transcribed from the "sense" strand of the target gene. See, for example, Rothstein et al, 1987; Smith et al, (1988) *Nature* 334, 724-726; Zhang et al, (1992) *The Plant Cell* 4, 1575-1588, English et al., (1996) *The Plant Cell* 8, 179-188. Antisense technology is also reviewed in Bourque, (1995), *Plant Science* 105, 125-149, and Flavell, (1994) *PNAS USA* 91, 3490-3496.

- 10 An alternative is to use a copy of all or part of the target gene inserted in sense, that is the same, orientation as the target gene, to achieve reduction in expression of the target gene by co-suppression. See, for example, van der Krol et al., (1990) *The Plant Cell* 2, 291-299; Napoli et al., (1990) *The Plant Cell* 2, 279-289; Zhang et al., (1992) *The Plant Cell* 4, 1575-1588, and US-A-5,231,020.

The complete sequence corresponding to the coding sequence (in reverse orientation for anti-sense) need not be used. For example fragments of sufficient length may be used. It is a routine matter for the person skilled in the art to screen fragments of various sizes and from various parts of the coding sequence to optimise the level of anti-sense inhibition. It may be advantageous to include the initiating methionine ATG codon, and perhaps one or more nucleotides upstream of the initiating codon. A further possibility is to target a conserved sequence of a gene, e.g. a sequence that is characteristic of one or more genes, such as a regulatory sequence.

30 The sequence employed may be about 500 nucleotides or less, possibly about 400 nucleotides, about 300 nucleotides, about 200 nucleotides, or about 100 nucleotides. It may be possible to use oligonucleotides of much shorter lengths, 14-23 nucleotides, although longer fragments, and generally even longer than about 500 nucleotides are preferable where possible, such as longer than about 600 nucleotides, than

about 700 nucleotides, than about 800 nucleotides, than about 1000 nucleotides or more.

It may be preferable that there is complete sequence identity in the sequence used for down-regulation of expression of a target sequence, and the target sequence, though total complementarity or similarity of sequence is not essential. One or more nucleotides may differ in the sequence used from the target gene. Thus, a sequence employed in a down-regulation of gene expression in accordance with the present invention may be a wild-type sequence (e.g. gene) selected from those available, or a mutant, derivative, variant or allele, by way of insertion, addition, deletion or substitution of one or more nucleotides, of such a sequence. The sequence need not include an open reading frame or specify an RNA that would be translatable. It may be preferred for there to be sufficient homology for the respective anti-sense and sense RNA molecules to hybridise. There may be down regulation of gene expression even where there is about 5%, 10%, 15% or 20% or more mismatch between the sequence used and the target gene.

Generally, the transcribed nucleic acid may represent a fragment of a gene, or the complement thereof, or may be a mutant, derivative, variant or allele thereof, in similar terms as discussed above in relation to alterations being made to a coding sequence and the homology of the altered sequence. The homology may be sufficient for the transcribed anti-sense RNA to hybridise with nucleic acid within cells of the plant, though irrespective of whether hybridisation takes place the desired effect is down-regulation of gene expression.

Thus, the present invention also provides a method of modifying, affecting, altering or modulating a characteristic of a plant, e.g. vernalization response, flowering time, leaf shape and/or shade avoidance response, the method including causing or allowing anti-sense transcription from heterologous

nucleic acid according to the invention within cells of the plant.

The present invention further provides the use of the
5 nucleotide sequence of VRN2, or a fragment, mutant,
derivative, allele, variant or homologue thereof for down-
regulation of gene expression, particularly down-regulation of
expression of a VRN2 gene or homologue thereof, preferably in
order to influence a physical characteristic of a plant,
.0 especially vernalization response, flowering time, leaf shape
and/or shade avoidance response.

When additional copies of the target gene are inserted in
sense, that is the same, orientation as the target gene, a
.5 range of phenotypes is produced which includes individuals
where over-expression occurs and some where under-expression
of protein from the target gene occurs. When the inserted
gene is only part of the endogenous gene the number of
under-expressing individuals in the transgenic population
10 increases. The mechanism by which sense regulation occurs,
particularly down-regulation, is not well-understood.
However, this technique is also well-reported in scientific
and patent literature and is used routinely for gene control.
See, for example, van der Krol et al., (1990) *The Plant Cell*
5 2, 291-229; Napoli et al., (1990) *The Plant Cell* 2, 279-289;
Zhang et al, 1992 *The Plant Cell* 4, 1575-1588.

Again, fragments, mutants and so on may be used in similar
terms as described above for use in anti-sense regulation.

30

Thus, the present invention also provides a method of
influencing a characteristic of a plant, e.g. vernalization
response, flowering time, leaf shape and/or shade avoidance
response, the method including causing or allowing expression
35 from nucleic acid according to the invention within cells of
the plant. This may be used to suppress activity of a product
with ability to influence vernalization response, flowering

time, leaf shape and/or shade avoidance response. Here the activity of the product is preferably suppressed as a result of under-expression within the plant cells.

5 Aspects and embodiments of the present invention will now be illustrated, by way of example, with reference to the accompanying figures. Further aspects and embodiments will be apparent to those skilled in the art. All documents mentioned in this text are incorporated herein by reference.

10

BRIEF DESCRIPTION OF THE FIGURES

Figure 1 shows total leaf number (Rosette plus Cauline) of *Ler* plants (squares), *fca-1* plants (diamonds) and *vrn2-1 fca-1* plants (circles) after various periods of vernalization (measured in days).

Figure 2 illustrates the Red Far-Red Light plant phenotype:

Figure 2A shows the area of the largest leaf of *Ler*, *fca-1* and *vrn2-1 fca-1* plants grown under white light (W) (open bars) or white light with supplementary FR light (W + FR) (shaded bars).

Figure 2B shows the rosette leaf number at bolting of plants treated as in the experiment of which results are shown in Figure 2A.

Figure 3 illustrates results of genetic and physical mapping of VRN2 in *Arabidopsis thaliana*.

Figure 4 illustrates cosmids and genes near VRN2 in the *Arabidopsis* genome.

Figure 5 illustrates the structure of the VRN2 gene of *Arabidopsis*, the 5K cDNA aberrant splicing, and the position and nature of the *vrn2-1* mutation. Exons are shown as open boxes. Untranslated regions are shown as shaded boxes. Introns are shown as lines.

Figure 6 shows the sequence of VRN2 cDNA, including coding sequence and predicted amino acid sequence of the encoded protein. Putative NLSs are boxed, the putative acidic activation domain is underlined. The putative zinc-finger motif is doubly underlined. The positions of introns are indicated with arrows. The position of the *vrn2-1* mutation is circled.

Figure 7 illustrates dCAPS Marker for the *vrn2-1* Mutation. A diagnostic derived CAPS (dCAPS) marker was designated for the *vrn2-1* mutation. This utilizes a primer (VRN2-AZ) that includes half of the recognition site for the XmnI restriction enzyme, the other half is supplied, specifically, by the sequence of the *vrn2-1* mutation. This results in a successful restriction digestion only when using PCR amplified genomic DNA from *vrn2-1* mutants as a template.

Figure 8 shows alignment of the *Arabidopsis* VRN2 amino acid sequence with similar proteins.

Figure 8A aligns the full-length VRN2 protein with four other proteins, using Clustal method with PAM250 residue weight table, performed on 17 January 1999 at 19:19 GMT.

Figure 8B aligns the zinc finger region, using Clustal method with PAM250 residue weight table, performed on 17 January 1999 at 19:25 GMT.

Abbreviations:

At *Arabidopsis thaliana*, Sc *Saccharomyces cerevisiae*, Sp

Schizosaccharomyces pombe, Ce *Caenorhabditis elegans*, Dm

Drosophila melanogaster, Hs *Homo sapiens*, Mm *Mus musculus*, Rn

Rattus norvegicus, Xm *Xiphophorus maculatus*.

LIST OF SEQUENCES

SEQ ID NO: \ \ SEQUENCE

5	1	Landsberg erecta VRN2 cDNA
	2	Landsberg erecta VRN2 amino acid
	3	Landsberg erecta VRN2 genomic
	4	Columbia VRN2 cDNA
	5	Columbia VRN2 amino acid
10	6	Columbia VRN2 genomic
	7	5K (Columbia, abberant splice) cDNA
	8	5K (Columbia, abberant splice) amino acid
	9	C72616 EST (modified) cDNA
	10	C72616 EST (modified) amino acid
15	11	AI163743 EST (modified) cDNA
	12	AI163743 EST (modified) amino acid
	13	At Hyp 2245035 (ATFCA7_4) (modified) cDNA
	14	At Hyp 2245035 (ATFCA7_4) (modified) amino acid
	15	KIAA0160 cDNA
20	16	KIAA0160 amino acid

Additional sequences included in the Figures:

	17	Landsberg erecta VRN2 zinc finger amino acid
25	18	At Di19 S51478 zinc finger 1 amino acid
	19	At Di19 S54178 zinc finger 2 amino acid
	20	At SUP U38946 zinc finger amino acid
	21	At Hyp 2191171 zinc finger amino acid
	22	At Hyp 3377806 zinc finger amino acid
30	23	Sc Pep7 91500 zinc finger amino acid
	24	Sc TFIIIA 730931 zinc finger amino acid
	25	Sp Hyp 1351713 zinc finger amino acid
	26	Ce Hyp 255942 zinc finger amino acid
	27	Ce Hyp 2854197 zinc finger amino acid
35	28	Ce Hyp 304459 zinc finger amino acid
	29	Dm BRCORE-NS-Z3 zinc finger amino acid
	30	Dm GAGA 729556 zinc finger amino acid
	31	Dm ken 3550814 zinc finger amino acid

- 32 Hs ATBF-1 976347 zinc finger amino acid
 33 Hs KIAA0160 zinc finger amino acid
 34 Hs ZNF142 3123312 zinc finger amino acid
 35 Mm FOG 2252814 zinc finger amino acid
 5 36 Mm Spalt 1296845 zinc finger amino acid
 37 Rn Roaz 2149792 zinc finger amino acid
 38 Xm ZF1 532083 zinc finger amino acid

EXAMPLE 1

- 10 *Characterisation and Cloning of VRN of Arabidopsis Thaliana and Mutant Alleles Thereof*

Isolation of vrn2 mutants

- 15 Two vrn2 mutant alleles (vrn2-1 and vrn2-2) were isolated by mutagenising fca-1 seeds with EMS as described by Chandler et al. (Plant J (1996) 10: 637-644). WO96/38560 (PCT/GB96/01332) discloses the sequence of fca and mutant alleles and their cloning and characterisation. The vrn2-1 fca-1 line used here
 20 has been backcrossed to fca-1 four times. For mapping purposes, the vrn2-1 allele was used (at the 2nd backcross).

Phenotypic Characterization

- 25 *Vernalization*

The vernalization response of vrn2 mutant plants was investigated by examining their flowering time in response to increasing durations of vernalization treatment.

- 30 Standard vernalization conditions were used, i.e. low light intensity $5 \mu\text{mol m}^{-2} \text{s}^{-1}$, 8 hr photoperiod, 5 ± 1 degree C, for varying periods (from between 1 and 42 days). Similar effects would be observed under continuous or no light, the
 35 temperature is more important.

In the absence of a vernalization treatment, *vrn2-1 fca-1* mutant plants showed a small but consistent delay in flowering compared to the parental (wild-type) *fca-1* controls (Figure 1: *vrn2-1* has a higher leaf number than *fca-1*, a reduced leaf number correlating with a transition from vegetative to reproductive (i.e. flowering) state). However, following vernalization, this difference was greatly magnified (Figure 1). The response exhibited by *vrn2-1 fca-1* plants was typically a 35% reduction in total leaf number after 6 weeks of vernalization, compared to 67% reduction of *fca-1* controls. The delay in flowering, both with and without a vernalization treatment, as measured by increased leaf number, was also observed if the days to flower i.e. the day at which the first floral bud was visible was used.

Red/Far-Red light perception

The response to vernalization in *Arabidopsis* has been positively correlated with the response to different ratios of Red(R) to Far-red(FR) light; mutants and ecotypes that respond strongly tend to respond strongly to conditions of low R:FR (Bagnall, Ann Bot (1993) 71: 75-83; Martinez-Zapater et al., Plant Physiol (1990) 92: 770-776). This response typically manifests itself in two distinct ways - an acceleration of flowering time (leading to an effect that mimics the effect of a vernalization treatment) and a reduction in leaf area (or shade avoidance). This response is believed to have evolved to allow plants to adapt to the availability of light allowing individuals to seek light when in competition with their neighbors.

We examined the ability of *vrn2-1 fca-1* mutants to respond to conditions that mimic such an environment.

Under these conditions, *vrn2-1 fca-1* plants showed a marked reduction in the shade avoidance response, with the mean area of the largest leaf decreasing by only 26%, compared to 74%

for the *fca-1* control (Figure 2A). However, the *vrn2-1* mutation does not appear to affect all aspects of the response to FR light, as *vrn2-1 fca-1* plants showed a similar acceleration of flowering in response to supplementary FR light as *fca-1* controls (Figure 2B).

These data provide indication that VRN2 plays a role in regulating the response to FR light, and may mediate changes specifically in leaf size (as flowering time is only slightly affected) under conditions of low R:FR ratios.

Genetic Mapping

The VRN2 gene was mapped in an F2 population derived from the cross *vrn2-1 fca-1* crossed to *fca-10*, following the procedure used to map the VRN1 gene (Chandler et al. supra.). The VRN2 gene was initially positioned using a population of 70 F2 individuals between the RFLP markers g13683 and mil12 (Schmidt et al., Plant J (1996) 9: 755-765) on the long arm of

Chromosome IV (or D), using conventional techniques. The map position of VRN2 was further refined by screening an additional 429 F2 plants with a SSLP derived from the marker g19247 (Schmidt et al., (1996) Plant J 9: 755-765) and the CAPS marker g4539 (Parker et al., Plant Cell (1998) 9: 1-17).

A total of 12 individual F2 plants that were recombinant between g19247 and g4539 were further analyzed with RFLP markers g13683 and CC36F6 (Bancroft et al., Weeds World 4ii:(1997)) and the CAPS marker C18 (Parker et al., supra.), and with two additional CAPS markers (VRN2RS, VRN2CD) generated using the published Columbia sequence (Bevan et al., Nature (1998) 391: 485-488)

(accession numbers Z97341 and Z97342) as a template. The VRN2 gene was localized to a 245 kb region defined at the centromeric (north) end by an RFLP detected with the cosmid CC36F6, and at the telomeric (south) end by the g4539 CAPS marker. This interval is defined by 3 recombinant individual

F2 plants; 1 recombinant between VRN2 and CC36F6, and 2 recombinants between g4539 and VRN2 (Figure 3).

Physical Mapping

5

The genetic interval defined by CC36F6 and g4539 is almost completely covered by the 3 BAC clones T1C7, I5D3 and T5O15. Cosmids derived from subclones of YAC EW16B10 in the binary vector 04541 (Bancroft *et al.*, *supra.*) (abbreviated as IB)

10 were positioned by end sequencing, and ordered relative to the published sequence of the Columbia ecotype in this region (Genbank accession numbers Z97341 and Z97342). We selected cosmids clones that extended from the complex RPP5 locus outwards to CC36F6 and g4539, reasoning that VRN2 was not
15 within the RPP5 locus, which is comprised of multiple repeats of RPP5-like genes in both Columbia and Landsberg ecotypes (Bevan *et al.*, *supra.*).

Additional Landsberg cosmids in the 04541 binary vector
20 covering the region not covered by the Columbia YAC subclone cosmids were identified by hybridization to the inserts from BACs T1C7 and T5O15, and aligned based on end sequencing, and compared to the published Columbia sequence (Bevan *et al.*, *supra.*) and to the sequence of the Landsberg ecotype in this
25 region. An almost complete cosmid contig was generated over this region.

Simultaneously with the isolation of cosmids, ordered cosmids, beginning with those at the centromeric end of the contig,
30 were transformed into *vrn2-1 fca-1* plants by *Agrobacterium tumefaciens*-mediated vacuum infiltration (Bechtold *et al.*, C R Acad Sci Paris (1993) 316: 1194-1199). (Figure 3). The presence of the cosmid in each transgenic line (T1 plants) was confirmed by a cosmid-specific diagnostic PCR, comprising an
35 insert specific primer (corresponding to a portion of the Columbia genomic DNA) and a primer present in the cosmid vector.

Cosmid Complementation

Cosmids introduced into *vrn2-1 fca-1* plants were tested for their ability to complement the *vrn2* phenotype. T2 seeds, from individual T1 plants segregating kanamycin resistance at a 3:1 ratio, were sown on soil and vernalized for two (in some experiments three) weeks. Plants were then transferred to greenhouse conditions, and after ten days pricked out into individual compartments of divided trays. Total leaf number was determined, and cosmids were scored as complementing if the segregation ratio of early to late plants (when compared to *fca-1* and *vrn2-1 fca-1* controls) plants was approximately 3:1.

Two Columbia cosmids (4A23, 2 out of 2 T1s; 6N1, 1 out of 1 T1) clearly complemented the phenotype of *vrn2-1 fca-1* mutants, with the earliest plants flowering at approximately the same time as vernalized *fca-1* plants.

Sequence Analysis and ORF Prediction

The sequence in common to both IB4A23 and IB6N1 cosmids has previously been annotated as containing 2 complete predicted genes (ATDL4445W and ATDL4450W) and (presumably non-functional) portions of two other genes - the 3' end of ATDL4440W and the 3' end of the RPP5-like gene, CHPR (ATDL4460W) (Bevan et al., supra.) Genbank accession number Z97342. In addition, a cognate cDNA (5K) not included in the annotation is present in this region, and appears to span two of the predicted genes (ATDL4445W and ATDL4450W) (Bevan et al., supra.). However, as two cosmids in the region (1 independent T1 line from each of cosmids IB4N6 and IB6C5) did not complement the mutant phenotype (Figure 4) this ruled out the predicted gene ATDL4445W. This left the unannotated cDNA 5K, and the predicted gene ATDL4450W as candidates for VRN2. However, the presence the cognate cDNA 5K from the Columbia ecotype that overlapped both ATDL4445W and ATDL4450W

necessitated a re-examination of the prediction for the ATDL4450W gene.

In order to define the structure of these genes, we used the
5 NetGene2 prediction program (Hebsgaard et al., Nucl Acids Res
(1998) 24: 3439-3452), using "Arabidopsis" as the organism
option (the only parameter that can be set manually). BLAST,
PSI-BLAST, PSORT and PROSITE programs were used to identify
potential function domains and similarities (Altschul et al.,
10 Nucleic Acids Res (1997) 25: 3389-3402; Bairoch et al., Nucl
Acids Res (1997) 25: 217-221; Nakai et al., Genomics (1992)
14: 897-911). Default parameters of TBLASTN, PSI-BLAST and
BLASTP were used (Expect = 10, BLOSUM62 matrix, gap penalty =
11, penalty per gap 1, lambda ratio 0.85). The NCBI/GenBank
15 database was used. The PSORT algorithm (Nakai) was used,
using the "plant" option as the source organism (the only
parameter that can be manually changed). The Profile Scan
program at PROSITE (Bairoch) was used to search for motifs in
VRN2, with default parameters (there are no parameters a user
20 can select, the results being "hit" or "no hit").

This analysis yielded predictions for two genes, 5K, a
putative nuclear localized protein that is highly
post-transcriptionally spliced (15 exons), represented by the
25 Columbia cognate cDNA; and a modified prediction for 4450,
with 6 putative membrane-spanning domains, represented at its
3' end by an Arabidopsis EST (accession number T22412).

30 Determination of the *vrn2-1* Mutation and Identification of the VRN2 gene

In an attempt to determine which gene (5K or 4450) is VRN2,
PCR primers were designed to amplify products encompassing the
entire predicted open reading frame of both genes.

35 Three independent RT-PCR reactions using total RNA prepared
from *fca-1, vrn2-1 fca-1* and *vrn2-2 fca-1* 14 day-old seedlings

grown on GM plates in continuous light were performed for each predicted gene with a high fidelity enzyme mix (Boehringer Mannheim, HiFi System). These PCR products were sequenced using both the primers used for PCR, and a series of internal
5 primers, using the BIGDYE kit (PE Applied Biosystems). The reactions were run on an ABI377 machine, and compiled using the SeqMan (DNASTar, Lasergene) program.

The sequences of the PCR confirmed our prediction for both
10 genes, and indicated that we had amplified across the entire open reading frame of 5K and ATDL4450W as anticipated.

Several minor polymorphic differences were detected between the published Columbia sequence, and the Landsberg erecta
15 sequence we amplified by PCR. These differences were consistent with the Landsberg erecta genomic sequence in this region. Furthermore, the Columbia cDNA for 5K appears to utilise a different splice donor site from that used in the Landsberg ecotype, and would produce a truncated, presumably
20 non-functional protein (Figure 5). However, we have also sequenced the Columbia 5K product derived independently by RT-PCR, and this appears to use the same splice site as Landsberg, and should encode a functional protein. A consistent difference between the *vrn2* mutants and *fca-1* was
25 detected in the 5K PCR product, a G to A change at position 1201 of the predicted cDNA in *vrn2-1 fca-1* (Figure 5). We are currently investigating the nature of the mutation in the *vrn2-2* allele. This type of mutation, a single base-pair change, is commonly observed following EMS mutagenesis. This
30 mutation converts a TGG codon (Tryptophan) to stop codon (TGA), and would result in the production of a truncated protein of 322 amino acids in the *vrn2-1* mutant, compared to 443 amino acids of wild type VRN2 (Figure 6). The presence of this mutation indicated that 5K was likely to be VRN2. The
35 presence of the *vrn2-1* mutation in the genome of *vrn2-1 fca-1* mutant plants was confirmed by a derived CAPS (dCAPS) (Michaels et al., Plant J (1998) 14: 381-385; Neff et al.,

Plant J (1998) 14: 387-392) marker specific for the *vrn2-1* mutation (Figure 7). This diagnostic test is specific for the *vrn2-1* mutation, as it detects wild type VRN2 in both *fca-1* and *vrn2-2 fca-1* mutants.

5

Analysis of the VRN2 gene

To gain an insight into the possible function of the VRN2 gene, and how the *vrn2-1* mutation may affect the function of the VRN2 protein, we compared the amino acid sequence of VRN2 to several databases of protein and translated nucleic acid sequences using BLASTP and TBLASTN programs at NCBI, using the default parameters as noted above.

Several molecules with a significant degree of similarity were identified (Table 1 and Table 2).

One such gene, represented by a human cDNA (KIAA0160) shares homology with VRN2 over a short region near the amino terminus of VRN2 (amino acids 63 to 132), and a longer, but less conserved region of homology towards the carboxy terminus (amino acids 263-366) (Figure 8a). Closer examination of the amino terminal conserved region revealed that it matches the consensus of a zinc-finger motif. Such motifs can take a variety of forms, but all co-ordinate zinc atoms through two cysteine residues, and two cysteine or histidine residues. VRN2 falls into the latter class, having a C2H2 motif comprised of two cysteines separated by 2 amino acids, and two histidines separated by two amino acids (Mackay et al., TIBS (1998) 23: 1-4).

Zinc-finger motifs are known to be capable of mediating both protein-DNA and protein-protein interactions. The zinc finger motif of VRN2 does not closely resemble the large EPF family of *Arabidopsis* C2H2 zinc fingers from *Arabidopsis*, which have a highly conserved QALGG motif in the middle of the zinc finger (Kubo et al., Nucl Acids Res (1998) 26: 608-615) (Figure

8b). In addition, VRN2 differs from the EPF proteins in that VRN2 has a single zinc finger motif, whereas most members of the EPF family (with the exception of SUP and AtZFP1) have between two and four zinc fingers (Kubo et al., supra.). This amino-terminal region (amino acids 63-132), and particularly the zinc-finger motif (amino acids 90-111) may thus represent a domain that mediates protein-protein or protein-DNA interactions.

10 The carboxy terminus of VRN2 (amino acids 263 to 366) is similar to several other candidate genes (Table 1 and Table 2). As mentioned above, there is limited homology to the human predicted protein KIAA0160. The molecule showing greatest homology to VRN2 is an EST sequence from poplar (Populus tremula L. x Populus tremuloides Michx (Accession Number AI163743) (Sterky et al., PNAS USA (1998) 95: 13330-13335) which has 52.8% identity over 127 amino acids (Table 1), as calculated with the BLASTP algorithm using default parameters (as noted above). VRN2 also shows significant similarity to a predicted Arabidopsis protein (ATFCA7_4, Accession Number 2245035) (Bevan et al., supra.), which is quite close to VRN2 on chromosome 4, only 30 kb away towards the centromere. A close examination of the sequence near this gene revealed that the prediction as annotated may be incorrect, as the use of a different splice site, resulting a different carboxy terminus to the protein, increases the degree of homology with VRN2. The similarity of these two Arabidopsis genes raises the possibility that VRN2 may be a member of a gene family in Arabidopsis, and their close position suggests that these genes may have arisen following a duplication. Arguing against this notion is the observation that these two genes, VRN2 and ATFCA7_4, are transcribed in opposite directions. A rice EST (C72616) also shares significant similarity with the carboxyl region of VRN2, suggesting that this region may form an evolutionarily conserved domain present in monocots and dicots.

This conserved carboxy region is predicted to be highly charged, as it is composed of a large number of acidic residues (D and E). This highly charged region is highly similar in the Poplar and rice ESTs (Table 2). Such acidic regions are found in a number of eukaryotic transcription factors, and often function as activation domains (Hahn, Cell (1993) 72: 481-483). It is therefore possible that VRN2 may function as a transcription factor, given it has both a DNA-binding motif (or protein binding) (amino acids 63-132) and a putative activation domain (amino acids 263-328). Furthermore, the amino portion of VRN2 contains two predicted nuclear localization signals (NLSS) (Figure 6). The first is a simple 4 residue basic signal, while the second is a bi-partite signal, that fits the consensus (R/K) (R/K) N10 (R/K) 4 (Dingwall et al., TIBS (1991) 16: 478-481).

EXAMPLE 2

Production and Characterisation of Arabidopsis Transgenic for VRN2

VRN2 cDNA in the sense orientation is cloned into plant expression vectors SLJ4D4 and SLJ4K1 (Jones et al., (1992) Transg. Res. 1, pp 285-297) according to the teaching of Sambrook J et al (1989) Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY. SLJ4D4 and SLJ4K1 place the VRN2 cDNA under the control of the Ca MV 35S promoter and include terminator sequences from octopine synthase (ocs) and nopaline synthase (nos) genes, respectively.

Antisense constructs are produced in the same manner except that the VRN2 cDNA is inserted into the expression vectors in the opposite orientation.

The VRN2 expression cassettes are then subcloned separately into the binary vector SLJ1714 (Jones et al., supra), and mobilised into *Agrobacterium* strains by tri-parental mating

according to the teaching of Hoekema et al., (1983) Nature 303, pp 179-180. *Arabidopsis* are transformed with the *Agrobacterium* strains carrying VRN2 expression constructs (either sense or antisense) following the teaching of Bechtold et al., (1993) C R Acad. Sci. Paris 316, pp 1194-1199.

Arabidopsis plants are assayed for changes in their response to changes in the ratio of far red light, essentially as described by Halliday et al., (1997) Plant J. 12, pp 1079-1090.

Results

Differences in vernalisation requirement and response are observed in *Arabidopsis* plants transgenic for VRN2 (sense or antisense orientation) relative to *Arabidopsis* plants transformed with empty vectors and non-transformed *Arabidopsis* plants.

EXAMPLE 3

Production and Characterisation of Tobacco Transgenic for VRN2

VRN2 cDNA in the sense orientation is cloned into plant expression vectors SLJ4D4 and SLJ4K1 as described in Example 2.

Antisense constructs are produced in the same manner except that the VRN2 cDNA is inserted into the expression vectors in the opposite orientation.

VRN2 expression cassettes subcloned separately into the binary vector SLJ1714 (Jones et al supra), are mobilised into *Agrobacterium* strains by tri-parental mating as in Example 2, and tobacco plants are transformed using the *Agrobacterium* strains carrying VRN2 expression constructs (either sense or

antisense) following the teaching of Horsch et al., (1985) Science 227, pp 1229-1231.

5 Tobacco plants are assayed for changes in their response to changes in the ratio of far red light, essentially as described by Halliday et al., (1997) Plant J. 12, pp 1079-1090.

Results

10

Differences in vernalisation requirement and response are observed in Tobacco plants transgenic for VRN2 (sense or antisense orientation) relative to Tobacco plants transformed with empty vectors and non-transformed Tobacco plants.

15

EXAMPLE 4

Production and Characterisation of Brassica (Oil Seed Rape, Winter Type) Transgenic for VRN2

20

Sense and antisense constructs are used to generate *Agrobacterium* strains carrying VRN2 expression constructs (either sense or antisense) as described in Example 2 and Example 3, and are used to transform oil seed rape following the teaching of Moloney et al., (1989) Plant Cell Rep. 8, pp

25

238-242.

Results

30

Differences in vernalisation requirement and response are observed in oil seed rape plants transgenic for VRN2 (sense or antisense orientation) relative to oil seed rape plants transformed with empty vectors and non-transformed oil seed rape plants.

35

EXAMPLE 5*Production and Characterisation of Rice Transgenic for VRN2*

VRN2 cDNA in the sense or antisense orientation is cloned into
5 constructs and used to generate respective *Agrobacterium*
strains. The *Agrobacterium* strains carrying VRN2 expression
constructs (either sense or antisense) are used to transform
rice following the teaching of Kohl A et al (1998) Proc.
Natl. Acad. Sci. USA 95, pp 7203-7208.

Results

Differences in vernalisation requirement and response are
observed in rice plants transgenic for VRN2 (sense or
15 antisense orientation) relative to rice plants transformed
with empty vectors and non-transformed rice plants.

EXAMPLE 6*Production and Characterisation of Wheat Transgenic for VRN2*

20 *Agrobacterium* strains carrying VRN2 expression constructs
(either sense or antisense) are generated as in preceding
Examples and are used to transform wheat following the
teaching of Becker D et al., (1994) Plant J. 5, pp 299-307.

Results

Differences in vernalisation requirement and response are
observed in wheat plants transgenic for VRN2 (sense or
30 antisense orientation) relative to wheat plants transformed
with empty vectors and non-transformed wheat plants.

METHODS AND MATERIALS**Plant Growth**

For vernalization treatments, seeds were sown on a damp layer

of fine grit (Levington's M3) on wet soil in individual pots, and vernalized for increasing durations at 4°C, 8hr light:16hr dark, 5 $\mu\text{mol m}^{-2} \text{sec}^{-1}$ light intensity. Seed sowing was staggered, with all plants removed from the vernalization conditions simultaneously. Following vernalization, plants were placed into a controlled environment chamber (Gallenkamp), 20°C, 16 hr light: 8hr dark 90 $\mu\text{mol m}^{-2} \text{sec}^{-1}$ light intensity. Plants receiving no vernalization treatment were stratified for 2 days under vernalization conditions, and grown for two days prior to transfer into the growth cabinet. Plants were grown for 10 days, and then pricked out into individual compartments of P40 trays. The flowering time, as measured by counting total leaf number (i.e. rosette and cauline leaves) was determined once the primary inflorescence had elongated sufficiently.

The phenotype of *vrn2-1 fca-1* plants was examined under different ratios of red to far-red (R:FR) light. Plants were stratified for 2 days, then grown for 10 days under continuous light, and then transferred to separate growth chambers with white light (W), R:FR ratio of 5.8, with or without supplementary FR light (W+FR), R:FR ratio 0.08. The number of rosette leaves was determined to measure flowering time, and the area of the largest leaf was used as an indicator of the shade-avoidance response.

Mapping

VRN2 was positioned on the long arm of Chromosome 4 (or D) through linkage to the RFLP marker m506 (Chang et al., Proc Natl Acad Sci USA (1988) 85: 6856-6860), in progeny of a cross between *vrn2-1 fca-1* (Ler background) and *fca-10* (Ws background). Further RFLP markers in this region (Liu et al., Plant J (1996) 10:733-736) were used to refine the position of VRN2. We used standard RFLP techniques, using 32P-labeled cosmid probes, and a PhosphorImager detection system. A Ler:Ws RFLP was detected when using EcoRI digested genomic DNA, and either g13683 or CC36F6 as probes. The g19247 marker is a SSLP marker (using the primers g19247F and g19247R, see

below), with Ler producing a PCR-amplified band of approximately 750 bp, while Ws produces a band of 862 bp. Fine mapping of VRN2 was performed using a series of PCR-derived markers, based on the Columbia genomic sequence in this region (Bevan et al., supra.). The VRN2CD marker was amplified with two primers, VRN2-C and VRN2-D, and digested with DdeI. This produces a CAPS marker, with Ler producing bands of (approximately) 480 bp, 290 bp and 190 bp, while Ws produces bands of (approximately) 330 bp, 290 bp and 150 bp. The VRN2RS marker is a dominant marker for Ws (i.e. Ler:Ws heterozygotes cannot be distinguished from Ws), produced by amplifying genomic DNA with VRN2-R and VRN2-S (see below), and digesting the product with *MboII*. This produces a single predominant band (and several much smaller unresolved bands) in Ler of approximately 400 bp, while Ws produces two bands, 400 bp and 300 bp.

Cosmid Isolation

Cosmids covering the region not covered by the subclones of EW16B10 YAC were identified through hybridization to BAC inserts derived from BACs T5015 and T1C7. BAC DNA was purified and the insert isolated following digestion with *NotI* and separation by pulsed field gel electrophoresis (PFGE) as described in (Bancroft et al., supra.). Purified BAC inserts were labeled with $\alpha^{32}\text{P}$ -dCTP by random primed labeling, and hybridized to arrayed grids of a Ler genomic cosmid library. Positively hybridizing cosmids were identified, and rescreened following restriction enzyme digestion, southern blotting and hybridized to the BAC insert probe used initially. Cosmids in the region of interest were selected, and genomic sequence was obtained from the ends of the insert using the BIGDYE cycle sequencing kit, and T3 and T7 primers, whose sequences flank the genomic DNA insert site. This sequence was aligned with that of the Columbia genomic sequence to accurately position the cosmids.

Complementation

Cosmids in the 04541 binary vector were mobilized into *Agrobacterium tumefaciens* (strain C58C1 Rif^R by tri-parental mating (Hoekema et al., Nature (1983) 303: 179-180). *vrn2-1*

5 *fca-1* plants were transformed with these *Agrobacterium* strains by vacuum infiltration (Bechtold et al, supra.). Transgenic T1 plants were selected on GM with Kanamycin (50 mg/mL), and transferred to soil when they had reached the 3-4 leaf stage. The presence of each cosmid in the transgenic lines was
10 confirmed using either a Ler/Col specific polymorphism (CAPS or SSLP marker) or more commonly, through the use of a specific diagnostic PCR reaction, using a primer present within the cosmid insert sequence and a primer present in the cosmid flanking the insert site. Transgenic plants were also
15 tested for the presence of the *fca-1* mutation, as the T0 plants should carry this mutation. Together, these two methods ensured that only *vrn2-1 fca-1* plants carrying the desired cosmids were analyzed further. We aimed to produced 5 to 6 independent T1 transformants for each cosmid, but for
20 some cosmids only a single line was produced. However, as complementation was observed before we had generated T1s for all of the cosmids, we are continuing to produce additional transgenic T1 plants carrying the cosmids near VRN2. T1 plants were grown in a controlled environment chamber
25 (conditions as above), and allowed to self. T2 seed were collected, and analyzed for the segregation of Kanamycin resistance or sensitivity on GM plates containing Kanamycin (as above), scored 14-20 days after germination. Progeny from T1 plants that segregated a 3:1 ratio of resistant to
30 sensitive plants were tested for their ability to complement the *vrn2-1* mutant phenotype, by vernalizing for 3 weeks and recording the total leaf number.

Sequencing ORFs

35 Two potential open reading frames were sequenced following RT-PCR using RNA isolated from *fca-1* and *vrn2-1 fca-1* plants. cDNAs were reverse transcribed, primed by a dT12-18 primer,

and specific primers were then used to PCR amplify regions corresponding to the ORFs for ATDL4450W and 5K (VRN2). The Boehringer Mannheim HiFi PCR system was used to increase the fidelity of amplification. The primers VRN2-AL and VRN2-AM were used to prime ATDL4450W, and VRN2-AI and VRN2-AJ for 5K. For 5K, the PCR reaction for the full length product (VRN2AI-VRN2AJ) was inefficient, so subsequent reactions were performed to amplify the cDNA in two overlapping fragments, using the primer combinations VRN2-AI with VRN2-AS; and VRN2-AO with VRN2-AJ. The PCR products were isolated and purified, and sequenced directly using the BIGDYE sequencing kit (PE Applied Biosystems). At least two independent PCR products were sequenced from each allele. We sequenced the ATDL4450W PCR products with the amplifying primers VRN2-AL VRN2-AM, and VRN2-AU through VRN2-AX. The 5K cDNA was sequenced with VRN2-AI, VRN2-AJ and VRN2-AO through VRN2-AT. Sequences were aligned into contigs using the DNASTar software package (LaserGene).

20 Sequence Comparisons

EST and cDNA sequences were first translated using the MapDraw program of DNASTar (LaserGene). This revealed several regions where the sequence appeared to be incorrect, as small changes to the described sequences drastically improved the similarity to VRN2. Modified nucleic and amino acid sequences were initially aligned using programs within the MegAlign Package of DNASTar (LaserGene), as follows:

Amino acid sequences were initially aligned using the Clustal V method (Higgins and Sharp (1989) CABIOS vol. 5, no.2, 151-153). Default parameters were used: Gap penalty 10, Gap length penalty 10, ktuple 2, and the PAM 250 residue weight table. Alignment was refined by eye and hand, making minor adjustments to position of gaps to improve alignment.

Nucleic acid (EST and cDNA) sequences were initially aligned with the Hein method (Hein (1990) Methods in Enzymology, vol. 183, 626-645), using default parameters: Gap penalty 11, Gap

length penalty 3, ktuple 2, and the weighted residue weight table. Where the nucleotide alignment (when translated) did not correspond to the amino acid alignment, the positions of gaps were adjusted to correspond with the gaps in the amino acid alignments.

dCAPS Marker for the *vrn2-1* Mutation

A derived CAPS (dCAPS) marker was designed that was specific for the *vrn2-1* mutation. Following PCR amplification from genomic DNA with the primers VRN2-AY and VRN2-AZ, the 170 bp product was digested overnight with XmnI restriction enzyme, and the products resolved on a 4% agarose gel. Wild type plants (VRN2) produce a single band of 170 bp following digestion, while *vrn2-1* mutants produce two bands, of 137 bp and 33 bp.

Primers Used to Identify VRN2

As indicated on Figure 3 and Figure 5. All primer sequences are indicated 5' to 3'.

g19247F	ACT GTT CGT CTC CTT CAT CAT G
g19247R	TTG CTT GCC TGA AAA AAG TAT G
VRN2-C	TGT CGA TAT GCG ACC AGT ACC
VRN2-D	CAG GCT TAG ACC CAA TTG ACC
VRN2-R	AGG TAG GAT CCG ACA TCG TCT TCT TAT TTA CCG
VRN2-S	CTC TTG AAT TCA AAA CTA TTC CTA CTC TCA CAC
VRN2-AI	GCC AAT CGG TGT TTT CGC AGC TTT C
VRN2-AJ	AAG AAT AAG TTA CAA TCC GAT AAA TCG G
VRN2-AL	CAG TGG TTG AAG CTT AAG GAG G
VRN2-AM	GCA ATG AAT AAA TCA TAA TCT TGG
VRN2-AO	TCT ACT GGG ATG GTA GTT TTC
VRN2-AP	ATA TCC CGA GGC AAC AGA GCT TG
VRN2-AQ	CAT CTT TGG AAC TCG TTT G
VRN2-AR	CTC AGT TGT AAT AGT TGC CC
VRN2-AS	AAG AGT GGG CTA TGG CTG G
VRN2-AT	GCA ACT CTT TCT CGT AAA ATC TTG
VRN2-AU	GCC TCC ATA ACT GTC ATC ACA TC
VRN2-AV	TTT CAT TGG TCA TGG GAT GG

VRN2-AW GAC TTC AGA GAT GGG TTT ATG C
VRN2-AX TCC ATA TCT AGC TCC TTC GCC
VRN2-AY TGC GTT CAT TAA GTA GGC AAC AGA AAA TGG
VRN2-AZ GAG AAG TAG TTA CCT TTG TTT TCT TAC AGA AGA GT

Table 1 Comparison of VRN2 Nucleotide and Amino Acid Sequence to Database Sequences

Sequence	Nucleotides			Amino Acids		
	Identity (%)	Length	Range ^a	Identity (%)	Similarity (%) ^b	Range ^c
VRN2 Col	96.5	1722	1-1722	96.1	96.8	1-445
C72616 Region I	32.4	219	681-899	15.1	42.5	151-223
C72616 Region II	71.7	247	951-1197	72.7	85.7	241-322
C72616 Complete	47.7	517	681-1197	40.1	58.1	151-322
At163743 Region I	41.0	61	839-899	27.3	68.1	202-223
At163743 Region II	71.6	264	951-1214	66.7	77.1	241-328
At163743 Complete	65.8	376	839-1214	52.8	66.6	202-328
At Hyp 2245035	66.3	570	924-1493	63.7	79.5	232-421
KIAA0160 Region I	36.6	396	231-626	20.4	39.4	1-132
KIAA0160 Region II	35.5	904	819-1722	17.7	43.4	197-445
KIAA0160 Complete	41.1	1492	231-1722	16.0	36.0	1-445

^a Numbered relative to VRN2 cDNA sequence

^b Similarity defined as identity plus similarity on the basis of amino acids grouped into four classes - (D, E), (R, K, H), (S, T, N, Q, Y), and (L, I, V, M, A, G, W, F, P, C)

^c Numbered relative to VRN2 amino acid sequence

Table 2 Putative Domains of the VRN2 Protein

"Domain"	"Sub-domain"	Length	Position ^a	Identity (%)	Similarity (%) ^b	Molecule
DNA/Protein-Binding		70	63-132	30.0	51.4	KIAA0160
	Zinc Finger Motif	22	90-111	50.0	68.1	Mm Spalt 1296845
		22	90-111	45.4	68.1	Sc TFIIIA 730931
		22	90-111	40.1	72.7	Ce Hyp 2854197
		22	90-111	36.4	50.0	KIAA0160
Activation	Conserved Region	41	76-116	43.9	61.0	KIAA0160
		66	263-328	89.4	95.4	At163743
		68	263-330	83.0	93.2	C72616
		104	263-366	58.6	76.0	At Hyp 2245035
		104	263-366	29.8	49.0	KIAA0160
Conserved Acidic Region		36	281-316	94.4	97.2	At163743
		36	281-316	86.1	94.4	C72616
		36	281-316	58.3	72.2	At Hyp 2254035
		36	281-316	30.5	50.0	KIAA0160

^a Position relative to VRN2 Amino Acid sequence

^b Similarity was calculated as defined in Table 1

SEQ ID NO: 1

CAAGCTTCTTCAATTTTGCTTGCTCTCTCTTACACAGCCAATCGGTGTTTTTCGCAGCTTCA
GGCCTCAATCCAAGACATTCTATATAAGCATATTGCAGAAGAGGCGGTTCTAATTGTTGCAT
5 TGAGTTTATCGCTATGACGTAGGGAAATTCTAATTTAGGGGAGGCCTCAGAGTTTGCCTAA
CTTCATAATCGGCTCTTGACGTTGTTGAGTGTAATTGAACAAGAATGTGTAGGCAGAATTGT
CGCGCGAAATCCTCACCGGAGGAAGTGATTTCAACTGATGAGAATCTCTTGATATATTGTAA
ACCTGTTGCACTATATAACATCTTTACCTTCGCTCTCTAGGCAACCCATCGTTTCTTCCAA
GATGCTTGAACACAAAATTGGAGCAAAGCGCAAAGAAAGTCAAGATCTACTGGGATGGTA
10 GTTTTCAACTATAAGGATTGTAATAACACATTACAGAAAAGTGAAGTTAGGGAGGATTGTTT
TTGTCCATTTTGCTCTATGCTATGTGGTAGCTTCAAGGGGCTGCAATTTCAATTTGAATTCAT
CTCATGATTTATTTGAATTTGAGTTCAAGCTTTTCGAAGAATACCAGACAGTTAATGTTTCT
GTAAAACTTAATTCCTTCATATTTGAGGAAGAAGGAAGTGATGACGATAAATTTGAGCCCTT
CTCTCTCTGCTCGAAACCTCGTAAGCGGAGACAAAGAGGTGGCAGAAATAACACCAGGAGAC
15 TTAAAGTATGCTTTTTACCGTTGGATTCAACCCAGTTTAACTAATGGCACAGAAAATGGAATC
ACCCTACTTAATGATGGAAACCGTGGTTTAGGATATCCCGAGGCAACAGAGCTTGCTGGACA
ATTTGAGATGACCAGCAACATTCCACCAGCCATAGCCCACTCTTCTCTGGACGCTGGTGCTA
AAGTTATATTGACAAGCGAAGCTGTGGTCCCTGCTACTAAGACAAGAAAGTTATCTGCTGAG
CGATCAGAGGCTAGAAGCCACCTACTTCTTCAGAAACGCCAATTCTATCATTCTCACAGAGT
20 CCAGCCAATGGCGCTTGAGCAAGTAATGTCTGACCGGGATAGCGAGGATGAAGTCGATGACG
ATGTTGCAGATTTTGAAGATCGCCAGATGCTTGATGACTTTGTGGATGTGAATAAAGATGAA
AAGCAATTCATGCATCTTTGGAACCTCGTTTGTAGAAAACAAAGGGTTATAGCAGATGGTCA
TATCTCTTGCGCATGTGAAGCATTTCAGATTTTACGAGAAAGAGTTGCACCGTTACTCAT
CACTCTTCTGGTGTGGAGATTGTTTTTGATTAACTATGGAACCATGGACTTGTGACTCA
25 GCCACCATCAACAACTGCAATACCATCCTCGAGAATTGCCGTAATAGCTCAGACACCACCAC
CACCAACAACAACAAGTGTGGATCGTCCAGTGACTCAAACACCAACAACAATAACATTG
TGGATCATCCCAATGACATAAACAACAAGAACAATGTTGACAACAAGGACAATAACAGCAGA
GACAAAGTAATTAAATAGGAAAATCTCCGGCTTTTATGATACCGATTATCGGATTGTAAT
TATTCTTCTTTCTTAAAAAATTGTTTAGGAGCAAACAAATTTTTTATATGTTAGTGTATTCA
30 ACTGATTACATTTTTAGTTAAAAAATAATGGATTCTGCTTATAACT

SEQ ID NO: 2

35 MCRQNCRAKSSPEEVIISTDENLLIYCKPVRLYNIFHLRSLGNPSFLPRCLNYKIGAKRKRKS
RSTGMVVFNYKDCNNTLQKTEVREDSCSPFCSMLCGSFKGLQFHLNSSHDLFEFEFKLFEEY
QTVNVSVKLN SFIFEEEGSDDDKFEPFSLCSKPRKRRQRGGRNNTRRLLKVCFLPLDSPSLTN
GTENGITLLNDGNRGLGYPEATELAGQFEMTSNIPPAIAHSSLDAGAKVILTSEAVVPATKT

RKLSAERSEARSHLLLQKRQFYHSHRVQPMALQVMSDRDSEDEVDDDDVADFEDRQMLDDFV
DVNKDEKQFMHLWNSFVRKQRVIADGHISWACEAFSRFYEKELHRYSSSLFWCWRLFLIKLWN
HGLVDSATINNNTILENCRNSSDTTTTNNNNSVDRPSSNTNNNNIVDHPNDINNKNNVNDN
KDNNSRDKVIK

5

SEQ ID NO: 3

AAAGAGAATGCTTTGACTCTCTCATTTGGTCAAACCTGACTGTATTTATATGCGTTATTGTGT
10 GGTAAAGTTTCGACCTTTGACTTTACAAGTTGGCGTTAAGAAGAGAGATGCGTAGATCAGCG
AGTGGTTTCGAGAGTTTTGGATCATTTTCCCCGACTTCACGGTCTCCACGTCGATCTCAGAG
CATTACATCATTGGAAGATGATGTGGAGGTGCTTTTGCCTAGGTACGATCCGAATTCTCAAG
CGGGGAAGAGAGAGAAGTCAAGATTCAGATTTGCAGAAAACGTCATCCATTTGATTCTCTC
ATTCTTCTTCTCTGTATCGCAATCCTCTGGCTCTCCTCTTATTTCAGGTAAGCCGAGAAATTG
15 ATTCAATCTCTATGAATCCATAATTGATATGTGAACTTAATTAGGGATTTTACAAAGGCTC
ATATGGATATGATATGAGGATCGAGATGTCTCTGTAAACATTAGAATCTTGTGTTGAATTATT
GTTTCAATTTGTTTCATATTATACTAAACCGGTGATGGATTTGGAATTTGTCAGCAGCGTTAA
GGAGTTGAGTTCAAGAAGCAACATGTTGTCTTGTCTCCATGGGAACTCATCATATTTCAGTTT
TGGGAAAGGAAACAATTTTTTTTACCGCCGGTGATTATGTGCCGCAAACCATACGTAACTTT
20 TGTAATTTTTCGGTTCTGTAGACACATAAAAGGATCTCTCGTTTTCATGAAATGTATGTTTAA
TATTTCACTATACATCACACAACCTCAAGTAGAAAACACTGATGGTTATCCATTAATCATCAT
TCTATTGGTTCGAAAACAAGGATTAGTTTCAACTTATTGCTACCTTAGTGATTAGATGTTCTT
GTGAGTTTCAGCTAGCCAAGTCAACTAGAGTTAAACAATGGAATCAAAATACATATTTCAGTA
ATTTATTTTAACTCTGACTATTTATGTAAACAAAAATGGAAATTAAATTTGAAGGTCATGA
25 AGATTCTATTCTTAGTATGAAAAGTATAGATCAATGATAAAAGTATATACCAGAACAGTGGT
GGATCTAGAAACATATTTAGTATATGGCACAATATATTTAACATATACAAATTTTAATCTAA
AAGTTGTATTTCATTTATGAAAAGACWTCTGAATGAAGCAAATTTATTTGATGTGTTAATCAT
CCATTTATGTGTTAATCAGCCATTGATGTTAGTATAGTACTCTATGCTAACATAATTTTTTT
ATACTATAAATTAAAAAATAGGTAAGAAAAGAAAAATAGATTAATATAAAAAGCATTTTAT
30 TAGCTGAAATAAATAAAATGAAAGAAGATAATACTAATTGACTAAAAAATTAGTAGAGCAT
ATGGGGCACAATACACTAAGTATTTTCATCTTTACTATAAAATGTAACAAATTTCAAATTTAT
CAAACGTATATAGGGCACGTGCCTAGGTACCAATAGACGTACGTCCGCCCTGAAATAAGTT
GGTGAATATGGTTTTAATTCCTCTAATACTCACTGTACTGCCATGGTAGAGGTGAAAAAAC
AATTTTAGAAATATTATAATGGATTAAGCTGTCCAAGTTGGTCGTATTTTCTTTACATTTTA
35 TTAACATAAATAAATAAATAAGTTCAACTATTTATTGACTAGTAATAATACGTGTAAATGT
CTATTGGTTTTAAATATGGGCCATAAGGCCCAGACTTGAAAAAAAACCTTGAAACCCAAAGT
TATATTTTACTTGTCTTCTTTCTCAGTGAATATCTCCAATCAAGCTTCTTCGATTTTG
CTCTCTCTTACACAGCCAATCGGTGTTTTTCGCAGCTTTTCAGGTTTGTCTCAATCTCAAATTA

AATCGGAGTCAAGTAATAACAATTGATAAACCTAATTGTTTCCATTGTATTGTAAGATTTGA
AATTTTGCTGTAGATCCGGAATCGAATTCTAGTTCTGGAATCGTTGATCTCGATGGAATTTT
TTTTTTAAGATTTCTTCTTACACATTTGGTTCAAAAGATCACATAGTTTTATTTTAATTTGA
TAAGTATGATGATTCTGCTAAGTGGCATTGGATAAAGTTTTTCGTTTTTGCAATACGTCTAAA
5 CTTGTCTATGTCTTGAATGAACTCTCTGAGTTGCTTAAAAAGTCTTGTGCTTTCTTTATTAC
ACAGGCCTCAATCCAAGACATTCTATATAAGCATATTGCAGAAGAGGCGGTTCTAATTGTTG
CATTGAGTTTATCGCTATGACGTAGGGAAATTCTAATTTAGGGGAGGCCTCAGAGTTTGCAC
TAACTTCATAATCGGCTCTTGACGTTGTTGAGTGTAATTGAACAAGAATGTGTAGGCAGAAT
TGTCGCGCGAAATCCTCACCGGAGGAAGTGATTTCAACTGATGAGAATCTCTTGATATATTG
10 TAAACCTGTTGACTATATAACATCTTTCACCTTCGCTCTCTAGGCAACGTATGATTTGCCT
TCCTCTCTCATCATATTAGCTCAGTAATCTTTCATCTCCTGTGTAGATCACCCACTAATAGT
TTGAGTTTGCTAAGCTGATTATGGTCTGATTCATGGCGAGTGTGTGCTTCTTTTGTCTCCTA
AATTTGAACTTGTTGTTTGTGTTGTCAGCCATCGTTTCTTCCAAGATGCTTGAACCTACAAAA
TTGGAGCAAAGCGCAAAGAAAGTATGTTTTCTTCTTGAATGTAGCTGCTACAGTGATATGT
15 TATTTATCTTACTTCTAATATGGAAGCTGATGACCTATTTTATCTTTGTTGAGTAGATATGG
ACATAATGAATGGTTTCTTCTTGTTCATGCTATAAACTTACATTTTATAAAATTGTGTTTT
GGTTAGGTCAAGATCTACTGGGATGGTAGTTTTCAACTATAAGGATTGTAATAACACATTAC
AGAAAACCTGAAGGTTAGTCTTTTTCTGTTTCGTCGACAAAATTCGATGTCAATGTCTATGTTT
CTCTAGATGATTTGTTATTTACTATTTTTTTCTGTATTGTCATGCAGTTAGGGAGGATTGTT
20 CTTGTCCATTTTGCTCTATGCTATGTGGTAGCTTCAAGGTGGGCAACTATTACAACCTGAGGT
TTCTTCCGGGGCCTTTCATATCTAACACTGTGAAATGCTACTGCTGTTTCATGCTGTATACT
TTCACTGTTTGGTTACATATTTTTGTGTTTGTGTTTGTCTTCTCACTCTTTTCGAACTGCT
GAGTGTGTGCTTATCTGAGAAAACATGTCCCAGATGGAGCTTACAACCAATTGTCTTGTGTC
TATGCAGGGGCTGCAATTTCAATTTGAATTCATCTCATGATTTATTTGAATTTGAGTTCAAGG
25 TATGTGGTTTTATGGAAATCTTGATTTGCTATGCCTTTATTAATGAGGTTATAGTTAAAAA
AGGGTCTTTCCTATTGTAGCTTTCGGAAGAATACCAGACAGTTAATGTTTCTGTAAACTTA
ATTCCTTCATATTTGAGGTCAGTTACTTTAAACTTGGTTAATTGGGAAATCCGATAGCTGGT
GAAAATTTTGTTTATATTCCATCCTTATTTGTACTAGGAAGAAGGAAGTGATGACGATAAAT
TTGAGCCCTTCTCTCTCTGGTAACCCTCAGAACCCCTTCGATTAAATACCTTAATAGCAGTA
30 ACTCCTTGCTTCTCTTGTGAGTACATCTCTGTAAATCCAACCATAATGTTTTGCAGCTCGAA
ACCTCGTAAGCGGAGACAAAGAGGTGGCAGAAATAACACCAGGAGACTTAAAGTATGCTTTT
TACCGTTGGATTACCCAGTTTAACTAATGGCACAGAAAATGGAATCACCCCTACTTAATGAT
GGTAAAATCATATCTTCTTCTGTGCGTTCCTTGTGGCTTAGAACTTCATATTACAGAAGAAG
ATACAATGGCCTGATTGTTTGTAGTTTTTGTACTTCTCCTCGCATTCCTTCTGCGAGGGTATTG
35 TTACCAGAACTGATGTACAAAATTAATGGCATGCTACAGGAAACCGTGGTTTAGGATATCCC
GAGGCAACAGARCTTGCTGGACAATTTGAGATGACCAGCAACATTCCACCAGCCATAGCCCA
CTCTTCTCTGGACGCTGGTGCTAAAGTTATATTGACAAGCGAAGCTGTGGTCCCTGCTACTA
AGACAAGAAAGTTATCTGCTGAGCGATCAGAGGCTAGAAGGTTTGTTCATCATGACACCCCG

TCATCATAATTACCATTCCTGTTGTTACAAATGTTCTTCCTATTATGGATAAGTGTTTATAG
TACTGCCATATTAACCGAGAAAATTTCTTCAGCCACCTACTTCTTCAGAAACGCCAATTCT
ATCATTCTCACAGAGTCCAGGTGATCCAAGTTCCTTCACCTACTTCTTAGGCATTTTCTTTA
AATTGCTCATGATGATATCTTATCAAAGCATACTTGGTTTGTCTCATCCAAATTTGTATTT
5 TGATCTGTATGTATCAACGCAAAATAGTTATGTCCATGTTGTCTCCGTTTTATTGCCACTAA
CCAAAAAATGCATGTTTTCTGTGACAAGCCAATGGCGCTTGAGCAAGTAATGTCTGACCGGGA
TAGCGAGGATGAAGTCGATGACGATGTTGCAGATTTTGAAGATCGCCAGGTATTCCATGATT
TCTTTCTGCGTTCATTAAATAGACAACAGAAAATGGTATATGATGTAACCTTGCTAATGGCTT
TTGAAACTTAAAAAAGCTGCAGATGCTTGATGACTTTGTGGATGTGAATAAAGATGAAAAGC
10 AATTCATGCATCTTTGGAACCTGTTTGTAAGAAAACAAAGGTAACCTACTTCTCTTACACATG
AACAGACACAAAAAGACCTTATGTCTTACATTCCATACCTGTCTAAATGATTTTGCTTATGG
AACTTTGAGCTCAATTATGATTGTTGATGTTTCAGGGTTATAGCAGATGGTCATATTTCTTG
GGCATGTGAAGCATTTTCAAGATTTTACGAGAAAGAGTTGCACCGTTACTCATCACTCTTCT
GGTAATATAAGTACACCAAACATATACAGACACATAACTACACTATCAATCTTGTTTTCGTTT
15 TCTGAAAAAAAAATAAAAATTTCCAGGTGTTGGAGATTGTTTTTGATTAACTATGGAACCA
TGGACTTGTCGACTCAGCCACCATCAACAACGCAATACCATCCTCGAGAATTGCCGTAATA
GCTCAGACACCACCACCACCAACAACAACAGTGTGGATCGTCCCAGTGACTCAAACACC
AACAACAATAACATTGTGGRTCATCCCAATGACATAAACAACAAGAACAATGTTGACAACAA
GGACAATAACAGCAGAGACAAAGTAATTAAATAGGAAAATCTCCGGCTTTTATGATACCGAT
20 TTATCGGATTGTAACCTATTCTTCTTTCTTAAAAAATGTTTAGGAGCAAACAAATTTTTTA
TATGTTAGTGTATTCAACTGATTACATTTTTTAGTTAAAAAAAAAATGGATTCTGCTTATAA
CTAAAAACTGAAAAAAAAAGAAAAGTTTCCTTAATTTTTCTTTTTGACTTGAGAAAAGCTCC
TCTAGTAAATATGAGTTATATATTAATCAAGTACATAACATAAAAAATAGTATATATTAAGTG
CAAATAGATTGAAAACAAATCAAGAAGAAATTAATTAAGACAGAGTGATTAAGCTTAAAACC
25 CCATTTGGACTTGTTCTTTCTCAATGAATCCCTCACAAGCAGCAAGCTTCTTCGATTTTGCT
TTGACACCACCAATCGGTGTTTTTGAATCTTTAGGTTTGTCTCGATTTCAATCTAGATCGG
AGTCAAGTAATAAAATTGATTAACCTAAGTATTTCCCGTTCTCTCGTAAGAGTTGGGATTTAG
CAGTAGATCGGAAATCGGAATTTACGTTTTTGTTAAAAGATTGATGGTTTAGGTAATGGAAC
ATAGTTCTGGATTCATTGCTTCTAGTTGATTCTCGAATTGTTTGATTTGCAATGCACATTT
30 TTGTTTCAAAGGATCACAGAATTTGATTTAAAATTTGACAAAATTCATCAATTTCTCATAT
TAGGGTTTATATTTCTTCTAGTAACTCGAACTTGTTGGAACCTGTATACTCTGTGCTATGT
AGATAAAGTCTTAACATTTTGGTCAACTTTGTTTGATCTCTAACTAGTTTGGGCTCTCTGT
TTTAAAGTTTTGTGCTTTCACTATTACACAGGTCTCATACAAGACTACAGTCTCAAGAAGCA
TAATATCGTCGACTCTGTTTTGAGTTTCTCAACAGTGGTTGAAGCTTAAGGAGGTTCTTATG
35 TGCGTTTTGATATC

SEQ ID NO: 4

CAAGCTTCTTCAATTTTGCTTGCTCTCTCTCTTACACGGCCAATCGGTGTTTTTCGCAGCTTT
CAGGCCTCAATACAAGACATTCTATATAAGCATATTGCAGAAGAGGCGGTTCTAATTGTTGC
5 ATGGAGTTGAACAATATGACGTAGGGAAATTCTAATTTAGGGGAGGCCTCAGAGTTTGCAC
AACTTCATAATCAGCTCTGGACGTTGTTGATTGTATTTGAACAAGAATGTGTAGGCAGAATT
GTCGCGCGAAATCCTCACCGGAGGAAGTGATTTCAACTGATGAGAATCTCTTGATATATTGT
AAACCTGTTTCGACTATATAACATCTTTCACCTTCGCTCTCTAGGCAACCCATCGTTTCTGCC
AAGATGCTTGAAC TACAAAATTGGGGCAAAGCGCAAAGAAAGTCAAGATCTACTGGGATGG
10 TAGTTTTCAACTATAAGGATTGTAATAATACATTACAAAGAACTGAAGTTAGGGAGGATTGT
TCTTGTC CATTTTGCTCTATGCTATGTGGTAGCTTCAAGGGGCTGCAATTTCAATTTGAATTC
ATCTCATGATTTATTTGAATTTGAGTTCAAGCTTTTGAAGAATAACCAGACAGTTAATGTTT
CTGTAAACTTAATTCCTTCATATTTGAGGAAGAAGGAAGTGATGATGATAAATTTGAGCCC
TTCTCTCTCTGCTCGAAACCTCGTAAGCGTAGACAAAGAGGTGGCAGAAATAACACCAGGAG
15 ACTTAAAGTATGCTTTTTTACCGTTGGATTCAACCAGTTTAGCTAATGGCACAGAAAATGGAA
TTGCCCTGCTGAATGATGGAAACCGTGGTTTAGGATATCCCGAGGCAACAGAGCTTGCTGGA
CAATTTGAGATGACTAGCAACATTCCACCAGCCATAGCCCACTCTTCTCTGGACGCTGGTGC
TAAAGTTATATTAACAACCGAAGCTGTGGTCCCTGCTACTAAGACAAGAAAGTTATCTGCTG
AGCGATCAGAGGCTAGAAGCCACCTACTTCTTCAGAAACGCCAATTCTATCATTTCTCACAGA
20 GTCCAGCCAATGGCGCTTGAGCAAGTAATGTCTGATCGGGATAGCGAGGATGAAGTCGATGA
CGATGTTGCAGATTTTGAAGATCGCCAGATGCTTGATGACTTTGTGGATGTGAATAAAGATG
AAAAGCAATTCATGCATCTTTGGAACCTGTTTGTAAGAAAACAAAGGGTTATAGCAGATGGT
CATATCTCTTGGGCATGTGAAGTATTTTCAAGATTTTACGAGAAAGAGTTGCACTGTTACTC
ATCACTCTTCTGGTGTTGGAGATTGTTTTTTGATTAACTATGGAACCATGGACTTGTCTGACT
25 CAGCCACCATCAACAACCTGCAATACCATCCTCGAGAATTGCCGTAATACCTCAGTCACTAAC
AACAACAACAACAGTGTGGATCATCCAGTGACTCAAACACCAACAACAATAACATTGTGGA
TCATCCGAATGACATAAAAAACAAGAACAATGTTGACAACAAGGACAATAACAGCAGAGACA
AGTAATTAAATAGGAAACACTCCGGTTTAGATGATACCGATCTATCGGATTGTAAC TTATTC
TTCTTTCTTAAAAAAATTGTTTAGGAGCAAACAAAGATTTTATTTGTTAGTGTATTCAACTG
30 ATTACATTTT TAGTTAAAAAAATGGATTCTCCTTAATAACT

SEQ ID NO: 5

35 MCRQNCRAKSSPEEVISTDENLLIYCKPVRLYNIFHLRSLGNPSFLPRCLNYKIGAKRKRKS
RSTGMVVFNYKDCNNTLQRTREVREDCSFPFC SMLCGSFKGLQFHLNSSHDLFEFEFKLLEEY
QTVNVSVKLNSFIFEEEGSDDDKFEPFSLCSKPRKRQRGRNNTNRLKVCFLPLDSPSLAN
GTENGIALLNDGNRGLGYPEATELAGQFEMTSNIPPAIAHSSLDAGAKVILTTEAVVPATKT

RKLSAERSEARSHLLLQKRQFYHSHRVQPMALEQVMSDRDSEDEVDDDVADFEDRQMLDDFV
DVNKDEKQFMHLWNSFVRKQRVIADGHI SWACEVFSRFYEKELHCYSSLFWCWRLFLIKLWN
HGLVDSATINNCNTILENCRNTSVTNNNNNSVDHPSDSNTNNNNIVDHPNDIKNKNNVDNKD
NNSRDK

5

SEQ ID NO: 6

AAAGAGAAGAGCTTTGACTCTCTCATTGGTCAAACCTGACTGTATTTATATGCGTTATTGTG
10 TGGTAAAGTTTCGACCTTTGACTTGACAAGTTGCCGTTAAGAAGAGAGATGCGTAGATCAGC
GAGTGGTTCTAGAGTTTTGGATCATTTCGCGGCGACTTCAAGGTCTCCGCCTCGATCTCAGA
GTGTTACAGCAATGGAAGATGATGTGGAGCTGCTTTTGCCCTAGGTACGATCCGAATTCTCAA
GCGGGGAAGAGAGAGAAATCAAGATTCAGATTTTCAGAAAACGTCATCCATTTGATTCTCT
CATTCTTCTTCTCTGTGTGCGCAATCCTCTGGCTCTCCTCTTACTCAGGTAAGCCGAGAAATT
15 GTTTC AATCTCTATGAATCCATAATTGATCTGTGAACTTAATTAGGGATTTTACAAAGACT
CATATGGATATGAGGATCGAGATGTCTCTGCAACGTTAGAATCTTGTGTTGAATTATGGTTT
CAATTTGTTTCAATAATACTAAATCGGTGATGGATTTGGAATTTGTGAGCAGCGTTAAGGAG
TTGAGTTCCAAAAGCAACATGTTGTCTTGTCTCCATGGGAACTCATATTCAGTTTTGGGAAA
GGAAACAATTTCTTTTACCGCCGGTGATTTTGTGCCGCAAACCATTCGTATTTGTAATTTTGT
20 GTTCTGTAGACACACAAAAGGATCTCTCGTTTTTCAAGAAATGTATGTTTAATATTTTCAAGTGA
TATACATCACACAACTCAAGTAGAAAACACTGATGGTTATCCATTAATCATTCTATTGGTCG
AAAAAAGATTAGTTTCAACTTAATGCCACCTTAGGATTATATGTTCCCTGTGAGTTTCAAGT
AGCCAACTCAACTAGAGTTAAACAATGGAATCAAAATACATATTCAGTAATTTATTTTAAAC
TCTGACTATTTATGTAAACACAAATGGAAATCAAAATTGAAGGTCATGAAGATTCTATTCT
25 TAGTGTGAAAAGTATAGATCAATGATTCTTAATTTCTTCATCCTCCACGCATAGATCAATGG
TGAATATGGTTTTTAAATCCTCTAATACTCACTGTACTGCCATGGTAGAGTTAAAAACAAT
TTTAGAAATATTAGTGGATTAAAGGCATTAAGCTGTCCAAGTTGCTTGTATTTTCTTTTCATT
TTATTAATTAAAAAAAAGTTCAACTATTTATTGACTAATAATAATACGTGTTAAATGGTTA
TCGGTTTTAAATATGGGCCATAGGCCAGACTTGAAGAAAACTTGAAACCCAAAGTTTTAT
30 TTTTACTTGTTTTCTTTCTCAGTGAATATCTCCCAATCAAGCTTCTTCAATTTTGCTTGCTC
TCTCTCTTACACGGCCAATCGGTGTTTTTCGCAGCTTTCAGGTTTGTCTCAATCTCAAATTAA
ATCGGAGTCAAGTAATAACAATTGATAACCCTAATTGTTTCAATTATATTGTAAGATTTGAA
ATTTTGCAGTAGATCCGGAATCGTATTCTAGTTCTGGAATCGTTGATCTCGATGGAATTTTT
TTTAAGATTTCTTCATACACATTTGGTTCAAAAGATCACATAATTTTATTTTAATTGATAA
35 GTATGATGATTCTGCTAAGTGGCATTGGATAAAGTTTTCATTTTTGCAATACGTCTAAACTT
GTCTATGTCTTGAATGAACTCTCTGAGTTGCTTAAAAAGTCTTGTGCTTTCTTTATTACACA
GGCCTCAATACAAGACATTCTATATAAGCATATTGCAGAAGAGGCGGTTCTAATTGTTGCAT
GGAGTTGAACAATATGACGTAGGGAAATTTCTAATTTAGGGGAGGCCTCAGAGTTTGCACTAA

CTTCATAATCAGCTCTGGACGTTGTTGATTGTATTTGAACAAGAATGTGTAGGCAGAATTGT
CGCGCGAAATCCTCACCGGAGGAAGTGATTTCAACTGATGAGAATCTCTTGATATATTGTAA
ACCTGTTTCGACTATATAACATCTTTCACCTTCGCTCTCTAGGCAACGTATGATTTGGCCTTC
CTCTCTCATCATTTTAGCTTAGTAATCTTTCATCTCCTGTGTAGATCACCCACTAATAGTTT
5 GAGTTTGCTAAGCTGATTATGGTCTGACTCATGGCGAGTGTGTGCTTCTTTTGTCTCCTAAT
GTTATTTGAACTTGTTGTTTGTGTTGTCAGCCATCGTTTCTGCCAAGATGCTTGAACTACAA
AATTGGGGCAAAGCGCAAAAGAAAGTATGCGTTTCTTCTTGAATGTAGTTGCCACAGTGATA
TGTTATTTATCTTACTTCTAATATGGAAGCTGATGAACTATTTATCTTTGTTGAGTAGATAT
GGACATAATGAATGGTTTCTTCTTTGTTTCATGCTATACACTTATATTTTACAAAATTGTGTT
10 TTGCTTAGGTCAAGATCTACTGGGATGGTAGTTTTCAACTATAAGGATTGTAATAATACATT
ACAAAGAACTGAAGGTTAGTCTTTTTCTGTTCTTCGACAAAATTCGATGTCAATGTCTATGT
TTCTCTAGATGATTTGTTATTTACTATTTTTTTCTGTATTGTCACGCAGTTAGGGAGGATTG
TTCTTGTCCATTTTGCTCTATGCTATGTGGTAGCTTCAAGGTGGGCAACTATTACAACTGAG
GTTTTCTTCCGGGGCCTTTCATATCTAACACTGTGAAATGCTACTGCCGTTTAATGCTATATA
15 CTTTCACTGTTTGGTTACATATTTTTGTGTTTGTGTTTGTCTTCTTGCTCTTTTTTAACTG
CTGAGTGTGTGCTTATCTGAGAAAACATGTTCCAGTTCGAGCTTACAATCCATTGTCTTGTG
TCTATGCAGGGGCTGCAATTTCAATTGAATTCATCTCATGATTTATTTGAATTTGAGTTCAA
GGTATGTGGTTTTATGGAATTTCTTGTTTTGCCTATGCCGTTAGTAATGAGGTTATAGTTAA
AAAAGGGTCTTTTCCATTGTAGCTTTTGGAGAATAACCAGACAGTTAATGTTTCTGTAAAAC
20 TTAATTCCTTCATATTTGAGGTCAGTTACTTTAACTTGGTTAATTGGGAAATCCTATAGCT
GGTGAAAATTTGGTTTATATTCCATCCTTATTTGTACTAGGAAGAAGGAAGTGATGATGATA
AATTTGAGCCCTTCTCTCTCTGGTAACTCTCAGAACCCCTTGATTAAATACCTTAATAGCAG
TAACTCCTTGCTTTTCTTGTCTAGTACTTCTCTATAAATCCAACCACAATGTTTTGCAGCTCG
AAACCTCGTAAGCGTAGACAAAGAGGTGGCAGAAATAACACCAGGAGACTTAAAGTATGCTT
25 TTTACCGTTGGATTACCCAGTTTAGCTAATGGCACAGAAAATGGAATTGCCCTGCTGAATG
ATGGTAAAATCACATCTTCTTCTGTGGTATTCGTTGTGGCTTAGAACTTCATTTTACAGAAG
AAGATACAATGTCTGATTGTTTAGTTTTTGTACTTCTCCTCGCATTCTTCTTGTGAGGGTA
ATGTTACCAGAACTGATGTACAAAATTAATGGCATGCTACAGGAAACCGTGGTTTTAGGATAT
CCCGAGGCAACAGAGCTTGCTGGACAATTTGAGATGACTAGCAACATTCCACCAGCCATAGC
30 CCACTCTTCTCTGGACGCTGGTGCTAAAGTTATATTAACAACCGAAGCTGTGGTCCCTGCTA
CTAAGACAAGAAAGTTATCTGCTGAGCGATCAGAGGCTAGAAGGTTTGTTTCATCATGACACC
CCGTCATCATAATTACCATACCTGTTGTTACAAATGTTCTTCCCTATTATGGATAAGTGTTTA
CTGTACTGCCATATTAACCGAGAAAATTTCTTCCAGCCACCTACTTCTTCAGAAACGCCAAT
TCTATCATTTCTCACAGAGTCCAGGTGATCCAAGTTCCTTCACCTACTTCTTAGGCATTTTCT
35 TTAAATTGCTCATGATGATATCTTATCAAAGCATACTTGGTTTGTCTCATCTAAATTTGTA
TTTTGATTCTGTATGTATCAACGCAAAAAAATTATGTCCATGTTGTCTCCGTTTTATTGCCA
CTAACCAAAAACTGCATGTTTTCTTGTGACAAGCCAATGGCGCTTGAGCAAGTAATGTCTGAT
CGGGATAGCGAGGATGAAGTCGATGACGATGTTGCAGATTTTGAAGATCGCCAGGTATTCCA

E09111-02306P11

TGATTTCTTTCTGCGTTCATTAAGTAGGCAACAGAAAATGGTATACGATGTAACCTTGCTAAT
GGCTTTTGAACTTAAAAAGCTGCAGATGCTTGATGACTTTGTGGATGTGAATAAAGATGA
AAAGCAATTCATGCATCTTTGGAACTCGTTTGTAGAAAACAAAGGTAACCTACTTCTCTTAC
ACTTGAACACACACAAAAAGACCTTATGTCTTACATTCCATACCTGTCTAAATGATTCTGCT
5 TATGGAACCTTTGAGCTCAAATTATGATTGATGTTTGCAGGGTTATAGCAGATGGTCATATCT
CTTGGGCATGTGAAGTATTTTCAAGATTTTACGAGAAAGAGTTGCACTGTTACTCATCACTC
TTCTGGTAATATAAGTACACCAACATATACAGACACATAACTACACTATCAATTTTGTTC
GTTTTTCTGAAAGAAAAATAAAAAATTCAGGTGTTGGAGATTGTTTTTGATTAAACTATGG
AACCATGGACTTGTGCACTCAGCCACCATCAACAACCTGCAATACCATCCTCGAGAATTGCCG
10 TAATACCTCAGTCACTAACAACAACAACAACAGTGTGGATCATCCAGTGACTCAAACACCA
ACAACAATAACATTGTGGATCATCCGAATGACATAAAAAACAAGAACAATGTTGACAACAAG
GACAATAACAGCAGAGACAAGTAATTAAATAGGAAACACTCCGGTTTAGATGATACCGATCT
ATCGGATTGTAACCTTATTCTTCTTTCTTAAAAAATTTGTTTAGGAGCAAACAAGATTTTAT
TTGTTAGTGTATTCAACTGATTACATTTTGTAGTTAAAAAATGGATTCTCCTTAATAACTAA
15 AGACTGAAAAATAAGATAAGTTTCCTTAATTTTCTTTTTGACTTGAGAAAAAGCTCCTCTA
GACCTCTAGTAAATAGGAGTTATATATTAATCAAGTACATAAAAAATATATATATTAA
GTGCAATAGATTGAAAACAAATCAAGAAATTAATTAAGACACAGTGATTAAGCTTAAACC
CCATTTTGACTTGTTCTTTCTCAATGAATCCCTCACAAGCAGCAAGCTTCTTCGATTTTGCT
TTGACACCACCAATCAGTGTTTTCGAATCTTTCAGGTTTGTCTCGATTTCAAACCTAGATCGG
20 AGTCAAGTGATAAAATTGACTAACATAATTATCCCGTTCTCTCGTAAGAGTTGGGATTTAG
CAGTAGATCGGAAATCGGAATTTACGTTTTTGTAAAAGATTGATGGTTTAGGTAATAAAAC
ATAGTTCTGGATTCATTGCTTCTAGTTGATTCTCGAATTGTTTGATTTGCAATGCACATTT
TTGGTTCAAAGGATCACATAATTTGCTTTAAAATTTGACAAAACATAACCATCAAATTTCTCA
TATTTCTTCAAGTAACTCGAACTTGTTGGAAATCTATATACTCTGGGCTATGTAGATAAAGT
25 CTTAACATTTTGGTCAACATTGTTTGTCTCTAAACTAGTTTGGGTTCTCTGTTTTAAAGTT
TGGTGCTTTCACTATTACACAGGTCTTATACAAGACTACAGTCTCTAGAAGCATAATATCGT
CGACTCTGTTTTGAGTTTCCCAACAGTGGTTGAAGCTTAAGGAGGTTCTTATGTGCCTTTTG
AAATC

30

SEQ ID NO: 7

35

CAAGCTTCTTCAATTTTGCTTGCTCTCTCTTACACGGCCAATCGGTGTTTTCGCAGCTTT
CAGGCCTCAATACAAGACATTCTATATAAGCATATTGCAGAAGAGGCGGTTCTAATTGTTGC
ATGGAGTTGAACAATATGACGTAGGGAAATCTAATTTAGGGGAGGCCCTCAGAGTTTGCAT
AACTTCATAATCAGCTCTGGACGTTGTTGATTGTATTTGAACAAGAATGTGTAGGCAGAATT
GTCGCGCGAAATCCTCACCGGAGGAAGTGATTTCAACTGATGAGAATCTCTTGATATATTGT
AAACCTGTTGCACTATATAACATCTTTCACCTTCGCTCTCTAGGCAACCCATCGTTTCTGCC

AAGATGCTTGAAC TACAAAATTGGGGCAAAGCGCAAAGAAAGTCAAGATCTACTGGGATGG
TAGTTTTCAACTATAAGGATTGTAATAATACATTACAAAGAACTGAAGTTAGGGAGGATTGT
TCTTGTCCATTTTGTCTCTATGCTATGTGGTAGCTTCAAGGTGGGCAACTATTACAAC T GAGG
GGCTGCAATTTCAATTTGAATTCATCTCATGATTTATTTGAATTTGAGTTCAAGCTTTTGGAA
5 GAATACCAGACAGTTAATGTTTTCTGTAAACTTAATTCCTTCATATTTGAGGAAGAAGGAAG
TGATGATGATAAAATTTGAGCCCTTCTCTCTCTGCTCGAAACCTCGTAAGCGTAGACAAAGAG
GTGGCAGAAATAACACCAGGAGACTTAAAGTATGCTTTTTTACCGTTGGATTCACCCAGTTTA
GCTAATGGCACAGAAAATGGAATTGCCCTGCTGAATGATGGAAACCGTGGTTTAGGATATCC
CGAGGCAACAGAGCTTGCTGGACAATTTGAGATGACTAGCAACATTCCACCAGCCATAGCCC
10 ACTCTTCTCTGGACGCTGGTGCTAAAGTTATATTAACAACCGAAGCTGTGGTCCCTGCTACT
AAGACAAGAAAGTTATCTGCTGAGCGATCAGAGGCTAGAAGCCACCTACTTCTTCAGAAACG
CCAATTCTATCATTCTCACAGAGTCCAGCCAATGGCGCTTGAGCAAGTAATGTCTGATCGGG
ATAGCGAGGATGAAGTCGATGACGATGTTGCAGATTTTGAAGATCGCCAGATGCTTGATGAC
TTTGTGGATGTGAATAAAGATGAAAAGCAATTCATGCATCTTTGGAAC TCGTTTGTAAGAAA
15 ACAAAGGGTTATAGCAGATGGTCATATCTCTTGGGCATGTGAAGTATTTTCAAGATTTTACG
AGAAAGAGTTGCACTGTTACTCATCACTCTTCTGGTGTTGGAGATTGTTTTTGATTAAACTA
TGGAACCATGGACTTGTCGACTCAGCCACCATCAACAAC T GCAATACCATCCTCGAGAATTG
CCGTAATACCTCAGTCACTAACAACAACAACAACAGTGTGGATCATCCAGTGACTCAAACA
CCAACAACAATAACATTGTGGATCATCCGAATGACATAAAAAACAAGAACAATGTTGACAAC
20 AAGGACAATAACAGCAGAGACAAGTAATTAAATAGGAAACACTCCGGTTTAGATGATACCGA
TCTATCGGATTGTAAC T TATCTTCTTTCTTAAAAAAATGTTTAGGAGCAAACAAAGATTT
TATTTGTTAGTGTATTCAACTGATTACATTTT TAGTTAAAAAAATGGATTCTCCTTAATAAC
T

25

SEQ ID NO: 8

MCRQNCRAKSSPEEVISTDENLLIYCKPVRLYNIFHLRSLGNPSFLPRCLNYKIGAKRKRKS
RSTGMVVFNYKDCNNTLQRTEVRED CSCPFC SMLCGSFKVGNYYN

30

SEQ ID NO: 9

35

ACATTTTCGTACCGCTCAAGATTTAAGAAGCGTAAAAGGGTGGAATCTCAAGTGATAAAAT
TAGGCATGTACATCCACATATTGTGGATTCAGGATCACCTGAAGATGCCCAGGCAGGATCTG
AAGACGATTACGTGCAGAGGGAAAATGGTAGTTCTGTAGCACACGCTTCTGTTGATCCTGCT
AATTCATTACACGGTAGCAATCTTTCAGCACCAACAGTGTACAGTTTGGGAAGACAAGAAA
GCTGTCTGTTGAACGAGCTGATCCAGAAATCGGCAGCTCCTACAAAAACGCCAGTTCTTTT

ATTCTCACAGGGCTCAACCAATGGCATTGGGAGCAGTTTTCTCAGATCGTGATAGTGAAGAT
GAGGTTGATGATGACATTGCTGATTTTGAAGATAGACAGATGCTTGATGATTTTGTGATGT
TACCAAAGACGAACTTATTATGCATATGG

5

SEQ ID NO: 10

TFSYRSRFKKRKRVEISSDKIRHVHPHIVDSGSPEDAQAGSEDDYVQRENGSSVAHASVDP
NSLHGSNLSAPTVLQFGKTRKLSVERADPRNRQLLQKRQFFHSHRAQPMALGAVFSDRDS
10 EVDDDIADFEEDRQMLDDFVDVTKDELIMHM

SEQ ID NO: 11

15 ACATGCATATCCTGATGCTGAATGTGCTCAATTGGTACCTGGGAATAATCTTGACCTCCTG
CCATGCTACAATTTGCAAAGACAAGAAAATTATCAATTGAACGGTCTGACATGAGAAACCGT
ACACTCCTTCACAAACGACAATTTTTTCACTCACATAGAGCTCAGCCAATGGCAGCTGAGCA
AGTTATGTCAGATCGGGATAGTGAGGATGAAGTTGACGATGATGTTGCAGATTTTGAAGACC
GAAGGATGCTTGATGATTTTGTAGACGTGACTAAAGATGAGAAGCAAATGATGCACTTGTGG
20 AACTCATTTGTGAGG

SEQ ID NO: 12

25 HAYPDAECAQLVPGNNLAPPAMLQFAKTRKLSIERSDMRNRLLHQRQFFHSHRAQPMAAEQ
VMSDRDSEDEVDDDVADFEDRRMLDDFVDVTKDEKQMMHLWNSFVR

SEQ ID NO: 13

30 ATGGATCCGATTAAGCTGACAACAGAAGCTAAGGTCCCTGCTAAGCGATCAAAGGCTACAAG
CCACTACTTGCTCTTCATAAACGCCAGTTCTATCATTCCCGAACCGGTGAGCCATTGTCAC
TTGAGCAAGTTATGTCTGACCGAGATAGCGAAAATGACGTCGACAAAAATGATGATGCTGCA
CATCTCGAAGAAAGCCAGATGCTTAATGGTTCCATGGATGAGAATGAAATCGTAGCAGAGAG
ATTCATAAACTTTGGAACCTCTTTGTAAACAGCAAAGGATTGTTGCAGATGCTCATATTC
35 CTTGGGCATGTGAAGCATTTCTCAAGATTACACCTGCAAGAGCTGCGCAGTAACTTATCACTC
GACTTGTGCTGGAGACAATTCATGATCAAACAATGGGATTATGGACTTCTTGACAGAGTCAC
CATGAACAAATGCAATACCATCATCTACCATAATATCTCAACTACCAACGATGACATAAACA
ATAACAACACAAGGACGACTGATAATATGGATGTTGTGCGACGATGACATAAACAGAGACAAG

SEQ ID NO: 14

MDPIKLTTEAKVPAKRSKATSHYLPLHKRQFYHSRTGQPLSLEQVMSDRDSENDVDKNDDAA
5 HLEESQMLNGSMDENEIVAERFIKLWNSFVKQQRIVADAHIPWACEAFSRLHLQELRSNLSL
DLCWRQFMIKQWDYGLLDRVTMKNCNTIIYHNI STTND DINNNNTRTTDNMDVVDDDINRDK

SEQ ID NO: 15

10

15

20

25

30

35

CTCTGAGGAGACACTTTTTTTTTTCTCTCCCTCCTTCCCTCCTCTCCTCCTCCCTTCCCTTCCC
CTCTCCTCCCCTCTCTCCTCCTTCCCCCCTCGGTCCGCCGGAGCCTGCTGGGGCGAGCGGTT
GGTATTGCAGGCGCTTGCTCTCCGGGGCCGCCGGCGGGTAGCTGGCGGGGGGAGGAGGCAG
GAACCGCGATGGCGCCTCAGAAGCACGGCGGTGGGGGAGGGGGCGGCTCGGGGCCAGCGCG
15 GGGTCCGGGGGAGGCGGCTTCGGGGGTTCGGCGGCGGTGGCGGCGGCGACGGCTTCGGGCGG
CAAATCCGGCGGCGGGAGCTGTGGAGGGGGTGGCAGTTACTCGGCCTCCTCCTCCTCCTCCG
CGGCGGCAGCGGCGGGGGCTGCGGTGTTACCGGTGAAGAAGCCGAAAATGGAGCACGTCCAG
GCTGACCACGAGCTTTTCTCCAGGCCTTTGAGAAGCCAACACAGATCTATAGATTTCTTCG
AACTCGGAATCTCATAGCACCAATATTTTTGCACAGA ACTCTTACTTACATGTCTCATCGAA
20 ACTCCAGAACAAACATCAAAAGGAAAACATTTAAAGTTGATGATATGTTATCAAAAGTAGAG
AAAATGAAAGGAGAGCAAGAATCTCATAGCTTGTCAGCTCATTTGCAGCTTACGTTTACTGG
TTTCTTCCACAAAATGATAAGCCATCACCAA ACTCAGAAAATGAACAAAATTTCTGTTACCC
TGGAAGTCCTGCTTGTAAGTTTGCCACAAAAAAGAAAGGATGTAAGTTGTCCAATAAGG
CAAGTTCCACAGGTAAAAAGCAGGTGCCTTTGATTCTTGACCTCAATCAAACAAAACCCGG
25 AAATTTCCCGTCCCTTGACGTTTCCAGTAATGAATTTGAACCTAGTAACAGCCATATGGTGA
AGTCTTACTCGTTGCTATTTAGAGTGA CTCTCCAGGAAGAAGAGAGTTTAATGGAATGATT
AATGGAGAAACCAATGAAAATATTGATGTCAATGAAGAGCTTCCAGCCAGAAGAAAACGAAA
TCGTGAGGATGGGGAAAAGACATTTGTTGCACAAATGACAGTATTTGATAAAAACAGGCGCT
TACAGCTTTTAGATGGGGAATATGAAGTAGCCATGCAGGAAATGGAAGAATGTCCAATAAGC
30 AAGAAAAGAGCAACATGGGAGACTATTCTTGATGGGAAGAGGCTGCCTCCATTCGAAACATT
TTCTCAGGGACCTACGTTGCAGTTC ACTCTTCGTTGGACAGGAGAGACCAATGATAAATCTA
CGGCTCCTATTGCCAAACCTCTTGCCACTAGAAATTCAGAGAGTCTCCATCAGGAAAACAAG
CCTGGTT CAGTTAAACCTACTCAA ACTATTGCTGTAAAGAATCATTGACTACAGATCTACA
AACAAGAAAAGAAAAGGATACTCCAAATGAAAACCGACAAAATTAAGAATATTTTATCAGT
35 TTCTCTATAACAACAATACAAGGCAACAACTGAAGCAAGAGATGACCTGCATTGCCCTTGG
TGTA CTCTGAACTGCCGCAA ACTTTATAGTTTACTCAAGCATCTTAACTCTGCCATAGCAG
ATTTATCTTCAACTATGTTTATCATCCAAAAGGTGCTAGGATAGATGTTTCTATCAATGAGT
GTTATGATGGCTCCTATGCAGGAAATCCTCAGGATATTCATCGCCAACCTGGATTTGCTTTT

AGTCGCAACGGACCAGTTAAGAGAACACCTATCACACATATTCTTGTGTGCAGGCCAAAACG
AACAAAAGCAAGCATGTCTGAATTTCTTGAATCTGAAGATGGGGAAGTAGAACAGCAAAGAA
CATATAGTAGTGGCCACAATCGTCTGTATTTCCATAGTGATACCTGCTTACCTCTCCGTCCA
CAAGAAATGGAAGTAGATAGTGAAGATGAAAAGGATCCTGAATGGCTAAGAGAAAAAACCAT
5 TACACAAATTGAAGAGTTTTCTGATGTTAATGAAGGAGAGAAAGAAGTGATGAAACTCTGGA
ATCTCCATGTCTATGAAGCATGGGTTTATTGCTGACAATCAAATGAATCATGCCTGTATGCTG
TTTGTAGAAAATTATGGACAGAAAATAATTAAGAAGAATTTATGTGAAACTTCATGCTTCA
TCTAGTCAGCATGCATGACTTTAATCTTATTAGCATAATGTCAATAGATAAAGCTGTTACCA
AGCTCCGTGAAATGCAGCAAAAATTAGAAAAGGGGAATCTGCTTCCCCTGCAAACGAAGAA
10 ATAAGTGAAGAACAAAATGGGACAGCAAAATGGATTTAGTGAAATTAACCTCAAAAGAGAAAGC
TTTGGAAACAGATAGTGTCTCAGGGGTTTCAAAACAGAGCAAAAAACAAAACCTCTGAAAAG
CTCTAACCCCATGTTATGGACAAACACTGAAATTACATTTTAGGGAATTCATCCTCTAAGAA
TTATGTTTTTGTTTTTAATCATATGTTCCAAACAGGCACTGTTAGATGAAGTAAATGATTTT
AACAAGGATATTTGTATCAGGGTCTACTTCATTTCATTATGCAGCATTACATGTATATCAC
15 TTTTATTGATGTCATTAAACATTCTGTACTTTAAGCATGAAAAGCAATATTTCAAAGTATT
TTTAAACTCAACAAATGTCATCAAATATGTTGAATTGATCTAGAAATTATTTTCATATATAAA
TCAGAATTTTTTTGCATTTATGAACGGCTGTTTTTCTACTTTGTAATTGTGAGACATTTTCT
TGGGGAGGGAAAATTGGAATGGTTCCCTTTTTTAGAAATTGAAGTGGTCTTCATATGTCAAC
TACAGAAAAGGAAAAAATAGAAATTGAAGGATTTTTATGAAATTATATTGCATTACTATTT
20 GCAGTCAAACCTTGATCCTTGTTTTGAAATCATTTGTCAATTCGGAATGAAAAATTATAAT
GTAATTTTACATTACATAAGTTCCTTTTACAATTAATAAATAGCACTTCTTCATCTTATGCC
TGTTTGAGAAGATATTAAATTTTCACATTGTTGACAGTGAAATGCTATGTTGGTTTATAAGA
TTACAGACCATTTGTTTTCATGTGGATAATTTTAGTGCATTGCTCACCCGGTATGTTTTTTT
TTTTTAACTTGAACATTTTGCTTGTTTTGTTTTTCTTTTTTAAATTAGATAATCACACGGAAA
25 ATTAAGCTGTTTCATATCTTTAAATTAGGATTGCAAACCAAGGAAAGAACGCATTTGAGATTT
TAAGATGTCACTTATAAGGGGAGAAGTGTTCTTAAAAAGTCAACCAGAAAACCTGTTATGCCT
TTTATTTGTTTGCAAGGATGTCTTTGTAATGTGTTTCATGAATAGAATATCCAATAGAGATA
AGCTGACTTGAATCATTTTGAGCAATTTTGCCCTGTGTTATATGTGTTTCACGCACATATTT
GCAGTTGGATTTTCTCCAACAGAAAGTGGATTCACTACTGGCACATTAACAAGCACCAATAG
30 GTTTTTATTCCAACCTCCGAGCACTGTGGTTGAGTAACATCACCTCAATTTTTTATTATCCTT
AAAGATATTGCATTTTCATATTCTTTATTTATAAAGGATCAATGCTGCTGTAAATACAGGTA
TTTTTAATTTTAAAATTTTCAATCCACCACCATCAGATGCAGTTCCTTATTTTGTTTAATGAA
GGGATATATAAGCTTTCTAATGGTGTCTTCAGAAATTTATAAAATGTAAATACTGATTTGAC
TGGTCTTTAAGATGTGTTTAACTGTGAGGCTATTTAACGAATAGTGTGGATGTGATTTGTCA
35 TCCAGTATTAAGTTCTTAGTCATTGATTTTTGTGTTTAAAAAATAAGGAAAGAGGGAAAC
TGCAGCTTTTCATTACAGATTCTTGATTGGTAAGCTCTCAAATGATGAGTTCTAGTAAACT
CTGATTTTTGCCTCTGGATAGTAGATCTCGAGCGTTTATCTCGGGCTTTAATTTGCTAAAGC
TGTGCACATATGTAAAAAAGATTATTTTAGGGGAGATGTAGGTGTAGAATT

ATTGCTTATGTCATTTCTTAAGCAGTTATGCTCTTAATGCTTAAAAGAAGGCTAGCATTGTT
TGCACAAAAAGTTGGTGATTCCCACCCCAAATAGTAATAAAATTACTTCTGTTGAGTAAACT
TTTTATGTCATCGTAAAAGCTGGAAAAATCCCTTTGTTTCTATTTATAAAAAAAGTGCTTTT
CTATATGTACCTTGATAACAGATTTTGAAGAAATCCTGTAAGATGATAAAGCATTGGAATG
5 GTACAGTAGATGTAAAAAAATTGAGTTTAAAAGAACATTTGTTTTTACATTAAATGTTTAT
TTGAAATCAAATGATTTTGTACATAAAGTTCAATAATAT

SEQ ID NO: 16

10

15

20

LRRHFFFPPSFPPLLLPSLPLSSPLSSFPSPRSAGACWGERLVLQALALRGRPAGSWRGEEAG
TAMAPQKHGGGGGGSGPSAGSGGGGFGGSAAVAAATASGGKSGGGSCGGGGSYSASSSSSA
AAAAGAAVLPVKKPKMEHVQADHELFLQAFEKPTQIYRFLRTRNLIAPIFLHRTLTYMSHRN
SRTNIKRKTFKVDDMLSKVEKMKGEQESHLSAHLQLTFTGFFHKNDKPSPSNEQNSVTL
EVLLVKVCHKRQDVSCPIRQVPTGKKQVPLIPDLNQTKPGNFPSLAVSSNEFEPNSHMKV
SYSLFRVTRPGRREFNGMINGETNENIDVNEELPARRKRNREDGEKTFVAQMTVFDKNRRL
QLLDGEYEVAMQEMEECPISKKRATWETILDGKRLPPFETFSQGPTLQFTLRWTGETNDKST
APIAKPLATRNSSESLHQENKPGSVKPTQTIAVKESLTDLQTRKEKDTPNENRQKLRIFYQF
LYNNNTRQQTEARDDLHCPWCTLNCRKLYSLLKHLKLCHSRFIFNYVYHPKGARIDVSINEC
YDGSYAGNPQDIHRQPGFAFSRNGPVKRTPIITHILVCRPKRTKASMSEFLESEGEVEQQRT
YSSGHNRLYFHSOTCLPLRPQEMEVDSEDEKDPEWLREKTIITQIEEFSDVNEGEKEVMKLWN
LHVMKHGFIADNQMNHACMLFVENYGQKI I KKNLCRNFMHLVSMHDFNLISIMSIDKAVTK
LREMQQKLEKGESASPAEIEETEEQNGTANGFSEINSKEKALETDSVSGVSKQSKKQKL

CLAIMS:

1. An isolated nucleic acid obtainable from the VRN2 locus of a plant, which nucleic acid encodes a polypeptide which is capable of affecting one or more physical characteristics of a plant into which the nucleic acid is introduced, the physical characteristics being selected from vernalization response, flowering time, leaf size and/or shape or shade avoidance response.
2. A nucleic acid according to claim 1 which is capable of reducing the vernalization requirement of the plant for flowering.
3. A nucleic acid according to claim 1 or claim 2 which comprises a VRN2 nucleotide sequence which encodes a polypeptide of SEQ ID No. 2.
4. A nucleic acid according to claim 3 wherein the VRN2 nucleotide sequence consists of the sequence of SEQ ID No. 1 or is degeneratively equivalent thereto.
5. A nucleic acid according to claim 1 or claim 2 which comprises a VRN2 nucleotide sequence which encodes a polypeptide of SEQ ID No. 5.
6. A nucleic acid according to claim 5 wherein the VRN2 nucleotide sequence consists of the sequence of SEQ ID No. 4 or is degeneratively equivalent thereto.
7. A nucleic acid according to claim 1 or claim 2 which comprises a VRN2 nucleotide sequence which encodes a polypeptide of SEQ ID No. 8.
8. A nucleic acid according to claim 7 wherein the VRN2 nucleotide sequence consists of the sequence of SEQ ID No. 7 or is degeneratively equivalent thereto.

9. An isolated nucleic acid obtainable from the VRN2 locus of a plant which nucleic acid comprises a nucleotide sequence of SEQ ID No. 3 or SEQ ID No. 6, or a nucleic acid degenerative equivalent thereof.

5

10. A nucleic acid according to claim 9 which comprises a sequence having promoter and/or regulatory function.

10 11. An isolated nucleic acid which comprises a variant sequence which is a homologous variant of a nucleotide sequence of any one of claims 4, 6, 8, 9 or 10 and which shares at least about 50% identity therewith.

15 12. A nucleic acid according to claim 11 wherein the variant sequence is capable of affecting one or more physical characteristics of a plant into which the nucleic acid is introduced, the physical characteristics being selected from vernalization response, flowering time, leaf size and/or shape or shade avoidance response

20

13. A nucleic acid according to claim 11 or claim 12 wherein the variant is an allelic variant of a nucleotide sequence of any one of claims 4, 6, 8, 9 or 10, or is a nucleic acid degenerative equivalent thereof.

25

14. A nucleic acid according to claim 11 or claim 12 wherein the variant sequence is a VRN2 sequence obtainable from a plant species other than *Arabidopsis thaliana*.

30 15. An isolated nucleic acid sequence which comprises a derivative of a nucleotide sequence of any one of claims 4, 6, 8, 9 or 10, which is a derivative by way of one or more of addition, insertion, deletion or substitution of a said nucleotide sequence and wherein the derivative sequence is
35 either capable of affecting one or more physical characteristics of a plant into which the nucleic acid is introduced, the physical characteristics being selected from vernalization response, flowering time, leaf size and/or shape

or shade avoidance response or has promoter and/or regulatory function.

16. An isolated nucleic acid which comprises a sequence which
5 is a fragment of a sequence of any one of claims 1 to 15 and
either is capable of affecting one or more physical
characteristics of a plant into which the nucleic acid is
introduced, the physical characteristics being selected from
vernalization response, flowering time, leaf size and/or shape
10 or shade avoidance response or has promoter and/or regulatory
function.

17. An isolated nucleic acid which comprises a sequence which
15 is the complement of a sequence of any one of claims 1 to 16.

18. An isolated nucleic acid for use as a probe or primer
which comprises a sequence that encodes an amino acid sequence
that is partly, substantially or completely conserved between
a VRN2 sequence of SEQ ID Nos. 2, 5 or 8 and at least one of
20 the other sequences shown in Figure 8a or 8b.

19. An isolated nucleic acid for use as a probe or primer
which comprises a sequence that is partly, substantially or
completely conserved between two or more of the VRN2
25 nucleotide sequences of claim 4, 6, 8 9 or 10 or the
complements thereof.

20. A nucleic acid according to claim 18 or claim 19 which is
15 to 40 nucleotides in length.

21. A nucleic acid according to claim 20 which is 19 to 28
nucleotides in length.

22. A pair of primers each comprising a nucleic acid
35 according to any one of claims 18 to 21.

23. A pair of primers according to claim 22 which is selected from:

VRN2-AP and VRN2-AJ;
VRN2-AO and VRN2-AS; and
5 VRN2-AI and VRN2-AJ.

24. A process for producing a nucleic acid which is a derivative according to claim 15 which process comprises the step of modifying

25. A method for identifying or cloning a nucleic acid according to any one of claims 1 to 17, which method comprises using a nucleotide sequence of a probe or primer of claim 18
15 or 19 in a database search.

26. A method for identifying or cloning a nucleic acid according to any one of claims 1 to 17, which method employs a probe or primer according to any one of claims 18 to 21 or a
20 pair of primers according to claim 22 or 23.

27. A method for determining the presence of a nucleic acid according to any one of claims 1 to 17 within the genetic make-up of a plant, which method employs a probe or primer
25 according to any one of claims 18 to 21 or a pair of primers according to claim 22 or 23.

28. A method according to claim 26 or claim 27, which comprises the steps of:

30 (a) providing a preparation of nucleic acid from a plant cell;

(b) providing a nucleic acid molecule which is a probe according to any one of claims 19 to 21;

(c) contacting nucleic acid in said preparation with
35 said probe under conditions for hybridisation; and

(d) identifying a nucleic acid according to any one of claims 1 to 17 if present by its hybridisation with said nucleic acid probe.

29. A method according to claim 26 or claim 27, which method comprises the steps of:

(a) providing a preparation of nucleic acid from a plant cell;

(b) providing a pair of nucleic acid molecule primers suitable for PCR, at least one of said primers being a primer of any one of claims 18 to 21;

(c) contacting nucleic acid in said preparation with said primers under conditions for performance of PCR;

(d) performing PCR and determining the presence or absence of an amplified PCR product.

30. A method according to claim 29 wherein the pair of nucleic acid molecule primers are according to claim 22 or claim 23.

31. A method of selecting a plant having a desired allele of the VRN2 gene, which method employs a probe or primer according to any one of claims 18 to 21 or a pair of primers according to claim 22 or 23.

32. A recombinant vector which comprises the nucleic acid of any one of claims 1 to 17.

33. A vector according to claim 32 wherein the nucleic acid comprised in the vector is capable of regulating one or more genes involved in the transition from vegetative to reproductive growth and/or capable of regulating one or more genes involved in the determination of leaf size and/or shape.

34. A vector according to claim 32 or claim 33 wherein the nucleic acid is operably linked to a promoter for transcription in a host cell, wherein the promoter is optionally an inducible promoter.

35. A vector according to claim 34 wherein the promoter is a constitutive promoter.

36. A vector according to any one of claims 32 to 35 which is a plant vector.

37. A method which comprises the step of introducing a vector
5 according to any one of claims 32 to 36 into a host cell such as to transform the host cell.

38. A host cell which is transformed with a heterologous nucleic acid of any one of claims 1 to 17.

39. A host cell according to claim 38 which is a plant cell, optionally present in a plant.

40. A method for producing a transgenic plant, which method
15 comprises the steps of:
 (a) performing a method according to claim 37
 (b) regenerating a plant from the transformed host cell.

41. A transgenic plant which is obtainable by the method of
20 claim 40, or which is a clone, or selfed or hybrid progeny or other descendant of said transgenic plant, which in each case includes the plant cell of claim 39.

42. A plant according to claim 41 which is an agricultural or
25 horticultural plant.

43. A plant according to claim 41 or claim 42 selected from the list consisting of: rice, maize, wheat, barley, oats, rye, oil seed rape, sugar beet, sunflower, soybean, sorghum,
30 lettuce, endive, cabbage, broccoli, cauliflower, carnation, geranium, tobacco, cotton, canola, tomato, mango, peach, apple, pear, strawberry, banana, melon, carrot, onion, pea, celery.

35 44. A plant according to claim 43 which is selected from tobacco, oil seed rape, rice and wheat.

45. A part or propagule from a plant according to any one of claims 41 to 44, which includes the plant cell of claim 39.

46. An isolated polypeptide which is encoded by a nucleotide
5 sequence according to any one of claims 1 to 17.

47. A polypeptide according to claim 46 which comprises an amino acid sequence which consists of the sequence of SEQ ID Nos. 2, 5 or 8.

10

48. A polypeptide according to claim 46 which is a fragment of a polypeptide of claim 47.

15

49. An isolated polypeptide which consists of the sequence of SEQ ID Nos. 2, 5 or 8.

20

50. An isolated polypeptide which is a fragment of a polypeptide according to claim 47 and which comprises at least 5 contiguous amino acids of that polypeptide.

25

51. A fragment according to claim 50 which comprises amino acids 90 to 111 (zinc finger motif), amino acids 63 to 132 (amino terminal region), amino acids 263 to 366 (carboxy terminus) or amino acids 263 to 328 (activation domain).

30

52. A fragment according to any one of claims 48 to 51 which is capable of affecting one or more physical characteristics of a plant expressing said fragment, the physical characteristics being selected from vernalization response, flowering time, leaf size and/or shape or shade avoidance response.

35

53. An isolated nucleic acid which encodes for a fragment according to claim 50 or claim 51, or claim 52 as dependent therefrom.

54. An isolated nucleic acid which is the complement of the nucleic acid of claim 53.

55. A method of making the polypeptide of any one of claims 46 to 52, which method comprises the step of causing or allowing expression from a nucleic acid of any one of claims 1 to 17 or 53 in a suitable host cell.

5

56. An antibody which has specific binding affinity for a polypeptide according to any one of claims 46 to 52.

57. A polypeptide which comprises the antigen-binding site of the antibody of claim 56.

10

58. A method for affecting a physical characteristic of a plant selected from vernalization response, flowering time, leaf size and/or shape or shade avoidance response, which method comprises either the step of:

15


(i) causing or allowing transcription from a nucleic acid according to claim 17 or claim 54 in the plant; or

(ii) causing or allowing transcription from a nucleic acid according to any one of claims 1 to 16 or claim 53.

20

59. A method according to claim 58 which method comprises causing or allowing transcription from a nucleic acid according to any one of claims 1 to 16 or claim 53 thereby to reduce VRN2 expression by co-suppression.

Figure 1






A**2/12****B****Fig. 2**

Figure 3



4/12





Fig. 4

5/12

Figure 5



6/12

TTCTTCAATTTTGCTTGCTCTCTTTACACAGCCAATCGGTGTTTTTCGCAGCTTTCAGGCCTCAATCCAAGACAT	5
TCTATATAAGCATATTGCAGAAGAGGCGGTTCTAATTGTTGCATTGAGTTTATCGCTATGACGTAGGGAATTTCT	80
AATTTAGGGGAGGCGCTCAGAGTTTGACTAAGTTTCATAATCGGCTCTTGACGTTGTTGAGTGAATTGAACAAGA	155
ATGTGTAGGCAGAATTGTTCGCGCGAAATCCTCACCGGAGGAAGTGATTTCAACTGATGAGAATCTCTTGATATAT	230
M C R Q N C R A K S S P E E V I S T D E N L L I Y	305
TGTAAACCTGTTTCGACTATATAACATCTTTACCTTCGCTCTCTAGGCAACCCATCGTTTCTTCCAAGATGCTTG	25
C K P V R L Y N I F H L R S L G N P S F L P R C L	380
AACTACAAAATTGGAGCAAAGCGCAAAGAAAGTCAAGATCTACTGGGATGGTAGTTTCAACTATAAGGATTGT	50
N Y K I G A <u>K R K R K</u> S R S T G M V V F N Y K D C	455
AATAACACATTACAGAAAAGTGAAGTTAGGAGGATTGTTCTTGTCCATTTTGTCTCTATGCTATGTGGTAGCTTC	75
N N T L Q K T E V R E D C S <u>C P F C S M L C G S F</u>	530
AAGGGCTGCAATTTTCAATTTGAATTCATCTCATGATTATTGTAATTTGAGTTCAAGCTTTTGAAGAATACCAG	100
<u>K G L Q F H L N S S H</u> D L F E F E F K L F E E Y Q	605
ACAGTTAATGTTTCTGTAAAACCTAATTCTTCATATTTGAGGAAGAAGGATGATGACGATAAATTTGAGCCC	125
T V N V S V K L N S F I F E E E G S D D D K F E P	680
TTCTCTCTCTGCTCGAAACCTCGTAAGCGGAGACAAAGAGGTGGCAGAAATAACACCAGGAGACTTAAAGTATGC	150
F S L C S K P <u>R K</u> R R Q R G G R N N T <u>R R L K V</u> C	755
TTTTTACCGTTGGATTACCCAGTTTAACTAATGGCACAGAAAATGGAATCACCTACTTAATGATGGAAACCGT	175
F L P L D S P S L T N G T E N G I T L L N D G N R	830
GGTTTAGGATATCCCGAGGCAACAGAGCTTGCTGGACAATTTGAGATGACCAGCAACATTCCACCAGCCATAGCC	200
G L G Y P E A T E L A G Q F E M T S N I P P A I A	905
CACTCTTCTCTGGACGCTGGTGCTAAAGTTATATTGACAAGCGAAGCTGTGGTCCCTGCTACTAAGACAAGAAAG	225
H S S L D A G A K V I L T S E A V V P A T K T R K	980
TTATCTGCTGAGCGATCAGAGGCTAGAAGCCACCTACTTCTTCAGAAACGCCAATTCATCTCTCACAGAGTC	250
L S A E R S E A R S H L L L Q K R Q F Y H S H R V	1055
CAGCCAATGGCGCTTGAGCAAGTAATGTCTGACCGGGATAGCGAGGATGAAGTCGATGACGATGTTGCAGATTTT	275
Q P M A L <u>E Q V M S D R D S E D E V D D D V A D F</u>	1130
GAAGATCGCCAGATGCTTGATGACTTTGTGGATGTGAATAAAGATGAAAAGCAATTCATGCATCTTTGSAACTCG	300
E D R Q M L D D F V D V N K D E K Q F M H L <u>(W)</u> N S	1205
TTTGTAAGAAAACAAAGGGTTATAGCAGATGGTCATATCTCTTGGGCATGTGAAGCATTTTCAAGATTTTACGAG	325
F V R K Q R V I A D G H I S W A C E A F S R F Y E	1280
AAAGAGTTGCACCGTTACTCATCACTCTTCTGGTGTGGAGATTGTTTTTGATTAAGTATGGAACCATGGACTT	350
K E L H R Y S S L F W C W R L F L I K L W N H G L	1355
GTCGACTCAGCCACCATCAACAACCTGCAATACCATCCTCGAGAATTGCCGTAATAGCTCAGACACCACCACCACC	375
V D S A T I N N C N T I L E N C R N S S D T T T T	1430
AACAACAACAACAGTGTGGATCGTCCAGTGACTCAAACACCAACAACAATAACATTGTGGATCATCCCAATGAC	400
N N N N S V D R P S D S N T N N N N I V D H P N D	1505
ATAAACAACAAGAACAATGTTGACAACAAGGACAATAACAGCAGAGACAAAGTAATTAATAGGAAAATCTCCGG	425
I N N K N N V D N K D N N S R D K V I K	1580
CTTTTATGATACCGATTTATCGGATTGTAACCTATTCTCTTCTTAAAAAATTGTTTAGGAGCAAACAAATTTT	445
TTATATGTTAGTGTATTCAACTGATTACATTTTGTAGTAAAAAATAATGGATTCTGCTTATAACT	1655
	1722

Figure 6
SUBSTITUTE SHEET (RULE 26)

09/890220-1244

Figure 7

fca-1
vrn2-1

W323
GAAAAGCAATTTCATGCATCTT TGG AACTCGTTTGTAAGAA
TGA
STOP

GAAAAGCAATTTCATGCATCTTTTGAAACTCGTTTGTAAGAA
CTNNNNNAAG
XmnI site

Diagnostic Primer: VRN2-AZ Antisense 3' TGAGAAAGACATCTTTTGTTCATTCATGAAGAG 5'
(contains a A and G mismatches at positions 5,7) (CTT)NNNNNAAG
XmnI half-site

Upstream Primer: VRN2-AY 5' TCGGTTTCATTAAAGTAGGCAACAGAAAAATGG 3'

Product: 170 bp PCR product for both *fca-1* and *vrn2-1*

PCR Products:

fca-1 GAAAAGCAATTTCATGCATCTTTTGAAACTCTTCTGTAAGAA
vrn2-1 GAAAAGCAATTTCATGCATCTTTTGAAACTCTTCTGTAAGAA

XmnI digest => *fca-1* no XmnI site 170 bp
vrn2-1 single XmnI site 137 bp, 33 bp fragments

Figure 8a

VRN2 Ler	M	C	R	Q	N	C	R	A	K	S	S	P	E	E	V	I	S	T	D	E	20
AI163743 Prot	1
Rice C72616	1
At Hyp 2245035	1
KIA00160	I	A	K	P	L	A	T	R	N	S	E	S	L	H	Q	E	452
VRN2 Ler	N	L	L	I	Y	C	K	P	V	R	L	Y	N	I	F	H	L	R	S	L	40
AI163743 Prot	1
Rice C72616	1
At Hyp 2245035	1
KIA00160	N	K	P	G	S	V	K	P	T	Q	T	I	464
VRN2 Ler	G	N	P	S	F	L	P	R	C	L	N	Y	K	I	G	A	K	R	K	R	60
AI163743 Prot	1
Rice C72616	1
At Hyp 2245035	1
KIA00160	A	V	K	E	S	L	T	T	D	L	Q	T	R	K	E	K	D	T	P	N	484
VRN2 Ler	K	S	R	S	T	G	M	V	V	F	N	Y	K	D	C	N	N	T	L	Q	80
AI163743 Prot	1
Rice C72616	1
At Hyp 2245035	1
KIA00160	E	N	R	Q	K	L	R	I	F	Y	Q	F	L	Y	N	N	N	T	R	Q	504
VRN2 Ler	K	T	E	V	R	E	D	C	S	C	P	F	C	S	M	L	C	G	S	F	100
AI163743 Prot	1
Rice C72616	1
At Hyp 2245035	1
KIA00160	Q	T	E	A	R	D	D	L	H	C	P	W	C	T	L	N	C	R	K	L	524
VRN2 Ler	K	G	L	Q	F	H	L	N	S	S	H	D	L	F	E	F	E	F	K	L	120
AI163743 Prot	1
Rice C72616	1
At Hyp 2245035	1
KIA00160	Y	S	L	L	K	H	L	K	L	C	H	S	R	F	I	F	N	Y	V	Y	544

9/12

Figure 8a continued

VRN2 Ler	F	E	E	Y	Q	T	V	N	V	S	V	K	L	N	S	F	I	F	E	E	140	
AI163743 Prot	1	
Rice C72616	1	
At Hyp 2245035	1	
KIA00160	H	P	K	G	A	R	I	D	V	S	I	N	557	
VRN2 Ler	E	G	S	D	D	D	K	F	E	P	F	S	L	C	S	K	P	R	K	R	160	
AI163743 Prot	1	
Rice C72616	T	F	S	Y	R	S	R	F	K	K	10	
At Hyp 2245035	1	
KIA00160	557	
VRN2 Ler	R	Q	R	G	G	R	N	N	T	R	R	L	K	V	C	F	L	P	L	D	180	
AI163743 Prot	1	
Rice C72616	R	K	R	V	E	I	S	S	D	K	I	R	H	V	H	P	H	I	V	D	30	
At Hyp 2245035	1	
KIA00160	557	
VRN2 Ler	S	P	S	L	T	N	G	T	E	N	G	I	T	L	L	N	D	G	N	R	200	
AI163743 Prot	1	
Rice C72616	S	G	S	P	E	D	A	Q	A	G	S	E	D	D	Y	V	Q	R	E	N	50	
At Hyp 2245035	1	
KIA00160	E	C	Y	D	560	
VRN2 Ler	G	L	G	Y	P	E	A	T	E	L	A	G	Q	Q	F	E	M	T	S	N	I	220
AI163743 Prot	.	H	A	Y	P	D	A	A	S	.	C	A	Q	Q	L	V	P	G	N	N	L	17
Rice C72616	G	S	.	V	A	H	.	.	.	D	P	A	N	S	L	H	G	S	N	N	L	70
At Hyp 2245035	1	
KIA00160	G	S	Y	A	G	N	P	Q	D	I	H	R	Q	.	P	G	F	A	S	R	580	
VRN2 Ler	P	P	A	I	A	H	S	S	L	D	A	G	A	K	V	I	L	T	S	E	240	
AI163743 Prot	21	
Rice C72616	S	A	74	
At Hyp 2245035	M	D	P	I	C	K	L	T	E	9	
KIA00160	N	G	P	V	K	R	T	P	I	T	H	I	L	V	.	.	P	K	R	.	600	

Figure 8a continued

WO 00/44918

10/12

09/890220

PCT/GB00/00248

VRN2 Ler	A V V P A	T K T R K L S	A I V	E E E R R S	E D D K Q	A R S	260
AI163743 Prot	A M L Q F F	K K T R K L S	A I V	E E E R R S	E D D K Q	A R S	40
Rice C72616	T V L Q F F	K K T R K L S	A I V	E E E R R S	E D D K Q	A R S	93
At Hyp 2245035	A K V P A	E E E R R S	E D D K Q	A R S	21
KIA00160	K A S M S	. F L E S E D	. G	E E E R R S	E D D K Q	A R S	620
VRN2 Ler	H L : L L L L L	Q H Q H Q H	S S S S S	H H H R R	V A A G C	M A	279
AI163743 Prot	R T : L L L L L	Q H Q H Q H	S S S S S	H H H R R	V A A G C	M A	59
Rice C72616	R Q : L L L L L	Q H Q H Q H	S S S S S	H H H R R	V A A G C	M A	112
At Hyp 2245035	H Y S	L L L L L	S S S S S	H H H R R	V A A G C	M A	41
KIA00160	H Y S	L L L L L	S S S S S	H H H R R	V A A G C	M A	639
VRN2 Ler	L E E Q V M	S S S S S	D E E D E	V V V V V	. . . N .	D D V	297
AI163743 Prot	L E E Q V M	S S S S S	D E E D E	V V V V V	. . . N .	D D V	77
Rice C72616	L E E Q V M	S S S S S	D E E D E	V V V V V	. . . N .	D D V	130
At Hyp 2245035	L E E Q V M	S S S S S	D E E D E	V V V V V	. . . N .	D D V	61
KIA00160	L E E Q V M	S S S S S	D E E D E	V V V V V	. . . N .	D D V	655
VRN2 Ler	A D F E E E E	D D D D D	F F F F F	V V V V V	N K D	. E E	316
AI163743 Prot	A D F E E E E	D D D D D	F F F F F	V V V V V	N K D	. E E	96
Rice C72616	A D F E E E E	D D D D D	F F F F F	V V V V V	N K D	. E E	149
At Hyp 2245035	A D F E E E E	D D D D D	F F F F F	V V V V V	N K D	. E E	81
KIA00160	A D F E E E E	D D D D D	F F F F F	V V V V V	N K D	. E E	674
VRN2 Ler	K Q F M H L	W N S F V	R K Q R V	I A D G			336
AI163743 Prot	K Q F M H L	W N S F V	R K Q R V	I A D G			108
Rice C72616	K Q F M H L	W N S F V	R K Q R V	I A D G			154
At Hyp 2245035	K Q F M H L	W N S F V	R K Q R V	I A D G			101
KIA00160	K Q F M H L	W N S F V	R K Q R V	I A D G			694
VRN2 Ler	H I S W A G E	A F S R F	Y E K	E L H R Y			356
AI163743 Prot	H I S W A G E	A F S R F	Y E K	E L H R Y			108
Rice C72616	H I S W A G E	A F S R F	Y E K	E L H R Y			154
At Hyp 2245035	H I S W A G E	A F S R F	Y E K	E L H R Y			121
KIA00160	H I S W A G E	A F S R F	Y E K	E L H R Y			714

Figure 8a continued

VRN2 Ler	S	S	L	F	W	C	W	R	L	F	L	I	K	L	W	N	H	G	L	V	376
AI163743 Prot																				108	
Rice C72616	L	S	L	D	L	C	W	R	Q	F	M	I	K	Q	W	D	Y	G	L	L	154
At Hyp 2245035	.	N	L	C	R	N	F	M	L	H	L	V	S	M	H	D	F	N	L	I	141
KIA00160																				733	
VRN2 Ler	D	S	A	T	I	N	C	N	T	I	L	E	N	C	R	N	S	S	D		396
AI163743 Prot																				108	
Rice C72616	D	R	V	T	M	N	K	C	N	T	I	I	Y	H	N	I	S	T	T	N	154
At Hyp 2245035	S	I	M	S	I	D	K	A	V	T	K	L	R	E	M	Q	K	L	E		161
KIA00160																				753	
VRN2 Ler	T	T	T	T	N	N	N	N	S	V	D	R	P	S	D	S	N	T	N	N	416
AI163743 Prot																				108	
Rice C72616	D	D	I	N	N	N	N	T	R	T	T	D	N	M	D	V	V	D	D	D	154
At Hyp 2245035	K	G	E	S	A	S	P	A	N	E	E	I	T	E	E	Q	N	G	T	A	181
KIA00160																				773	
VRN2 Ler	N	N	I	V	D	H	P	N	D	I	N	N	K	N	N	V	D	N	K	D	436
AI163743 Prot																				108	
Rice C72616	I	N	R	D	K															154	
At Hyp 2245035	N	G	F	S	E	I	N	S	K	E	K	A	L	E	T	D	S	V	S	G	186
KIA00160																				793	
VRN2 Ler	N	N	S	R	D	K	V	I	K											445	
AI163743 Prot																				108	
Rice C72616																				154	
At Hyp 2245035	V	S	K	Q	S	K	K	Q	K	L										186	
KIA00160																				803	

[illegible]

Figure 8b

VRN2 Ler
AI D119 S51478
AI D119 S51478
AI SUP U38946
AI SUP 2191171
AI Hyp 3377806
Sc Pep7 91500
Sc TFLIA 730931
Sp Hyp 1351713
Ce Hyp 255942
Ce Hyp 2854197
Ce Hyp 304459
Dm BRCORE-NS-Z3
Dm GAGA 729556
Dm ken 3550814
Hs ATBF-1 976347
Hs KIA00160
Hs ZNF142 3123312
Mm FOG 252814
Mm Spalt 1296845
Rn Roaz 2149792
Xm ZF1 532083

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of)
)
Caroline Dean et al.)
)
Serial No. 09/890/220)
)
Filed: July 27, 2001)
)
For: "Methods and Means for)
Modification of Plant)
Characteristics Using)
The Vernalization Gene)
VRN2")

SUBMISSION OF SEQUENCE LISTING

UNDER 37 C.F.R. §§1.821-1.825 AND THIRD PRELIMINARY AMENDMENT


The present submission is in response to the Official communication dated August 24, 2001 enclosing a Notification To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures in connection with the above-identified patent application.

To comply with the requirements under 37 C.F.R. §§1.821-1.825, submitted herewith is a sequence listing of the amino acids and nucleotides presented in the above-referenced application. The sequence listing is being submitted in both paper copy and computer-readable form. Applicants respectfully request entry of the sequence listing into the above-identified patent application. The undersigned hereby verifies that the paper copy and computer readable form of the sequence listing are identical and do not contain any new matter.

In the event that a fee is required, the Commissioner is authorized to charge the account of the undersigned, Account No. 04-1406. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

DANN, DORFMAN, HERRELL AND SKILLMAN
A Professional Corporation

By 
Kathleen D. Rigaut, Ph.D., J.D.
PTO Registration No. 43,047

Telephone: (215) 563-4100

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of)
)
Caroline Dean et al.)
)
Serial No. 09/890/220)
)
Filed: July 27, 2001)
)
For: "Methods and Means for)
Modification of Plant)
Characteristics Using)
The Vernalization Gene)
VRN2")

SUBMISSION OF SEQUENCE LISTING

UNDER 37 C.F.R. §§1.821-1.825 AND THIRD PRELIMINARY AMENDMENT


The present submission is in response to the Official communication dated August 24, 2001 enclosing a Notification To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures in connection with the above-identified patent application.

To comply with the requirements under 37 C.F.R. §§1.821-1.825, submitted herewith is a sequence listing of the amino acids and nucleotides presented in the above-referenced application. The sequence listing is being submitted in both paper copy and computer-readable form. Applicants respectfully request entry of the sequence listing into the above-identified patent application. The undersigned hereby verifies that the paper copy and computer readable form of the sequence listing are identical and do not contain any new matter.

In the event that a fee is required, the Commissioner is authorized to charge the account of the undersigned, Account No. 04-1406. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

DANN, DORFMAN, HERRELL AND SKILLMAN
A Professional Corporation

By 
Kathleen D. Rigaut, Ph.D., J.D.
PTO Registration No. 43,047

Telephone: (215) 563-4100

<110> Dean, Caroline
Gendall, Anthony

<130> Mewburn

<141> 2001-07-27

<151> 2000-01-28

<151> 1999-01-28

<160> 77

<170> PatentIn Ver. 2.1

<210> 1

<211> 1722

<212> DNA

<213> Arabidopsis thaliana

<400> 1

caagctctctt	caatttttgt	tgtctctctt	tacacagcca	atcggtgttt	tcgcagcttt	60
caggcctcaa	tccaagacat	tctatataag	catattgcag	aagaggcggt	tctaattggt	120
gcattgagtt	tatcgctatg	acgtagggaa	attctaattt	aggggaggcc	tcagagtttg	180
cactaacttc	ataatcggct	cttgacgttg	ttgagtgtaa	ttgaacaaga	atgtgtaggc	240
agaattgtcg	cgcgaaatcc	tcaccggagg	aagtgatttc	aactgatgag	aatctcttga	300
tatattgtaa	acctgttcga	ctatataaca	tctttcacct	tcgctctcta	ggcaacccat	360
cgtttcttcc	aagatgcttg	aactacaaaa	ttggagcaaa	gcgcaaaaga	aagtcaagat	420
ctactgggat	ggtagttttc	aactataaag	attgtaataa	cacattacag	aaaactgaag	480
ttagggagga	ttgttcttgt	ccatttttgt	ctatgctatg	tggtagcttc	aaggggtcgc	540
aatttctatt	gaattcatct	catgattttat	ttgaatttga	gttcaagctt	ttcgaagaat	600
accagacagt	taatgtttct	gtaaaaactta	attccttcat	atttgaggaa	gaaggaagtg	660
atgacgataa	atttgagccc	ttctctctct	gctcgaaacc	tcgtaagcgg	agacaaagag	720
gtggcagaaa	taacaccagg	agacttaaa	tatgcttttt	accgttggat	tcacccagtt	780
taactaatgg	cacagaaaat	ggaatcacc	tacttaatga	tggaaaccgt	ggtttaggat	840
atcccagggc	aacagagctt	gctggacaat	ttgagatgac	cagcaacatt	ccaccagcca	900
tagcccactc	ttctctggag	gctggtgcta	aagttatat	gacaagcgaa	gctgtggttc	960
ctgctactaa	gcacagaaga	ttatctgctg	agcgatcaga	ggctagaagc	cacctacttc	1020
ttcagaaaacg	ccaattctat	cattctcaca	gagtcagccc	aatggcgctt	gagcaagtaa	1080
tgtctgaccg	ggatagcgag	gatgaagtgc	atgacgatgt	tgcagatttt	gaagatcgcc	1140
agatgcttga	tgactttgtg	gatgtgaata	aagatgaaaa	gcaattcatg	catcttttga	1200
actcgtttgt	aagaaaacaa	agggttatag	cagatggtca	tatctcttgg	gcatgtgaag	1260
cattttcaag	attttacgag	aaagagttgc	accgttactc	atcactcttc	tggtgttgga	1320
gattgttttt	gattaaacta	tggaaccatg	gacttgctga	ctcagccacc	atcaacaact	1380
gcaataccat	cctcgagaat	tgccgtaata	gctcagacac	caccaccacc	aacaacaaca	1440
acagtgtgga	tcgtcccagt	gactcaaaaa	ccaacaacaa	taacattgtg	gatcatccca	1500
atgacataaa	caacaagaac	aatgttgaca	acaaggacaa	taacagcaga	gacaaagtaa	1560
ttaaatagga	aaatctccqg	cttttatgat	accgattttat	cggattgtaa	cttattcttc	1620

```
<210> 2
<211> 445
<212> PRT
<213> Arabidopsis thaliana
```

<400> 2																
Met	Cys	Arg	Gln	Asn	Cys	Arg	Ala	Lys	Ser	Ser	Pro	Glu	Glu	Val	Ile	
1				5					10					15		
Ser	Thr	Asp	Glu	Asn	Leu	Leu	Ile	Tyr	Cys	Lys	Pro	Val	Arg	Leu	Tyr	
			20					25					30			
Asn	Ile	Phe	His	Leu	Arg	Ser	Leu	Gly	Asn	Pro	Ser	Phe	Leu	Pro	Arg	
		35					40					45				
Cys	Leu	Asn	Tyr	Lys	Ile	Gly	Ala	Lys	Arg	Lys	Arg	Lys	Ser	Arg	Ser	
	50					55					60					
Thr	Gly	Met	Val	Val	Phe	Asn	Tyr	Lys	Asp	Cys	Asn	Asn	Thr	Leu	Gln	
65					70					75					80	
Lys	Thr	Glu	Val	Arg	Glu	Asp	Cys	Ser	Cys	Pro	Phe	Cys	Ser	Met	Leu	
				85					90					95		
Cys	Gly	Ser	Phe	Lys	Gly	Leu	Gln	Phe	His	Leu	Asn	Ser	Ser	His	Asp	
			100					105					110			
Leu	Phe	Glu	Phe	Glu	Phe	Lys	Leu	Phe	Glu	Glu	Tyr	Gln	Thr	Val	Asn	
		115					120					125				
Val	Ser	Val	Lys	Leu	Asn	Ser	Phe	Ile	Phe	Glu	Glu	Glu	Gly	Ser	Asp	
	130					135					140					
Asp	Asp	Lys	Phe	Glu	Pro	Phe	Ser	Leu	Cys	Ser	Lys	Pro	Arg	Lys	Arg	
145					150					155					160	
Arg	Gln	Arg	Gly	Gly	Arg	Asn	Asn	Thr	Arg	Arg	Leu	Lys	Val	Cys	Phe	
				165					170					175		
Leu	Pro	Leu	Asp	Ser	Pro	Ser	Leu	Thr	Asn	Gly	Thr	Glu	Asn	Gly	Ile	
			180					185					190			
Thr	Leu	Leu	Asn	Asp	Gly	Asn	Arg	Gly	Leu	Gly	Tyr	Pro	Glu	Ala	Thr	
		195					200					205				
Glu	Leu	Ala	Gly	Gln	Phe	Glu	Met	Thr	Ser	Asn	Ile	Pro	Pro	Ala	Ile	
	210					215					220					
Ala	His	Ser	Ser	Leu	Asp	Ala	Gly	Ala	Lys	Val	Ile	Leu	Thr	Ser	Glu	
225					230					235					240	
Ala	Val	Val	Pro	Ala	Thr	Lys	Thr	Arg	Lys	Leu	Ser	Ala	Glu	Arg	Ser	
				245					250					255		

Glu Ala Arg Ser His Leu Leu Leu Gln Lys Arg Gln Phe Tyr His Ser
 260 265 270
 His Arg Val Gln Pro Met Ala Leu Glu Gln Val Met Ser Asp Arg Asp
 275 280 285
 Ser Glu Asp Glu Val Asp Asp Asp Val Ala Asp Phe Glu Asp Arg Gln
 290 295 300
 Met Leu Asp Asp Phe Val Asp Val Asn Lys Asp Glu Lys Gln Phe Met
 305 310 315 320
 His Leu Trp Asn Ser Phe Val Arg Lys Gln Arg Val Ile Ala Asp Gly
 325 330 335
 His Ile Ser Trp Ala Cys Glu Ala Phe Ser Arg Phe Tyr Glu Lys Glu
 340 345 350
 Leu His Arg Tyr Ser Ser Leu Phe Trp Cys Trp Arg Leu Phe Leu Ile
 355 360 365
 Lys Leu Trp Asn His Gly Leu Val Asp Ser Ala Thr Ile Asn Asn Cys
 370 375 380
 Asn Thr Ile Leu Glu Asn Cys Arg Asn Ser Ser Asp Thr Thr Thr Thr
 385 390 395 400
 Asn Asn Asn Asn Ser Val Asp Arg Pro Ser Asp Ser Asn Thr Asn Asn
 405 410 415
 Asn Asn Ile Val Asp His Pro Asn Asp Ile Asn Asn Lys Asn Asn Val
 420 425 430
 Asp Asn Lys Asp Asn Asn Ser Arg Asp Lys Val Ile Lys
 435 440 445

<210> 3

<211> 6338

<212> DNA

<213> *Arabidopsis thaliana*

<400> 3

aaagagaatg ctttgactct ctcattgggtc aaacctgact gtattttatat gcggttattgt 60
 gtggtaaaagt ttcgaccttt gactttacaa gttggcggtta agaagagaga tgcgtagatc 120
 agcgagtggg tgcgagagttt tggatcattt tcccccgact tcacgggtctc cacgtcgatc 180
 tcagagcatt acatcattgg aagatgatgt ggaggtgctt ttgcctagggt acgatccgaa 240
 ttctcaagcg gggaagagag agaagtcaag attcagattt gcagaaaacg tcatccattt 300
 gattcctctc attcttcttc tctgtatcgc aatcctcttg ctctcctctt attcaggtaa 360
 gccgagaaat tgattcaatc tctatgaatc cataattgat atgtgaaact taattaggga 420
 ttttacaaag gctcatatgg atatgatatg aggatcgaga tgtctctgta acattagaat 480
 cttgtgttga attattgttt caatttggtc atattatact aaaccgggtga tggatttgga 540
 atttgtcagc agcggttaagg agttgagttc aagaagcaac atgttgtctt gtctccatgg 600
 gaactcatca tattcagttt tgggaaagga aacaattttt tttaccgccg gtgattatgt 660
 gccgcaaacc atacgtaact tttgtaattt tcggttctgt agacacataa aaggatctct 720
 cgtttttcatg aaatgtatgt ttaatatctt actatacatc acacaactca agtagaaaaac 780

acttgatgggtt	atccattaat	catcattcta	tgtgtcgaaa	acaaggatta	gtttcaactt	840
attgtctacct	tagtgattag	atgttcctgt	gagtttcagc	tagccaagtc	aactagagtt	900
aaacaatgga	atcaaaatac	atattcagta	atttatttta	aactctgact	atztatgtaa	960
acaaaaatgg	aaattaaaat	tgaagggtcat	gaagattcta	ttcttagtat	gaaaagtata	1020
gatcaatgat	aaaagtatat	accagaacag	tgggtggatct	agaaacatat	ttagtatatg	1080
gcacaatata	tttaacatat	acaaatttta	atctaaaagt	tgtattcatt	tatgaaaaga	1140
cwtctgaatg	aagcaaat	atgtgatgtg	ttaatcatcc	atztatgtgt	taatcagcca	1200
ttgatgttag	tatagtactc	tatgctaaca	taattttttt	atactataaa	ttaaaaaaat	1260
aggtaagaaa	agaaaaatag	attaatataa	aaagcatttt	attagctgaa	ataaaaaaaa	1320
tgaagaaga	taataactaa	ttagctaaaa	aattagtaga	gcatatggg	cacaatacac	1380
taagtatttc	atctttacta	tgaagtgtaa	caaatttcaa	aattatcaaa	ctgtatatag	1440
ggcagctg	taggtaccaa	tagacgtacg	tccgccttga	aataagttgg	tgaatatggt	1500
tttaattcct	ctaatactca	ctgtactgcc	atggtagagg	tgaaaaaaac	aatttttagaa	1560
atattataat	ggattaagct	gtccaaagttg	gtcgtatttt	ctttacattt	tattaactaa	1620
taaacataaa	taagttcaac	tattttattga	ctagtaataa	tacgtgtaaa	atgtctattg	1680
gtttaaaata	tgggccataa	ggcccagact	tgaaaaaaaa	acttgaaacc	caaagttata	1740
tttttacttg	tttcttcttt	ctcagtgaa	atctcccaat	caagcttctt	cgattttgct	1800
ctctcttaca	cagccaatcg	gtgttttctg	agctttcagg	tttgtctcaa	tctcaaatta	1860
aatcggagtc	aagtaataac	aattgataaa	cctaattggt	tccattgtat	tgtaaagattt	1920
gaaattttgc	tgtagatccg	gaatcgaatt	ctagttcttg	aatcgttgat	ctcgatggaa	1980
tttttttttt	aagatttctt	cttacacatt	tggttcaaaa	gatcacatat	ttttatttta	2040
atgtataaag	tatctagatt	ttgcaatag	gcattggata	aagttttcgt	ttttgcaata	2100
cgtctaaact	tgctatgtc	ctgatagaac	tctctgagtt	gcttaaaaag	tcttgtgctt	2160
tctttattac	acaggcctca	atccaagaca	ttctatataa	gcatattgca	gaagaggcgg	2220
ttctaattgt	tgcattgagt	ttatcgctat	gacgtaggga	aattcctaatt	taggggaggc	2280
ctcagagttt	gcactaactt	cataatcggc	tcttgacgtt	gttgagtgt	attgaacaag	2340
aatgtgtagg	cagaattgtc	gcgcgaaatc	ctcaccggag	gaagtgattt	caactgatga	2400
gaatctcttg	atatattgta	aacctgttcg	actatataac	atctttcacc	ttcgctctct	2460
aggcaacgta	tgatttgcct	tctctctca	tcatattagc	tcagtaatct	ttcatctcct	2520
gtgtagatca	cccactaata	gtttgagttt	gctaagctga	ttatgggtctg	attcatggcg	2580
agtgtgtgct	tcttttgtct	cctaaatttg	aacttgttgt	tttgttgtgc	agccatcggt	2640
tcttccaaga	tgcttgaact	acaaaattgg	agcaaagcgc	aaaagaaggt	atgttttctt	2700
cttgaatgta	gctgtctacg	tgtatgttta	tttatcttac	ttctaatatg	gaagctgatg	2760
acctatttta	tctttgttga	gtagatatgg	acataatgaa	tggtttcttc	tttgttcatg	2820
ctataaactt	acattttata	aaattgtgtt	ttggttagg	caagatctac	tgggatggta	2880
gttttcaact	ataaggattg	taataacaca	ttacagaaaa	ctgaagggtta	gtctttttct	2940
gttcgtcgac	aaaattcgat	gtcaatgtct	atgtttctct	agatgatttg	ttatttacta	3000
tttttttctg	tattgtcatg	cagttaggga	ggattgttct	tgtccatttt	gctctatgct	3060
atgtggtagc	ttcaagggtg	gcaactatta	caactgagg	ttcttccggg	gcctttcata	3120
tctaacactg	tgaaatgcta	ctgctgtttc	atgctgtata	ctttcactgt	ttggttacat	3180
atttttgtgt	ttgttgtttg	tcttctcact	cttttcgaac	tgtctagtgt	gtgcttatct	3240
gagaaaaacat	gtcccagatg	gagcttacia	ccaattgtct	tgtgtctatg	caggggctgc	3300
aattttcatt	gaattcatct	catgatttat	ttgaatttga	gttcaaggta	tgtgtgttta	3360
tggaaaattct	tgatttgcta	tgcctttatt	aatgaggtta	tagttaaaaa	agggtctttc	3420
ctattgtagc	tttcggaaga	ataccagaca	gttaatgttt	ctgtaaaact	taattccttc	3480
atatttgagg	tcagttactt	taaacttgg	taattgggaa	atccgatagc	tgggtgaaaat	3540
tttgtttata	ttccatcctt	atgtgtacta	ggaagaagga	agtgatgacg	ataaatttga	3600
gcccttctct	ctctggtaac	cctcagaacc	ccttcgatta	aataccttaa	tagcagtaac	3660
tcttctgctt	tcttgtcagt	acatctctgt	aaatccaacc	ataatgtttt	gcagctcgaa	3720
acctcgtaag	cggagacaaa	gaggtggcag	aaataacacc	aggagactta	aagtatgctt	3780
tttaccgttg	gattcaccca	gtttaactaa	tggcacagaa	aatggaatca	ccctacttaa	3840
tgatggtaaa	atcatatctt	cttctgtgcg	ttccttgtgg	cttagaactt	catattacag	3900
agaagatac	aatggcctga	ttgtttagtt	tttgtacttc	tctctgcatt	cttcttcgca	3960
gggtattggt	accgaactga	arctacaaaa	ttaatggcat	gctacaggaa	accgtgggtt	4020
aggatatccc	gaggcaacag	arctgtctgg	acaatttgag	atgaccagca	acattccacc	4080
agccatagcc	cactcttctc	tggacgctgg	tgctaaagtt	atattgacaa	gcgaagctgt	4140
ggctccctgct	actaagacaa	gaaagttatc	tgctgagcga	tcagaggcta	gaagggttgt	4200

```

tcatcatgac accccgcat cataattacc attcctgttg ttacaaatgt tcttcctatt 4260
atggataagt gtttatagta ctgccatatt aaccgagaaa atttcttcca gccacctact 4320
tcttcagaaa cgccaattct atcattctca cagagtccag gtgatccaag ttccttcacc 4380
tacttcttag gcattttctt taaattgtct atgatgatat cttatcaaag catacttggg 4440
ttgttctcat ccaaatttgt attttgatct gtatgtatca acgcaaaata gttatgtcca 4500
tggtgtctcc gttttattgc cactaaccaa aaaatgcatg tttctgtgac aagccaatgg 4560
cgcttgagca agtaatgtct gaccgggata gcgaggatga agtcgatgac gatgttgag 4620
atgttgagca tcgccaggta ttccatgatt tctttctgag ttcatataat agacaacaga 4680
aaatgggtata tgatgtaact tgctaattggc ttttgaaact taaaaaagct gcagatgctt 4740
gatgactttg tggatgtgaa taaagatgaa aagcaattca tgcattcttg gaactcgttt 4800
gtaagaaaac aaaggtaact acttctctta cacatgaaca gacacaaaaa gaccttatgt 4860
cttacattcc atacctgtct aaatgatttt gcttatggaa ctttgagctc aattatgatt 4920
gttgatgttt caggggtata gcagatggtc atatttcttg ggcattgtgaa gcattttcaa 4980
gattttacga gaaagatttg caccgttact catcactctt ctggtaatat aagtacacca 5040
aacatataca gacacataac tacactatca atcttgtttc gttttctgaa aaaaaataa 5100
aaatttccag gtgttgagaa ttgtttttga ttaaactatg gaacctgga cttgtcgact 5160
cagccaccat caacaactgc aataccatcc tcgagaattg ccgtaatagc tcagacacca 5220
ccaccaccaa caacaacaac agtgtggatc gtcccagtga ctcaaacacc aacaacaata 5280
acattgtggr tcatcccaat gacataaaca acaagaacaa tgttgacaac aaggacaata 5340
acagcagaga caaagtaatt aaataggaaa atctccggct tttatgatac cgatttatcg 5400
gattgttaact tattcttctt tcttaaaaaa ttgttttagga gcaaacaaat tttttatatg 5460
ttagtgtatt caactgatta catttttagt taaaaaaaaa aatggattct gcttataact 5520
aaaaactgaa aaaaaagaaa agtttcctta atttttcttt ttgacttgag aaaaagctcc 5580
tctagtaaat atgagttata tattaatcaa gtacataaca taaaaatagt atataattaag 5640
tgcaaataga ttgaaaacaa atcaagaaga aattaattaa gacagagtga ttaagcttaa 5700
aaccocattt ggacttggtc tttctcaatg aatccctcac aagcagcaag cttcttcgat 5760
tttgctttga caccaccaat cgggtgtttc gaatctttca ggtttgtctc gatttcaatc 5820
tagatcggag tcaagtaata aaattgatta acctaagtat tcccgttctc tcgtaagagt 5880
tggtgattag cagtagatcg gaaatcggaa tttacgtttt tgtaaaaaga ttgatgggtt 5940
aggtaatgga acatagttct ggattcattg cttctagttg attctcgaat tgtttgattt 6000
cgcaatgcac atttttgttt caaaggatca cagaatttga tttaaaattt gacaaaattc 6060
catcaatttc tcatattagg gtttatattt cttctagtaa ctcgaaactg ttggaactct 6120
gtatactctg tgctatgtag ataaagtctt aacattttgg tcaactttgt ttgatctcta 6180
aactagtttg ggctctctgt tttaaagttt tgtgctttca ctattacaca ggtctcatac 6240
aagactacag tctcaagaag cataatatcg tcgactctgt tttgagtttc tcaacagtgg 6300
ttgaagctta aggaggttct tatgtgcggt ttgatata 6338

```

<210> 4

<211> 1715

<212> DNA

<213> Arabidopsis thaliana

<400> 4

```

caagcttctt caattttgct tgctctctct cttacacggc caatcgggtg tttcgcagct 60
ttcaggcctc aatacaagac attctatata agcatattgc agaagaggcg gttctaattg 120
ttgcatggag ttgaacaata tgacgtaggg aaattctaat ttaggggagg cctcagagtt 180
tgcactaact tcataatcag ctctggacgt tggtgattgt atttgaacaa gaatgtgtag 240
gcagaattgt cgcgcgaaat cctcaccgga ggaagtgatt tcaactgatg agaatctctt 300
gatataattg aaacctgttc gactatataa catctttcac cttcgctctc taggcaacct 360
atcgtttctg ccaagatgct tgaactacaa aattggggca aagcgcaaaa gaaagtcaag 420
atctactggg atggtagttt tcaactataa ggattgtaat aatacattac aaagaactga 480
agttagggag gattgttctt gtccattttg ctctatgcta tgtggtagct tcaaggggct 540
gcaatttcat ttgaattcat ctcatgattt atttgaattt gagttcaagc ttttggaaga 600
ataccagaca gttaattgtt ctgtaaaact taattccttc atatttgagg aagaaggaag 660
tgatgatgat aaatttgagc ccttctctct ctgctcgaaa cctcgtaagc gtagacaaaag 720
agggtgcaga aataacacca ggagacttaa agtatgcttt ttaccgttgg attcaccag 780

```

```

tttagctaataat ggcacagaaaa atggaattgc cctgctgaat gatggaaacc gtgggttagg 840
atatccccgag gcaacagagc ttgctggaca atttgagatg actagcaaca ttccaccagc 900
catagcccac tcttctctgg acgctggcgc taaagtata ttaacaaccg aagctgtggt 960
ccctgctact aagacaagaa agttatctgc tgagcgatca gaggctagaa gccacctact 1020
tcttcagaaa cgccaattct atcattctca cagagtccag ccaatggcgc ttgagcaagt 1080
aatgtctgat cgggatagcg aggatgaagt cgatgacgat gttgcagatt ttgaagatcg 1140
ccagatgctt gatgactttg tggatgtgaa taaagatgaa aagcaattca tgcactcttg 1200
gaactcgttt gtaagaaaaac aaagggttat agcagatggc catatctctt gggcatgtga 1260
agtattttca agattttacg agaaagagtt gcactgttac tcatcactct tctggtgttg 1320
gagattgttt ttgattaaac tatggaacca tggacttgct gactcagcca ccatcaacaa 1380
ctgcaatacc atcctcgaga attgccgtaa tacctcagtc actaacaaca acaacaacag 1440
tgtggatcat cccagtgcact caaacaccaa caacaataac attgtggatc atccgaatga 1500
cataaaaaaac aagaacaatg ttgacaacaa ggacaataac agcagagaca agtaattaaa 1560
taggaaacac tccggttttag atgataccga tctatcggat tgtaacttat tcttctttct 1620
taaaaaaatt gtttaggagc aaacaaagat tttatttggt agtgtattca actgattaca 1680
tttttagtta aaaaaatgga ttctccttaa taact 1715

```

<210> 5

<211> 440

<212> PRT

<213> Arabidopsis thaliana

<400> 5

```

Met Cys Arg Gln Asn Cys Arg Ala Lys Ser Ser Pro Glu Glu Val Ile
  1             5             10             15

```

```

Ser Thr Asp Glu Asn Leu Leu Ile Tyr Cys Lys Pro Val Arg Leu Tyr
      20             25             30

```

```

Asn Ile Phe His Leu Arg Ser Leu Gly Asn Pro Ser Phe Leu Pro Arg
    35             40             45

```

```

Cys Leu Asn Tyr Lys Ile Gly Ala Lys Arg Lys Arg Lys Ser Arg Ser
    50             55             60

```

```

Thr Gly Met Val Val Phe Asn Tyr Lys Asp Cys Asn Asn Thr Leu Gln
    65             70             75             80

```

```

Arg Thr Glu Val Arg Glu Asp Cys Ser Cys Pro Phe Cys Ser Met Leu
      85             90             95

```

```

Cys Gly Ser Phe Lys Gly Leu Gln Phe His Leu Asn Ser Ser His Asp
    100            105            110

```

```

Leu Phe Glu Phe Glu Phe Lys Leu Leu Glu Glu Tyr Gln Thr Val Asn
    115            120            125

```

```

Val Ser Val Lys Leu Asn Ser Phe Ile Phe Glu Glu Glu Gly Ser Asp
    130            135            140

```

```

Asp Asp Lys Phe Glu Pro Phe Ser Leu Cys Ser Lys Pro Arg Lys Arg
    145            150            155            160

```

```

Arg Gln Arg Gly Gly Arg Asn Asn Thr Arg Arg Leu Lys Val Cys Phe
    165            170            175

```

Leu	Pro	Leu	Asp	Ser	Pro	Ser	Leu	Ala	Asn	Gly	Thr	Glu	Asn	Gly	Ile
			180				185						190		
Ala	Leu	Leu	Asn	Asp	Gly	Asn	Arg	Gly	Leu	Gly	Tyr	Pro	Glu	Ala	Thr
			195				200						205		
Glu	Leu	Ala	Gly	Gln	Phe	Glu	Met	Thr	Ser	Asn	Ile	Pro	Pro	Ala	Ile
			210				215						220		
Ala	His	Ser	Ser	Leu	Asp	Ala	Gly	Ala	Lys	Val	Ile	Leu	Thr	Thr	Glu
			225				230						235		
Ala	Val	Val	Pro	Ala	Thr	Lys	Thr	Arg	Lys	Leu	Ser	Ala	Glu	Arg	Ser
			245				250						255		
Glu	Ala	Arg	Ser	His	Leu	Leu	Leu	Gln	Lys	Arg	Gln	Phe	Tyr	His	Ser
			260				265						270		
His	Arg	Val	Gln	Pro	Met	Ala	Leu	Glu	Gln	Val	Met	Ser	Asp	Arg	Asp
			275				280						285		
Ser	Glu	Asp	Glu	Val	Asp	Asp	Asp	Val	Ala	Asp	Phe	Glu	Asp	Arg	Gln
			290				295						300		
Met	Leu	Asp	Asp	Phe	Val	Asp	Val	Asn	Lys	Asp	Glu	Lys	Gln	Phe	Met
			305				310						315		
His	Leu	Trp	Asn	Ser	Phe	Val	Arg	Lys	Gln	Arg	Val	Ile	Ala	Asp	Gly
			325				330						335		
His	Ile	Ser	Trp	Ala	Cys	Glu	Val	Phe	Ser	Arg	Phe	Tyr	Glu	Lys	Glu
			340				345						350		
Leu	His	Cys	Tyr	Ser	Ser	Leu	Phe	Trp	Cys	Trp	Arg	Leu	Phe	Leu	Ile
			355				360						365		
Lys	Leu	Trp	Asn	His	Gly	Leu	Val	Asp	Ser	Ala	Thr	Ile	Asn	Asn	Cys
			370				375						380		
Asn	Thr	Ile	Leu	Glu	Asn	Cys	Arg	Asn	Thr	Ser	Val	Thr	Asn	Asn	Asn
			385				390						395		
Asn	Asn	Ser	Val	Asp	His	Pro	Ser	Asp	Ser	Asn	Thr	Asn	Asn	Asn	Asn
			405				410						415		
Ile	Val	Asp	His	Pro	Asn	Asp	Ile	Lys	Asn	Lys	Asn	Asn	Val	Asp	Asn
			420				425						430		
Lys	Asp	Asn	Asn	Ser	Arg	Asp	Lys								
			435				440								

<210> 6
 <211> 5895
 <212> DNA
 <213> Arabidopsis thaliana

<400> 6

```

aaagagaaga gctttgactc tctcattggt caaacctgac tgtatattata tgcgttattg 60
tgtggttaaag tttcgacctt tgacttgaca agttgcccgtt aagaagagag atgcgtagat 120
cagcgagtgg ttctagagtt ttggatcatt ttccggcgac ttcaaggctc ccgcctcgat 180
ctcagagtgt tacagcaatg gaagatgatg tggagctgct tttgcctagg tacgatccga 240
attctcaagc ggggaagaga gagaaatcaa gattcagatt ttcagaaaac gtcattccatt 300
tgattcctct cattcttctt ctctgtgtcg caatcctctg gctctcctct tactcaggta 360
agccgagaaa ttgtttcaat ctctatgaat ccataattga tctgtgaaac ttaattaggg 420
attttataaa gactcatatg gatatgagga tcgagatgtc tctgcaacgt tagaatcttg 480
tgttgaatta tgggttcaat ttgttcatat aatactaaat cgggtgatga tttggaattt 540
gtcagcagcg ttaaggagtt gagttccaaa agcaacatgt tgtcttgtct ccatgggaac 600
tcatattcag ttttgggaaa ggaaacaatt cttttaccgc cgggtgattt gtgccgcaa 660
ccattcgtat ttgtaatttt tgggtctgtg gacacacaaa aggatctctc gttttcatga 720
aatgtatgtt taatatttca gtgatataca tcacacaact caagtagaaa aactgatgg 780
ttatccatta atcattctat tgggtcgaaaa aaagattagt ttcaacttaa tgccacctta 840
ggattatatg ttctgtgag tttcagctag ccaactcaac tagagttaaa caatggaatc 900
aaaatacata ttcagtaatt tatttttaaac tctgactatt tatgtaaaac acaaatggaa 960
atcaaaattg aaggtcatga agattctatt cttagtgtga aaagtataga tcaatgattc 1020
ttaatttctt catcctccac gcatagatca atggtgaata tgggttttaa tcctctaata 1080
ctcactgtac tgccatggta gagttaaaaa aacaatttta gaaatattag tggattaagg 1140
cattaagctg tccaagttgc ttgtattttt ttttcatttt attaatataa aaaaaagttc 1200
aactatttat tgactaataa taatacgtgt taaatggtta tcggttttaa atatgggcca 1260
taggcccaga cttgaagaaa aacttgaaac ccaaagtttt atttttactt gttttctttc 1320
tcagtgaata tctcccaatc aagcttcttc aattttgctt gctctctctc ttacacggcc 1380
aatcggtgtt ttcgcagctt tcaggtttgt ctcaatctca aattaaatcg gagtcaagta 1440
ataacaattg ataaccctaa ttgtttcaat tatattgtaa gatttgaaat tttgcagtag 1500
atccggaatc gtattctagt tctggaatcg ttgatctcga tgggaatttt ttttaagattt 1560
cttcatacac atttggttca aaagatcaca taattttatt ttaatttgat aagtatgatg 1620
attctgctaa gtggcattgg ataaagtttt catttttgca atacgtctaa acttgtctat 1680
gtcttgaatg aactctctga gttgcttaaa aagctctgtg ctttctttat tacacaggcc 1740
tcaatacaag acattctata taagcatatt gcagaagagg cggttctaatt tgttgcatgg 1800
agttgaacaa tatgacgtag ggaaattcta atttagggga ggcctcagag tttgcactaa 1860
cttcataatc agctctggac gttgttgatt gtatttgaac aagaatgtgt aggcagaatt 1920
gtcgcgcgaa atcctcaccg gaggaagtga tttcaactga tgagaatctc ttgatataat 1980
gtaaacctgt tcgactatat aacatctttc accttcgctc tctaggcaac gtatgatttg 2040
gccttctctc ctcatcattt tagcttagta atctttcctc tctgtgttag atcaccact 2100
aatagtttga gtttgctaag ctgattatgg tctgactcat ggcgagtgtg tgcttctttt 2160
gtctcctaatt gttatttgaa cttgttggtt gttgttgag ccacgtttc tgccaagatg 2220
cttgaactac aaaattgggg caaagcgcaa aagaaagtat gcgtttcttc ttgaatgtag 2280
ttgccacagt gatatgttat ttatcttact tctaatatgg aagctgatga actatttatc 2340
tttgttgagt agatatggac ataataaatg gtttcttctt tgttcatgct atacacttat 2400
attttataaaa attgtgtttt gcttaggtca agatctactg ggatggtagt tttcaactat 2460
aaggattgta ataatacatt acaaaagaact gaagggttagt cttttctgtt tcttcgacaa 2520
aattcagatg caatgtctat gtttctctag atgatttgtt atttactatt ttttctgta 2580
ttgtcacgca gttaggaggc attgttcttg tccattttgc tctatgctat gtggtagctt 2640
caaggtgggc aactattaca actgaggttt cttccggggc ctttcatatc taacactgtg 2700
aaatgctact gccgtttaat gctatatact ttactgttt gggtacatat ttttgtgtt 2760
gttgtttgtc ttcttgctct ttttaaaact ctgagtgtgt gcttatctga gaaaacatgt 2820
tccagttcga gcttacaatc cattgtcttg tgtctatgca ggggctgcaa tttcatttga 2880
attcatctca tgatttattt gaatttgagt tcaaggtagt tgggttttat gaatttcttg 2940
ttttgcctat gccgttagta atgaggttat agttaaaaaa ggggtcttcc tattgtagct 3000
tttgaagaa taccagacag ttaatgtttc tgtaaaactt aattccttca tatttgaggt 3060

```

cagttacttt aaacttggtt aattgggaaa tcctatagct ggtgaaaatt tggtttatat 3120
 tccatcctta tttgtactag gaagaaggaa gtgatgatga taaatttgag cccttctctc 3180
 tctggttaact ctcagaacct cttgattaaa taccttaata gcagtaactc cttgcttttc 3240
 ttgtcagtag ttctctataa atccaaccac aatgttttgc agctcgaaac ctcgtaagcg 3300
 tagacaaaga ggtggcagaa ataacaccag gagacttaaa gtatgctttt taccgttgga 3360
 ttcacccagt ttagctaattg gcacagaaaa tgggaattgcc ctgctgaatg atggtaaaat 3420
 cacatcttct tctgtggtat tcgttggtggc ttagaacttc attttacaga agaagatata 3480
 atgtcctgat tgtttagttt ttgtacttct cctcgcattc ttcttgtagg ggtaatgtta 3540
 ccagaactga tgtacaaaat taatggcatg ctacaggaaa ccgtgggtta ggatatcccc 3600
 aggcaacaga gcttgctgga caatttgaga tgactagcaa cattccacca gccatagccc 3660
 actcttctct ggacgctggg gctaaagtta tattaacaac cgaagctgtg gtccctgcta 3720
 ctaagacaag aaagttatct gctgagcgat cagaggctag aaggtttgtt catcatgaca 3780
 ccccgctatc ataattacca tacctgttgt tacaaatgtt cttcctatta tggataagtg 3840
 tttactgtac tgccatatta accgagaaaa tttctccag ccacctactt cttcagaaac 3900
 gccaatctta tcattctcac agagtccagg tgatccaagt tccttcacct acttcttagg 3960
 caatttcttt aaattgctca tgatgatata ttatcaaagc atacttggtt tgttctcatc 4020
 taaatttgta ttttgattct gtatgtatca acgcaaaaaa attatgtcca tgttgctctc 4080
 gttttattgc cactaaccaa aaactgcatg tttcttgatg caagccaatg gcgcttgagc 4140
 aagtaatgtc tgatcgggat agcggaggat aagtcgatga cgatgttgca gattttgaag 4200
 atcgccaggt attccatgat ttctttctgc gttcattaag taggcaacag aaaatggtat 4260
 acgatgtaac ttgctaattg cttttgaaac ttaaaaaagc tgcagatgct tgatgacttt 4320
 gtggatgtga ataaagatga aaagcaattc atgcatcttt ggaactcgtt tgtaagaaaa 4380
 caaaggtaac tacttctctt acacttgaac acacacaaaa agaccttatg tcttacattc 4440
 catacctgtc taaatgattc tgcttatgga actttgagct caaattatga ttgatgtttg 4500
 caggggtata gcagatgggc atatctcttg ggcagtgtga gtattttcaa gattttacga 4560
 gaaagagttg cactgttact catcactctt ctggtaatat aagtaaccca aacatataca 4620
 gacacataac tacactatca attttgttct gtttttctga aagaaaaata aaaaattcca 4680
 ggtgttgag attgtttttg attaaactat ggaaccatgg acttgctgac tcagccacca 4740
 tcaacaactg caataccatc ctcgagaatt gccgtaatat ctcagtcact aacaacaaca 4800
 acaacagtggt ggatcatccc agtgactcaa acaccaacaa caataacatt gtggatcatc 4860
 cgaatgacat aaaaaacaag aacaatgttg acaacaagga caataacagc agagacaagt 4920
 aattaaatag gaaacactcc ggttttagatg ataccgatct atcggattgt aacttattct 4980
 tctttcttaa aaaaattgtt taggagcaaa caaagatttt atttgtagt gtattcaact 5040
 gattacattt ttagttaaaa aaatggattc tccttaataa ctaaagactg aaaaataaga 5100
 taagtttctt taatttttct ttttgacttg agaaaaagct cctctagacc tctagtaaat 5160
 aggagttata tattaatcaa gtacataaca taaaaatata tatattaagt gcaaatagat 5220
 tgaaaacaaa tcaagaaatt aattaagaca cagtgattaa gcttaaaacc ccattttgac 5280
 ttgttctttc tcaatgaatc cctcacaagc agcaagcttc ttcgattttg ctttgacacc 5340
 accaatcagt gttttcgaat ctttcagggt tgtctcgatt tcaaactaga tcggagtcaa 5400
 gtgataaaat tgactaacat aattattccc gttctctcgt aagagttggg atttagcagt 5460
 agatcggaaa tcggaattta cgtttttgtt aaaagattga tggtttaggt aataaaacat 5520
 agttctggat tcattgcttc tagttgattc tcgaattgtt tgatttcgca atgcacattt 5580
 ttggttcaaa ggatcacata atttgcttta aaatttgaca aaacatacca tcaaatttct 5640
 catatttctt caagtaactc gaacttggtg gaaatctata tactctgggc tatgtagata 5700
 aagtcctaac attttggtca acattgtttg ttctctaaac tagtttggtt tctctgtttt 5760
 aaagtttggt gctttcacta ttacacaggt cttatacaag actacagtct ctagaagcat 5820
 aatatcgctg actctgtttt gagtttccca acagtgggtg aagcttaagg aggttcttat 5880
 gtgccttttg aaatc 5895

<210> 7

<211> 1737

<212> DNA

<213> Arabidopsis thaliana

<400> 7

caagcttctt caattttgct tgctctctct cttacacggc caatcggtgt tttcgcagct 60

```
<210> 8
<211> 107
<212> PRT
<213> Arabidopsis thaliana
```

```

<400> 8
Met Cys Arg Gln Asn Cys Arg Ala Lys Ser Ser Pro Glu Glu Val Ile
  1                      5                      10                      15

Ser Thr Asp Glu Asn Leu Leu Ile Tyr Cys Lys Pro Val Arg Leu Tyr
                20                      25                      30

Asn Ile Phe His Leu Arg Ser Leu Gly Asn Pro Ser Phe Leu Pro Arg
      35                      40                      45

Cys Leu Asn Tyr Lys Ile Gly Ala Lys Arg Lys Arg Lys Ser Arg Ser
  50                      55                      60

Thr Gly Met Val Val Phe Asn Tyr Lys Asp Cys Asn Asn Thr Leu Gln
  65                      70                      75                      80

Arg Thr Glu Val Arg Glu Asp Cys Ser Cys Pro Phe Cys Ser Met Leu
                85                      90                      95

Cys Gly Ser Phe Lys Val Gly Asn Tyr Tyr Asn
      100                      105

```


<210> 9
 <211> 463
 <212> DNA
 <213> Oryza sativa

<400> 9
 acatttttcgt accgctcaag atttaagaag cgtaaaaggg tggaaatctc aagtgataaa 60
 attagggcatg tacatccaca tattgtggat tcaggatcac ctgaagatgc ccaggcagga 120
 tctgaagacg attacgtgca gagggaaaat ggtagttctg tagcacacgc ttctgttgat 180
 cctgctaatt cattacacgg tagcaatctt tcagcaccaa cagtgttaca gtttgggaag 240
 acaagaaagc tgtctgttga acgagctgat cccagaaatc ggagctcct acaaaaacgc 300
 cagttctttc attctcacag ggctcaacca atggcattgg gagcagtttt ctcagatcgt 360
 gatagtgaag atgaggttga tgatgacatt gctgattttg aagatagaca gatgcttgat 420
 gattttgttg atgttaccaa agacgaactt attatgcata tgg 463

<210> 10
 <211> 154
 <212> PRT
 <213> Oryza sativa

<400> 10
 Thr Phe Ser Tyr Arg Ser Arg Phe Lys Lys Arg Lys Arg Val Glu Ile
 1 5 10 15
 Ser Ser Asp Lys Ile Arg His Val His Pro His Ile Val Asp Ser Gly
 20 25 30
 Ser Pro Glu Asp Ala Gln Ala Gly Ser Glu Asp Asp Tyr Val Gln Arg
 35 40 45
 Glu Asn Gly Ser Ser Val Ala His Ala Ser Val Asp Pro Ala Asn Ser
 50 55 60
 Leu His Gly Ser Asn Leu Ser Ala Pro Thr Val Leu Gln Phe Gly Lys
 65 70 75 80
 Thr Arg Lys Leu Ser Val Glu Arg Ala Asp Pro Arg Asn Arg Gln Leu
 85 90 95
 Leu Gln Lys Arg Gln Phe Phe His Ser His Arg Ala Gln Pro Met Ala
 100 105 110
 Leu Gly Ala Val Phe Ser Asp Arg Asp Ser Glu Asp Glu Val Asp Asp
 115 120 125
 Asp Ile Ala Asp Phe Glu Asp Arg Gln Met Leu Asp Asp Phe Val Asp
 130 135 140
 Val Thr Lys Asp Glu Leu Ile Met His Met
 145 150

<210> 11
 <211> 325
 <212> DNA
 <213> Populus tremula x Populus tremuloides

<400> 11
 acatgcatat cctgatgctg aatgtgctca attggtacct gggaataatc ttgcacctcc 60
 tgccatgcta caatttgcaa agacaagaaa attatcaatt gaacggtctg acatgagaaa 120
 ccgtacactc cttcacaaac gacaattttt tcactcacat agagctcagc caatggcagc 180
 tgagcaagtt atgtcagatc gggatagtga ggatgaagtt gacgatgatg ttgcagattt 240
 tgaagaccga aggatgcttg atgattttgt agacgtgact aaagatgaga agcaaagatg 300
 gcacttgagg aactcatttg tgagg 325

<210> 12
 <211> 108
 <212> PRT
 <213> Populus tremula x Populus tremuloides

<400> 12
 His Ala Tyr Pro Asp Ala Glu Cys Ala Gln Leu Val Pro Gly Asn Asn
 1 5 10 15
 Leu Ala Pro Pro Ala Met Leu Gln Phe Ala Lys Thr Arg Lys Leu Ser
 20 25 30
 Ile Glu Arg Ser Asp Met Arg Asn Arg Thr Leu Leu His Lys Arg Gln
 35 40 45
 Phe Phe His Ser His Arg Ala Gln Pro Met Ala Ala Glu Gln Val Met
 50 55 60
 Ser Asp Arg Asp Ser Glu Asp Glu Val Asp Asp Asp Val Ala Asp Phe
 65 70 75 80
 Glu Asp Arg Arg Met Leu Asp Asp Phe Val Asp Val Thr Lys Asp Glu
 85 90 95
 Lys Gln Met Met His Leu Trp Asn Ser Phe Val Arg
 100 105

<210> 13
 <211> 558
 <212> DNA
 <213> Arabidopsis thaliana

<400> 13
 atggatccga ttaagctgac aacagaagct aaggtccctg ctaagcgatc aaaggctaca 60
 agccactact tgcctcttca taaacgccag ttctatcatt cccgaaccgg tcagccattg 120
 tcacttgagc aagttatgtc tgaccgagat agcgaaaatg acgtcgacaa aaatgatgat 180
 gctgcacatc tcgaagaaag ccagatgctt aatgggttcca tggatgagaa tgaaatcgta 240
 gcagagagat tcataaaaact ttggaactcc tttgttaaac agcaaaggat tgttgcagat 300
 gctcatattc cttgggcatg tgaagcattc tcaagattac acctgcaaga gctgcgcagt 360
 aacttatcac tcgacttggt ctggagacaa ttcatgatca aacaatggga ttatggactt 420
 cttgacagag tcaccatgaa caaatgcaat accatcatct accataatat ctcaactacc 480

```
<400> 15
ctctgaggag  acactttttt  tttcctccct  ctttccctcc  tctcctcctc  ctttcccttc  60
ccctctcctc  ccctctctcc  tccttccccc  ctcggtccgc  cggagcctgc  tggggcgagc  120
ggttggtatt  gcaggcgctt  gctctccggg  gccgcccggc  gggtagctgg  cggggggagg  180
```


Arg Thr Leu Thr Tyr Met Ser His Arg Asn Ser Arg Thr Asn Ile Lys
 180 185 190
 Arg Lys Thr Phe Lys Val Asp Asp Met Leu Ser Lys Val Glu Lys Met
 195 200 205
 Lys Gly Glu Gln Glu Ser His Ser Leu Ser Ala His Leu Gln Leu Thr
 210 215 220
 Phe Thr Gly Phe Phe His Lys Asn Asp Lys Pro Ser Pro Asn Ser Glu
 225 230 235 240
 Asn Glu Gln Asn Ser Val Thr Leu Glu Val Leu Leu Val Lys Val Cys
 245 250 255
 His Lys Lys Arg Lys Asp Val Ser Cys Pro Ile Arg Gln Val Pro Thr
 260 265 270
 Gly Lys Lys Gln Val Pro Leu Ile Pro Asp Leu Asn Gln Thr Lys Pro
 275 280 285
 Gly Asn Phe Pro Ser Leu Ala Val Ser Ser Asn Glu Phe Glu Pro Ser
 290 295 300
 Asn Ser His Met Val Lys Ser Tyr Ser Leu Leu Phe Arg Val Thr Arg
 305 310 315 320
 Pro Gly Arg Arg Glu Phe Asn Gly Met Ile Asn Gly Glu Thr Asn Glu
 325 330 335
 Asn Ile Asp Val Asn Glu Glu Leu Pro Ala Arg Arg Lys Arg Asn Arg
 340 345 350
 Glu Asp Gly Glu Lys Thr Phe Val Ala Gln Met Thr Val Phe Asp Lys
 355 360 365
 Asn Arg Arg Leu Gln Leu Leu Asp Gly Glu Tyr Glu Val Ala Met Gln
 370 375 380
 Glu Met Glu Glu Cys Pro Ile Ser Lys Lys Arg Ala Thr Trp Glu Thr
 385 390 395 400
 Ile Leu Asp Gly Lys Arg Leu Pro Pro Phe Glu Thr Phe Ser Gln Gly
 405 410 415
 Pro Thr Leu Gln Phe Thr Leu Arg Trp Thr Gly Glu Thr Asn Asp Lys
 420 425 430
 Ser Thr Ala Pro Ile Ala Lys Pro Leu Ala Thr Arg Asn Ser Glu Ser
 435 440 445
 Leu His Gln Glu Asn Lys Pro Gly Ser Val Lys Pro Thr Gln Thr Ile
 450 455 460
 Ala Val Lys Glu Ser Leu Thr Thr Asp Leu Gln Thr Arg Lys Glu Lys
 465 470 475 480

Ala Leu Glu Thr Asp Ser Val Ser Gly Val Ser Lys Gln Ser Lys Lys
 785 790 795 800

Gln Lys Leu

<210> 17
 <211> 22
 <212> PRT
 <213> Arabidopsis thaliana

<400> 17
 Cys Pro Phe Cys Ser Met Leu Cys Gly Ser Phe Lys Gly Leu Gln Phe
 1 5 10 15

His Leu Asn Ser Ser His
 20

<210> 18
 <211> 21
 <212> PRT
 <213> Arabidopsis thaliana

<400> 18
 Cys Pro Phe Cys Ala Glu Ser Tyr Asp Ile Ile Gly Leu Cys Cys His
 1 5 10 15

Ile Asp Asp Glu His
 20

<210> 19
 <211> 20
 <212> PRT
 <213> Arabidopsis thaliana

<400> 19
 Cys Pro Val Cys Ser Leu Lys Val Gly Val Asp Ile Val Ala His Ile
 1 5 10 15

Thr Leu His His
 20

<210> 20
 <211> 21
 <212> PRT
 <213> *Arabidopsis thaliana*

<400> 20
 Cys Ser Phe Cys Lys Arg Glu Phe Arg Ser Ala Gln Ala Leu Gly Gly
 1 5 10 15
 His Met Asn Val His
 20

<210> 21
 <211> 21
 <212> PRT
 <213> *Arabidopsis thaliana*

<400> 21
 Cys Pro Phe Cys Ser Asp Tyr Phe Asp Ile Val Ser Leu Cys Cys His
 1 5 10 15
 Ile Asp Glu Asp His
 20

<210> 22
 <211> 21
 <212> PRT
 <213> *Arabidopsis thaliana*

<400> 22
 Cys Pro Phe Cys Ser Asp Asp Tyr Asp Leu Val Glu Leu Cys His His
 1 5 10 15
 Ile Asp Glu Glu His
 20

<210> 23
 <211> 22
 <212> PRT
 <213> *Saccharomyces cerevisiae*

<400> 23
 Cys Pro Ile Cys Leu Arg Lys Phe Asp Asn Leu Gln Ala Leu Asn Ala
 1 5 10 15
 His Leu Asp Val Glu His
 20

<213> Saccharomyces cerevisiae

His Met Ile Ile His
20

<213> Schizosaccharomyces pombe

His Ile Gln Arg Phe His
20

<213> Caenorhabditis elegans

His Leu Thr Ser Asn His
20

<213> Caenorhabditis elegans

His Met Asn Gln Lys His
20

```

<400> 28
Cys Pro Ile Cys Lys Cys Glu Cys Ser Gly Arg Glu Asp Cys Gln Leu
  1             5             10             15
His Met Tyr Ala Ser His
          20

```

```

<210> 29
<211> 22
<212> PRT
<213> Drosophila melanogaster

<400> 29
Cys Pro Tyr Cys Arg Arg Thr Phe Ser Cys Tyr Tyr Ser Leu Lys Arg
 1             5             10             15
His Phe Gln Asp Lys His
          20

```

```

<210> 30
<211> 22
<212> PRT
<213> Drosophila melanogaster

<400> 30
Cys Pro Ile Cys Tyr Ala Val Ile Arg Gln Ser Arg Asn Leu Arg Arg
 1             5             10             15
His Leu Glu Leu Arg His
          20

```

```

<210> 31
<211> 22
<212> PRT
<213> Drosophila melanogaster

<400> 31
Cys Cys Phe Cys Ser Met Cys Phe Glu Ser Val Gln Glu Leu Val Arg
 1             5             10             15
His Leu Ser Gly His His
                20

```

<210> 32
 <211> 22
 <212> PRT
 <213> Homo sapiens

<400> 32
 Cys Pro Phe Cys Arg Ala Leu Phe Lys Ala Lys Thr Ala Leu Glu Ala
 1 5 10 15
 His Ile Arg Ser Arg His
 20

<210> 33
 <211> 22
 <212> PRT
 <213> Homo sapiens

<400> 33
 Cys Pro Trp Cys Thr Leu Asn Cys Arg Lys Leu Tyr Ser Leu Leu Lys
 1 5 10 15
 His Leu Lys Leu Cys His
 20

<210> 34
 <211> 22
 <212> PRT
 <213> Homo sapiens

<400> 34
 Cys Glu Val Cys Ala Phe Ala Cys Lys Arg Lys Tyr Glu Leu Gln Lys
 1 5 10 15
 His Met Ala Ser Gln His
 20

<210> 35
 <211> 22
 <212> PRT
 <213> Mus musculus

<400> 35
 Cys Pro Tyr Cys Pro Pro Asn Gly Arg Val Arg Gly Asp Leu Val Glu
 1 5 10 15
 His Leu Arg Gln Ala His
 20

<210> 36
 <211> 21
 <212> PRT
 <213> Mus musculus

<400> 36
 Cys Arg Phe Cys Ala Lys Val Phe Gly Ser Asp Ser Ala Leu Gln Ile
 1 5 10 15
 His Leu Arg Ser His
 20

<210> 37
 <211> 22
 <212> PRT
 <213> Rattus norvegicus

<400> 37
 Cys Asn Tyr Cys Pro Glu Met Phe Ala Asp Ile Asn Ser Leu Gln Glu
 1 5 10 15
 His Ile Arg Val Ser His
 20

<210> 38
 <211> 22
 <212> PRT
 <213> Xiphophorus maculatus

<400> 38
 Cys Pro His Cys Glu Phe Arg Cys Ala Asp Gln Ser Asn Leu Lys Thr
 1 5 10 15
 His Ile Lys Ser Lys His
 20

<210> 39
 <211> 39
 <212> DNA
 <213> Arabidopsis thaliana

<220>
 <221> CDS
 <222> (1)..(39)

<400> 39
 gaa aag caa ttc atg cat ctt tgg aac tcg ttt gta aga
 Glu Lys Gln Phe Met His Leu Trp Asn Ser Phe Val Arg
 1 5 10 15
 39

<400> 40
Glu Lys Gln Phe Met His Leu Trp Asn Ser Phe Val Arg
1 5 10

```
<220>  
<221> CDS  
<222> (1)..(24)
```

39

<400> 42
Glu Lys Gln Phe Met His Leu
1 5

```
<220>
<221> CDS
<222> (1)..(33)
```

33

```
<210> 44
<211> 11
<212> PRT
<213> Arabidopsis thaliana
```

<400> 44
 Cys Gly Ser Phe Lys Gly Leu Gln Phe His Leu
 1 5 10

<210> 45
 <211> 54
 <212> DNA
 <213> Arabidopsis thaliana

<220>
 <221> CDS
 <222> (1)..(36)

<400> 45
 tgt ggt agc ttc aag gtg ggc aac tat tac aac tga ggggctgcaa 46
 Cys Gly Ser Phe Lys Val Gly Asn Tyr Tyr Asn
 1 5 10

tttcattt 54

<210> 46
 <211> 11
 <212> PRT
 <213> Arabidopsis thaliana

<400> 46
 Cys Gly Ser Phe Lys Val Gly Asn Tyr Tyr Asn
 1 5 10

<210> 47
 <211> 1722
 <212> DNA
 <213> Arabidopsis thaliana

<400> 47
 caagcttctt caatttttgc tgcctctctt tacacagcca atcgggtgtt tcgcagcttt 60
 caggcctcaa tccaagacat tctatataag catattgcag aagaggcggt tctaattgtt 120
 gcattgagtt tatcgctatg acgtagggaa attctaattt aggggaggcc tcagagtttg 180
 cactaacttc ataatcggct cttgacgttg ttgagtgtaa ttgaacaaga atgtgtaggc 240
 agaattgtcg cgcgaaatcc tcaccggagg aagtgatttc aactgatgag aatctcttga 300
 tatattgtaa acctgttcga ctatataaca tctttcacct tcgctctcta ggcaacccat 360
 cgtttcttcc aagatgcttg aactacaaaa ttggagcaaa gcgcaaaaga aagtcaagat 420
 ctactgggat ggtagttttc aactataagg attgtaataa cacattacag aaaactgaag 480
 ttagggagga ttgttcttgc ccatthttgc ctatgctatg tggtagcttc aaggggctgc 540
 aatttcattt gaattcatct catgatttat ttgaatttga gttcaagctt ttcgaagaat 600
 accagacagt taatgtttct gtaaaactta attccttcat atttgaggaa gaaggaagt 660
 atgacgataa atttgagccc ttctctctct gctcgaaacc tcgtaagcgg agacaaagag 720
 gtggcagaaa taacaccagg agacttaaaag tatgcttttt accgttggat tcaccagtt 780
 taactaatgg cacagaaaat ggaatcacc cacttaatga tggaaaccgt ggtttaggat 840
 atcccagggc aacagagctt gctggacaat ttgagatgac cagcaacatt ccaccagcca 900
 tagccactc ttctctggac gctggtgcta aagttatatt gacaagcgaa gctgtggtcc 960
 ctgctactaa gacaagaaa ttatctgctg agcgatcaga ggctagaagc cacctacttc 1020

```

ttcagaaaacg ccaattctat cattctcaca gagtccagcc aatggcgctt gagcaagtaa 1080
tgtctgaccg ggatagcgag gatgaagtcg atgacgatgt tgcagatttt gaagatcgcc 1140
agatgcttga tgactttgtg gatgtgaata aagatgaaaa gcaattcatg catctttgaa 1200
actcgtttgt aagaaaacaa agggttatag cagatgggtca tatctcttgg gcatgtgaag 1260
cattttcaag attttaacgag aaagagttgc accgttactc atcactcttc tgggtgttga 1320
gattgttttt gattaaacta tggaaccatg gacttgtcga ctcagccacc atcaacaact 1380
gcaataccat cctcgagaat tgccgtaata gctcagacac caccaccacc aacaacaaca 1440
acagtgtgga tcgtcccagt gactcaaaca ccaacaacaa taacattgtg gatcatccca 1500
atgacataaa caacaagaac aatggtgaca acaaggacaa taacagcaga gacaaagtaa 1560
ttaaatagga aaatctccgg cttttatgat accgatttat cggattgtaa cttattcttc 1620
tttcttaaaa aattgttttag gagcaaacaa attttttata tgttagtgtg ttcaactgat 1680
tacattttta gttaaaaaaa aaaatggatt ctgcttataa ct 1722

```

```

<210> 48
<211> 40
<212> DNA
<213> Arabidopsis thaliana

```

```

<400> 48
gaaaagcaat tcatgcatct ttggaactcg tttgtaagaa 40

```

```

<210> 49
<211> 40
<212> DNA
<213> Arabidopsis thaliana

```

```

<400> 49
gaaaagcaat tcatgcatct ttgaaactcg tttgtaagaa 40

```

```

<210> 50
<211> 10
<212> DNA
<213> Artificial Sequence

```

```

<220>
<221> misc_feature
<222> (4)..(7)
<223> n=a or g or c or t

```

```

<220>
<223> Description of Artificial Sequence: Xmn1 site

```

```

<400> 50
cttnnnnaag 10

```

```

<210> 51
<211> 35
<212> DNA
<213> Artificial Sequence

```

```

<220>
<223> Description of Artificial Sequence: Primer

```


<400> 51
gagaagtagt tacctttgtt ttcttacaga agagt 35

<210> 52
<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: PCR product

<400> 52
gaaaagcaat tcatgcatct ttggaactct tctgtaagaa 40

<210> 53
<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: PCR product

<400> 53
gaaaagcaat tcatggatct ttgaaactct tctgtaagaa 40

<210> 54
<211> 367
<212> PRT
<213> Homo sapiens

<400> 54
Ile Ala Lys Pro Leu Ala Thr Arg Asn Ser Glu Ser Leu His Gln Glu
1 5 10 15
Asn Lys Pro Gly Ser Val Lys Pro Thr Gln Thr Ile Ala Val Lys Glu
20 25 30
Ser Leu Thr Thr Asp Leu Gln Thr Arg Lys Glu Lys Asp Thr Pro Asn
35 40 45
Glu Asn Arg Gln Lys Leu Arg Ile Phe Tyr Gln Phe Leu Tyr Asn Asn
50 55 60
Asn Thr Arg Gln Gln Thr Glu Ala Arg Asp Asp Leu His Cys Pro Trp
65 70 75 80
Cys Thr Leu Asn Cys Arg Lys Leu Tyr Ser Leu Leu Lys His Leu Lys
85 90 95
Leu Cys His Ser Arg Phe Ile Phe Asn Tyr Val Tyr His Pro Lys Gly
100 105 110
Ala Arg Ile Asp Val Ser Ile Asn Glu Cys Tyr Asp Gly Ser Tyr Ala
115 120 125

Gly	Asn	Pro	Gln	Asp	Ile	His	Arg	Gln	Pro	Gly	Phe	Ala	Phe	Ser	Arg
130						135				140					
Asn	Gly	Pro	Val	Lys	Arg	Thr	Pro	Ile	Thr	His	Ile	Leu	Val	Cys	Arg
145					150					155					160
Pro	Lys	Arg	Thr	Lys	Ala	Ser	Met	Ser	Glu	Phe	Leu	Glu	Ser	Glu	Asp
				165					170					175	
Gly	Glu	Val	Glu	Gln	Gln	Arg	Thr	Tyr	Ser	Ser	Gly	His	Asn	Arg	Leu
			180					185					190		
Tyr	Phe	His	Ser	Asp	Thr	Cys	Leu	Pro	Leu	Arg	Pro	Gln	Glu	Met	Glu
		195					200					205			
Val	Asp	Ser	Glu	Asp	Glu	Lys	Asp	Pro	Glu	Trp	Leu	Arg	Glu	Lys	Thr
	210					215					220				
Ile	Thr	Gln	Ile	Glu	Glu	Phe	Ser	Asp	Val	Asn	Glu	Gly	Glu	Lys	Glu
225					230					235					240
Val	Met	Lys	Leu	Trp	Asn	Leu	His	Val	Met	Lys	His	Gly	Phe	Ile	Ala
				245					250					255	
Asp	Asn	Gln	Met	Asn	His	Ala	Cys	Met	Leu	Phe	Val	Glu	Asn	Tyr	Gly
			260					265					270		
Gln	Lys	Ile	Ile	Lys	Lys	Asn	Leu	Cys	Arg	Asn	Phe	Met	Leu	His	Leu
		275					280					285			
Val	Ser	Met	His	Asp	Phe	Asn	Leu	Ile	Ser	Ile	Met	Ser	Ile	Asp	Lys
	290					295					300				
Ala	Val	Thr	Lys	Leu	Arg	Glu	Met	Gln	Gln	Lys	Leu	Glu	Lys	Gly	Glu
305					310					315					320
Ser	Ala	Ser	Pro	Ala	Asn	Glu	Glu	Ile	Thr	Glu	Glu	Gln	Asn	Gly	Thr
				325					330					335	
Ala	Asn	Gly	Phe	Ser	Glu	Ile	Asn	Ser	Lys	Glu	Lys	Ala	Leu	Glu	Thr
			340					345					350		
Asp	Ser	Val	Ser	Gly	Val	Ser	Lys	Gln	Ser	Lys	Lys	Gln	Lys	Leu	
		355					360					365			

<400> 55
Gln Ala Leu Gly Gly
1 5

```
<400> 56
actgttcgtc tcttcatca tg                22
```

```
<400> 57
ttgcttgcct gaaaaaagta tg 22
```

<400> 58
tgtcgatatg cgaccagtac c 21

<220>
<223> Description of Artificial Sequence: Primer

<400> 59
 caggcttaga cccaattgac c 21

<210> 60
 <211> 33
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Primer

<400> 60
 aggtaggatc cgacatcgtc ttcttattta ccg 33

<210> 61
 <211> 33
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Primer

<400> 61
 ctcttgaatt caaaactatt cctactctca cac 33

<210> 62
 <211> 25
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Primer

<400> 62
 gccaatcggg gttttcgag ctttc 25

<210> 63
 <211> 28
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Primer

<400> 63
 aagaataagt tacaatccga taaatcgg 28

<210> 64
 <211> 22
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Primer

<400> 64
 cagtgggtga agcttaagga gg 22

<210> 65
 <211> 24
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Primer

<400> 65
 gcaatgaata aatcataatc ttgg 24

<210> 66
 <211> 21
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Primer

<400> 66
 tctactggga tggtagtttt c 21

<210> 67
 <211> 23
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Primer

<400> 67
 atatcccgag gcaacagagc ttg 23

<210> 68
 <211> 19
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Primer

<400> 68
catcttttggga actcgtttg 19

<210> 69
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Primer

<400> 69
ctcagttgta atagttgccc 20

<210> 70
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Primer

<400> 70
aagagtgggc tatggctgg 19

<210> 71
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Primer

<400> 71
gcaactcttt ctcgtaaaat cttg 24

<210> 72
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Primer

<400> 72
gcctccataa ctgtcatcac atc 23

<210> 73
<211> 20
<212> DNA
<213> Artificial Sequence

<223> Description of Artificial Sequence: Primer

tttcattggt catgggatgg

20

<211> 22

<213> Artificial Sequence

<223> Description of Artificial Sequence: Primer

gacttcagag atgggtttat gc

22

<211> 21

<213> Artificial Sequence

<223> Description of Artificial Sequence: Primer

tccatatcta gctccttcgc c

21

<211> 30

<213> Artificial Sequence

<223> Description of Artificial Sequence: Primer

tgcgttcatt aagtaggcaa cagaaaatgg

30

<211> 35

<213> Artificial Sequence

<223> Description of Artificial Sequence: Primer

gagaagtagt tacctttggt ttcttacaga agagt

35